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Abstract 
A COST ANALYSIS OF THE 
TREATMENT OF FIRST-LINE 
UNCOMPLICATED MALARIA IN THE 
TONGA DISTRICT OF 
MPUMALANGA 
by Justin Wilkins 
Supervisors: 
Dr Karen I Barnes 
Prof Peter I Falb 
Department of Phannacologi; 
Following the completion of a detailed baseline study of malaria in the region, a 
model was developed to assess the cost-effectiveness of switching from 
chloroquine to sulfadoxine-pyrimetharnine as first line treatment in the Tonga 
district of Mpumalanga, South Africa, where malaria is seasonal and the 
population is non-immune. In vivo drug resistance was used to create a resistance 
variable, which was used to assess the 1997 relative costs to the health care system 
of employing the two drugs, analysing factors such as drug costs, staff time, 
transport costs, maintenance costs, utility costs, training costs and consumables 
costs to generate an average cost-effectiveness ratio. The model was subsequently 
used to estimate the average cost-effectiveness ratios of nine other potential 
agents for the treatment of first line malaria, including artesunate monotherapy, 
artesunate combinations, pyronaridine, atovaquone-proguanil, co-artemether, 
halofantrine, amodiaquine, and mefloquine. It was found that sulfadoxine-
pyrimethamine was 5 times more cost-effective as first line therapy than 
chloroquine. Of the other modelled drugs, it was recommended that an artesunate 
combination should be implemented when it becomes necessary to replace 
sulfadoxine-pyrimethamine; artesunate-mefloquine and artesunate-SP were 
estimated to be 6 times and 9 times as cost-effective as chloroquine, respectively. 
This work was presented and subjected to 
peer review at the Economics of Malaria 
breakaway group at the MIM African 
Malaria Conference in Durban, South Africa, 
on Monday 15 March 1999. 
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Malaria results from infection by one or more of the four species of the protozoal genus 
Plasmodium. Infection in the field is generally facilitated by the bite of the disease's vector, 
mosquitoes of the Anopheles genus, but may result from any direct transfer of contaminated 
blood. At any one time it infects more than one third of the world's population, mostly in the 
third world. More than 400 million cases of Plasmodium Jalcipan1111 malaria occur globally every 
year, and 2 million children die (World Health Organisation, 1994). In sub-Saharan Africa, more 
than 15% of disability-adjusted life years (DALYs) lost annually are lost to malaria morbidity 
and mortality (Foster & Phillips, 1998). 
P. falciparum and P. malariae have a single cycle of liver cell invasion, which differentiates them 
from the other two species, P. vivax and P. ovale. The latter two may become dormant in hepatic 
cells, subsequently resulting in occasional relapses. P. Jalciparum and P. malariae, however, may 
only replicate in red blood cells. Of the four, P. Jalcipanmz is the most dangerous, and may be 
lethal if not treated correctly and promptly (Boyce, 1997). 
During a blood meal, an infected Anopheles mosquito transmits between 5 and 100 motile, 
unicellular sporozoites into the bloodstream of the organism upon which it is feeding. These 
rapidly migrate to the liver and gain access to hepatocytes, where they divide, eventually 
forming mature liver schizonts containing 2 000 to 40 000 uninucleate daughter merozoites. 
After 6 to 16 days, the schizonts rupture and 105 to 106 merozoites are released into the 
bloodstream. The merozoites rapidly invade red blood cells to form ring-shaped trophozoites, 
which differentiate into mature red cell schizonts within 48 hours (in P. Jalciparum, P. ovale, and 
P. vivax) or 72 hours (in P. malariae). Finally, between 6 and 24 new daughter merozoites are 
released to continue the reproduction cycle (see figure). P. vivax and P. ovale have a preference 
for reticulocytes, while P. malariae preferentially attacks senescent erythrocytes, with the result 
that parasitaemia rarely exceeds 2%. However, P. Jalcipanzm, despite preferring reticulocytes, 
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will invade all red blood cells, accounting for the substantially higher mortality found in those 
infected with it. Parasitaemia may exceed 50% in exceptional cases (Stanley, 1998). 
Also formed during the parasitic life cycle are sexual forms called gametocytes, which are 
differentiated from merozoites. Gametocytes circulate asymptomatically for months or years 
until they are ingested by anopheline mosquitoes, upon which they form large numbers of 
infective sporozoites in the mosquito midgut over a period of 8 to 35 days. The sporozoites 
migrate to the mosquito's salivary glands and the cycle begins anew (Stanley, 1998). 
Once infected by the parasite, an incubation period of between 10 and 35 days follows. Initial 
symptoms are non-specific, and the disease is often misdiagnosed as the common cold or 
influenza. Low-grade fever, headache, malaise, fatigue, abdominal discomfort, myalgia, and 
chills present, and last 2-3 days. A sequential pattern of attacks will then appear: a 48-hourly 
(or 72-hourly in P. malariae infections) periodic cycle of rigors, fever, and sweating. Symptoms 
occur due to the release of tumor necrosis factor (TNF-a) and inflammatory cytokines, which is 
in turn caused by cyclical red blood cell lysis (Stanley, 1998). 
In P. falcipant1n, additional complications may arise, including cerebral malaria, which includes 
symptoms of headache, mental disturbance, neurological signs, convulsions, delirium, and 
coma. Other symptoms include hyperpyrexia, haemolytic anemia, noncardiogenic pulmonary 
oedema, acute tubular necrosis and renal failure with concomitant dark urine production 
(blackwater fever), acute hepatopathy with centrilobular necrosis and jaundice, hypoglycaemia, 
adrenal insufficiency-like syndrome, cardiac dysrhythmias, gastrointestinal upset including 
secretory diarrhoea and dysentery, and fluid and electrolyte imbalance (Boyce, 1997). 
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Figure 1.1. Life cycle of the malaria parasite. (Image © BIODIDAC. Used with permission. See 
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Figure 1.2. Increase in laboratory-confirmed malaria cases in South Africa between 1971 and 1998. 
Data presented with permission of D Lombaard of the Division of Vector-Borne Diseases at the 
South African Department of Health. 
1.2. Malaria in Southern Africa 
Malaria infects 5% of the world's population at any one time; in Africa, the disease accounts for 
the largest number of lost disability-adjusted life years (DALYs) on the continent, a total of 32 
million in 1990 (Murray et al, 1994). 90% of the 1.5-million malaria deaths worldwide per 
annum occur in sub-Saharan Africa, mostly in children: 68% of fatalities in 1990 were under the 
age of four (Murray et al, 1994; le Sueur et al, 1996). In South Africa, the situation is worsening 
rapidly, with a large increase in cases and deaths over the past five years, reflected in official 
notification data from the Department of Health. This increase may be explained by increased 
rainfall, increased migration and developing resistance to chloroquine. 
Malaria accounts for 10%-30% of all new hospital admissions in Sub-Saharan Africa. Malaria 
was also responsible for the loss of 35.4 million disability-adjusted life years (DALYs) to the 
world in 1990, which was 2.6% of the global total. In Sub-Saharan Africa, malaria accounted 
for 10.8% of the regional total of lost DALYs (Murray et al, 1994). 
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Figure 1.3. Percentage malaria mortality in South Africa from 1971 to 1998. Data presented with 
permission of D Lombaard of the Division of Vector-Borne Diseases at the South African 
Department of Health. These figures may be an under-estimate, owing to under-reporting of deaths. 
1.3. Malaria in South Africa 
Malaria in South Africa is confined to KwaZulu-Natal, Mpumalanga and Northern Province. 
Most cases (about 95%) are the result of infection by Plasmodium falciparum, the most dangerous 
malarial agent, with the balance being composed of Plasmodium avale and Plasmodium malariae 
infections (Sharp & le Sueur, 1996; Murray et al, 1994). Figure 1.2 and Figure 1.3 illustrate the 
increasing number of cases in recent years and the mortality associated with this. 
The principle vector for the disease in South Africa is Anopheles arabiensis, a common species of 
mosquito in the border areas. Malaria is transmissible by most Anopheline mosquitoes, but 
other species have been all but eradicated by an exhaustive vector control programme. A. 
arabiensis has survived best due to its so-called 'hut-leaving' behaviour in the presence of DDT 
(Sharp et al, 1990). 
An effective vector control programme has led to an overall reduction in size of the malaria-
endemic areas within South Africa's borders since peak infection rates recorded in the 1930s, 
but in recent years these areas have been encroaching once more, with total annual cases 




Chloroquine- and sulfadoxine-pyrimethamine-resistant 
• Chloroquine-, sulfadoxine-pyrimethamine- and mefloquine resistant 
Figure 1.4. Global distribution of malaria and P. falciparum drug resistance in 19% (South African 
Department of Health, October 19%). 
The border districts generally record the highest levels of transmission, suggesting that a large 
proportion of South Africa's malaria problem is imported from bolo-endemic areas in 
Mozambique, Zimbabwe and Botswana, where malaria control efforts are hampered by lack of 
funds and more pressing health problems. In these areas transmission occurs throughout the 
year. The populations in these regions tend to be semi-immune. This is not the case in South 
Africa, where infection is seasonal, occurring during the warm, wet months between October 
and April when conditions for vector breeding are optimal. This leads to a greater number of 
severe and complicated malaria cases and deaths, since the effects of the disease on a non-
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Figure 1.5. Malaria transmission zones within the borders of South Africa. Illustration courtesy of 
the South African Medical Research Council, with permission. 
1.4. Antimalarial Drugs and Developing Resistance 
Resistance to chloroquine, the drug used almost universally to treat malaria until quite recently, 
appeared in Africa in 1979, a short time after it emerged in Southeast Asia and South America 
(Fogh et al, 1979), and spread to South Africa by 1980 (Bae et al, 1985). 
The relatively small number of drugs presently available for the treabnent of malaria have 
almost entirely evolved from armed conflicts involving wealthy nations that have occurred in 
tropical, malaria-endemic areas. The nations perennially affected by the disease do not possess 
the resources to develop drugs on their own (White, 1992). 
Plasmodium falciparum malaria has shown considerable ability to develop resistance to almost all 
the drugs with which it has been confronted over relatively short periods of time. 
For the drugs discussed below, in vivo efficacy figures have been used wherever possible. 
However, where data on in vivo response has not been readily available, in vitro figures have 
been used. It should be pointed out that there is no correlation between in vivo and in vitro 
results except at high levels of resistance, perhaps due to interference in the relationship 
between the two tests by the immune system (ref?). 
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1.4.1. 4-Aminoquinolines 
These are rapidly-acting blood schizontocides with some gametocytocidal activity. 
1.4.1.1 Amodiaquine 
Cl 
Arnodiaquine, a chloroquine analogue, has a nearly-identical resistance profile to that of 
chloroquine, suggesting a high degree of cross-resistance. It is slightly more effective than 
chloroquine against chloroquine-resistant strains of the parasite (White, 1992). In southern 
Africa, the majority of field isolates collected were resistant to the drug by 1990 (Freese et al, 
1994). In contrast, evidence from Gabon (Radloff et al, 1996) showed a cure rate of 71.83% using 
the drug, and a Cameroonian study (Ringwald et al, 1998) claimed a 100% cure rate. The latter 
study, however, did not quote patient numbers and ensured all patients were treated by 
weight, an ideal situation rarely found in the field. A review conducted by Olliaro et al in 1996 
found that the parasitological success rate (to day 14) of amodiaquine across 24 controlled trials, 
22 in Africa, was 85.44% (657 of 769 patients). However, in 1986 P. falcipantm isolates originating 
in Maputo, Mozambique, sensitivity was only 24%, contrasting with the 85% found in Zambia 
(Freese et al, 1994). 
The usefulness of amodiaquine is further limited by the concomitant risk of immune-mediated 
agranulocytosis (1 in 22000 travellers using the drug prophylactically), sometimes in association 
with hepatitis (1 in 15650 travellers). The drug causes a fatal reaction in 1 in 15500 travellers 
(White, 1996). It is no longer in use in the United States or the European Union, but is still 
available in parts of Africa and Oceania. Recent evidence suggests that large doses and several 
weeks of treatment are required to produce onset of an adverse reaction, indicating a possible 
application in short, intensive treatment of chloroquine-resistant P. Jalcipantm malaria (Olliaro et 
al, 1996; Tester-Dalderup, 1996). 
The WHO does not recommend it for treatment or prophylaxis. Amodiaquine was marketed as 
Camoquin in South Africa by Sterling-Winthrop until it was withdrawn from the market 




Chloroquine-4-aminoquinolone-is rapidly absorbed from the digestive tract, achieving peak 
serum levels in 1-6 hours. Its half-life has not been effectively determined, but is thought to 
range between 7-10 days and as long as 56 days. In doses recommended for prophylaxis and 
treahnent, side effects are rare, and are generally confined to skin rashes and pruritus. 
Overdosing, a danger because of increasing parasite resistance to the drug, can lead to toxicity 
and occasionally death, especially in infants (Tester-Dalderup, 1996). 
Chloroquine, once the most effective and best-tolerated antimalarial drug on the market, first 
exhibited resistance in the late 1950s; by the mid-1980s, resistance had spread throughout the 
world's malaria-endemic regions. The areas most seriously affected are sub-Saharan Africa and 
Southeast Asia. However, exceptions exist: resistance levels in Central America, Haiti and 
sections of West Africa are still relatively low. Spread of resistance in tropical regions appears 
to have occurred quickly, especially in Thailand. Poor malaria control policy and enormous 
drug pressure generated by large quantities of drug base appearing on the market, as well as 
subtherapeutic dosing, appear to have accelerated selection of resistant parasitic strains. Its 
biological half-life is typically between one and two months. Chloroquine is generally available 
without prescription, and is often used as a 'cure-all' for many other ailments. An example of 
the continuing problem is the consumption (according to the WHO) of 91 million metric tons of 
the drug in 1988, long after the appearance of resistance (White, 1992; Wernsdorfer, 1991). East 
Africa was identified as a new focus of resistance in 1977. Projections for future spread are not 
optimistic, based upon previous experience, and the prospects for renewed sensitivity in areas 
where chloroquine has been phased out, are similarly poor (Murray, 1994). 
In 1993 Bloland et al reported that chloroquine failed to produce adequate clinical or 
haematological resolution in very young children suffering from P. falciparum malaria in 
Malawi and Kenya, and recommended a shift to sulfadoxine-pyrimethamine as first-line 
treatment in those regions. 
In South Africa, resistance to chloroquine is high. Chloroquine-resistant isolates were detected 
by 1990 (Freese et al, 1994). An in vitro study conducted in Mpumalanga in 1996 found 
resistance levels approaching 80%, though this may be the result of the use of a hospital 
population in the study (Van Nierop & Frean, 1996). Routine data collected by the 
Mpumalanga Malaria Control Programme in that province between 1990 and 1995 indicate that 
resistance to chloroquine in the area has risen dramatically over those five years (Kruger et al, 
1996), with a concomitant increase in both fatalities and percentage mortality (see Fig. 1.3). This 
association is not necessarily causally related. 
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Chloroquine remains effective against P. vivax, P. ovate, and P. malariae, and is still used as first-
line treatment for these forms of malaria. In the former two species, treatment is immediately 
followed by a primaquine regimen to clear hypnozoites from the liver, thereby preventing 
relapse (White, 1996). 
Prophylactic use entails taking a single dose weekly, starting one week before entering the area, 
finishing 3-4 weeks after leaving, in combination with a daily dose of proguanil. Adult dosage 
for chloroquine-resistant areas is 300 mg per dose (usually 2 tablets); in children, dosage is 5 
mg/kg body weight. Its efficacy in Africa is approximately 72% (Bradley & Warhurst, 1995). 
Other antimalarials related to chloroquine include amopyroquin, a 4-aminoquinolone related to 
amodiaquine, as well as piperaquine, triperaquine and dabaquine. The latter three exhibit 
cross-resistance with chloroquine (Tester-Dalderup, 1996). 
Chloroquine is marketed in South Africa as Nivaquine by Rhone-Poulenc. Its recommended 
retail price in December 1997 was RlS.86 per pack of fourteen 200mg tablets. It is also available 
at R25.14 per 100ml bottle of 50mg/5ml syrup. Tender price to the Department of Health was 
and is substantially lower. 
1.4.2. 8-Aminoquinolines 
These are tissue schizontocides, used primarily for preventing relapse in vivax and ovale 
infections. They have gametocytocidal activity as well as some activity at other points in the 
parasitic life cycle. Primaquine is the most commonly-used drug in this category. 
1.4.3. Biguanides 
Biguanides are dihydrofolate reductase inhibitors, tissue schizontocides and slow-acting blood 
schizontocides. They include proguanil and chlorproguanil, and are mainly used for 
prophylaxis. 
1.4.3.1 . Proguanil 
Proguanil is almost exclusively used as a prophylactic drug. Standard doses are rapidly 
absorbed, but efficacy varies significantly between individuals. The drug is susceptible to a 
genetic polymorphism in one of the cytochrome P450 isoenzymes, CYP2C19, which may result 
in subtherapeutic plasma concentrations of its active metabolite, cycloguanil, in plasma. 
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Incidence of the polymorphism varies along ethnic lines (3-10% in Caucasians and up to 23% in 
Asians). However, in vitro evidence suggests that the metabolic polymorphism does not affect 
the effectiveness of the drug in combination with atovaquone (Edstein et al, 1996; see section 
1.5.2). 
Side effects are usually mild, and may include cutaneous rash, hair loss, mouth ulcers, 
abdominal discomfort and vomiting. Proguanil marketed as Paludrine in South Africa by 
Zeneca at R49.09 per hundred 100mg tablets (December 1997). Proguanil has been used in 
combination with atovaquone (see Section 1.5.2). 
When used as prophylaxis, proguanil is taken daily in combination wiL1i a weekly dose of 
chloroquine. The effectiveness of this regimen in Africa is roughly 72% (Chanterie, 1997). 
1.4.4. Diaminopyrinamides 
Diaminopyrinamides are dihydrofolate reductase inhibitors, tissue schizontocides and slow-
acting blood schizontocides. They have some sporontocidal activity, and are commonly used in 
combination with other antimalarials that inhibit other stages of folate synthesis; an example is 
sulfadoxine-pyrimethamine (see section 1.4.13). 
1.4.5. Hydroxynaphthoquinones 
This drug class is primarily used for its blood schizontocidal activity. It has also proved useful 





During World War II, quinine supplies were depleted faster than they could be replenished, 
and a replacement antimalarial was sought. This early work focussed on the 
hydroxynaphothoquinolones, and achieved little success. However, technological advances 
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made since then allowed Wellcome Research Laboratories to continue the work in the 1980's, 
culminating in the development of atovaquone (Hudson, 1993). 
Atovaquone has recently been used in the treatment of acute P. falciparum malaria 
(Looareesuwan et al, 1996). Results showed good antimalarial activity, but recrudescence was 
quite common. Research is presently underway to evaluate its effectiveness in combination 
with other drugs, such as proguanil and the tetracyclines, but at this time, the information is 
inconclusive (Looareesuwan et al, 1996). 
A 1996 study conducted by Radloff et al in Gabon found that a combination of atovaquone 
(1000 mg daily) and proguanil (400 mg daily) administered over 3 days to patients suffering 
from acute uncomplicated P. falciparum malaria resulted in an 87.32% cure rate, with only one 
recrudescence. This was significant compared witl1 the 72% found in the control group, treated 
with amodiaquine. A study in Peixoto de Azevedo in Brazil (de Alencar et al, 1997) also showed 
encouraging results (76 of 77 patients cured, a 98.7% cure rate), but extrapolation from South 
America to sub-Saharan Africa is not possible. Glaxo Wellcome recently made a donation of one 
million doses per year of the atovaquone-proguanil combination (Malarone) to malaria-
endemic areas in Africa, Southeast Asia, and South America, although reaction to this has been 
mixed. There has been debate over its impact on developing resistance, and whether a new 
non-essential antimalarial will do more harm than good for the continent. Atovaquone 
resistance stems from a single point mutation, suggesting the usefulness of the Malarone 
combination may be short-lived (Bloland et al, 1997; Phillips-Howard, 1998). 
In South Africa Glaxo Wellcome markets atovaquone alone as Wellvone. Its December 1997 
recommended retail price was R2348.86 per one hundred and eighty-nine 250mg tablets. 
Malarone's international price was recently fixed at UK £21 .00 per adult course. 
1.4.6. 4-Methano lquino lines 
4-Methanolquinolines are rapid-acting blood schizontocides with some gametocytocidal 
activity. 
1.4.6.1 . Mefloquine 
• HCI 
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Mefloquine, a highly active quinoline-methanol schizontocide, was developed by the U.S. 
Army's antimalarial research programme. Absorption is rapid and serum peak levels occur in 
1-4 hours. Half-life is extremely variable, falling between 7 and 30 days. Single, high doses 
produce good cure rates, and use of the drug for prophylaxis is common. However, 
epidemiological evidence has shown that therapeutic doses may produce mild side effects, 
including nausea, diarrhoea, abdominal pain, dizziness, vivid dreams, and insomnia. More 
rarely, severe neuropsychiatric derangement may occur, though the incidence of this is unclear 
(Tester-Dalderup, 1996). Mefloquine exhibits serious cardiac interactions with quinine, 
quinidine, chloroquine, and especially halofantrine (DRUGDEX®, 1998; World Health 
Organisation, 1998). 
Initial studies of mefloquine indicated high efficacy, but these results may have been optimistic. 
Resistance in Southeast Asia has increased dramatically since it was introduced as first-line 
agent in Thailand in late 1984. Intrinsic resistance was reported in West Africa in 1988, but in 
most other parts of the world, it remains a viable alternative therapy. There are, however, fears 
that resistance to mefloquine may in tum stimulate resistance to quinine, the only agent 
available for the treatment of severe and complicated malaria (White, 1992; Wernsdorfer, 1991). 
Mefloquine resistance in southern Africa had not appeared by 1994, though sample sizes used 
in the assessment of in vitro isolate sensitivity were small (Freese et al, 1994; Deacon et al, 1994). 
When used prophylactically, weekly doses of 250 mg (1 tablet) are indicated in adults. In 
children, dosage should be 5 mg/kg body weight per week. Prophylactic use should start one 
week before entering the area and end four weeks after leaving. Effectiveness as prophylaxis in 
East Africa has been reported to be 91 % (Steffen et al, 1993), while another study, using a 
smaller study population, reports a prophylactic failure rate of 33% (5 of 15 subjects) (Lobel et al, 
1998). A Nigerian study revealed a cure rate of 93.9% (31 of 33) in children with multi-drug 
resistant P. Jalciparum malaria (Okoyeh et al, 1997). Studies conducted in Burkina Faso indicated 
full sensitivity to mefloquine (Del Nero et al, 1993; Del Nero et al, 1994). 
WHO recommendations for treatment are 15 mg/kg (up to 1 000mg) as a single dose. However, 
current practice is to give 25 mg/kg over 2-3 days, up to 1 500 mg (personal communication, KI 
Barnes). Mefloquine is not currently registered for treatment in South Africa. 
Mefloquine is available in South Africa by Roche as Lari.am, at a recommended retail price of 




Oral quinine is well absorbed and has an elimination half-life of 11 hours. Plasma 
concentrations above the minimum inhibitory concentration must be maintained for the drug to 
be effective. Adverse effects occur commonly in overdose, or too-rapid intravenous treatment. 
These include central nervous system disorders, visual disorders, and cardiovascular problems 
(I'ester-Dalderup, 1996). 
Quinine, generally used in combination with tetracycline, has mainly retained its efficacy in 
most parts of the world (with the exception of Southeast Asia) in the 350 years since its 
discovery in Peru in the early 17th century. Meshnick has proposed that this may be due to a 
unique, specific mode of action in the parasite that is resistant to mutation, or because 
development of resistance has been so slow that it has not been noticed. A final possible 
explanation may be that its level of use has not been sufficient to produce enough drug pressure 
(Meshnick, 1997). Notable exceptions are Thailand and parts of Africa. Quinine, however, is not 
as useful a first-line agent as some other drugs due to its serious side effects in up to 70% of 
patients and concomitant low compliance rate (White, 1996; Luzzi & Peta, 1993). This, 
paradoxically, may also explain its low resistance levels. It is still, however, widely used in the 
treatment of severe and complicated malaria (White, 1992; Wernsdorfer, 1991). 
Quinine combinations are used as first-line treatment in urban non-malaria-endemic areas of 
South Africa, as well as in industrialised Western nations. It is not used as first-line therapy in 
rural areas because of its strict dosage regimen and side effects. Short-course quinine therapy 
combined with a single dose of sulfadoxine-pyrimethamine has been found to be effective in 
Kenya (Keuter et al, 1992) and Brazil (de Souza et al, 1985). Current South African 
recommendations support a full 7-day quinine regimen in combination with the standard single 
dose of sulfadoxine-pyrimethamine (South African Department of Health, 1996). Quinine is also 
used in combination with doxycycline (see section 1.4.4). 
African strains of P. Jalciparum are reportedly more sensitive to quinine than those originating in 
Southeast Asia and South America. In vivo studies conducted in Africa since 1980 have shown 
quinine sensitivity in virtually all cases (Salako, 1985; Freese et al, 1994). 
Intravenous quinine is generally administered, although quinidine is often substituted in the 
United States of America. Injectable quinine in lactate form is available as quinoform. Few data 
are available on the latter's side effect profile, but efficacy is identical to quinine (I'ester-
Dalderup, 1996). 
The oral formulation is marketed in South Africa by Lennon, as Lennon-Quinine Sulphate. 
Intravenous (Adco-Quinine) formulations are marketed by Adcock-Ingram. Cost in December 
1997 was R145.92 per pack of one hundred 300mg tablets and R115.65 per ten 1ml ampoules 
(containing 300mg). 
1.4.7. Naphthyridine derivatives 
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Developed in China in the early 1970's, the azacridine-derived drug pyronaridine has shown 
promise in the treatment of uncomplicated P. falcipnn1111 malaria in Southeast Asia. This and 
other research has also shown that it may be useful in chloroquine-resistant areas (Ringwald et 
al, 1996; WHO, 1996). The Ringwald study, conducted in Yaounde, Cameroon, found a 100% 
parasite clearance rate in patients treated with 32 mg/kg pyronaridine within 14 days, 
compared with 44% in chloroquine. Parasitaemia in the pyronaridine group (40 of 81) was 
cleared by day 4. Two further studies at Yaounde found 100% efficacy for P. malariae and P. 
avnle infections (Ringwald et al, 1997) and a 100% efficacy rate in falciparum-infected paediatric 
patients (41 of 41) in comparison with 60% (16 of 40) with chloroquine (Ringwald et al, 1998). 
Resistance of P. falcipan,m to pyronaridine in Africa has not been reported. A Thai study 
reported a 63% cure rate (38 of 60 subjects) after 28 days when treated with 1 200mg over 3 
days, and an 88% cure rate (23 of 32) after 28 days when using a regimen of 1 800mg over 5 
days (Looareesuwan et al, 1996). 
Dose schedules are empirical and little is known about the drug's pharmacokinetics. 
Furthermore, resistance is easily induced in vitro, and at a 1996 cost of roughly $3.00 per adult 
dose, it may prove to be an expensive alternative (Winstanley, 1996). 
1.4.8. 9-Phenanthrenemethanols 









Halofantrine is a phenanthrine-methanol compound, and is relatively slowly absorbed, with 
peak serum levels occurring within 3.5-6 hours. Side effects from normal dosages are mild, and 
include nausea, diarrhoea, headache and pruritus. Standard doses may produce severe cardiac 
effects. Its use with mefloquine is strongly contraindicated, due to the risk of serious cardiac-
related interaction (Tester-Dalderup, 1996; Nosten et al, 1993). Falade et al found an in vivo 
resistance level of 17.95% in Nigeria in 1998, which corresponds well to the 18% found in 
Brazzaville, Congo (Brasseur et al, 1993). Brasseur et al also noted a rapid onset of resistance, 
thought to be due to high drug pressure in the region. However, a study conducted in 
Lambarene, Gabon found a 100% cure rate (35 of 35 adult patients with uncomplicated 
falciparum malaria) when comparing 8 mg/kg halofantrine, given 6-hourly for 3 doses, with 
chloroquine-antibiotic combinations (Kremsner et al, 1994). Another study, evaluating malaria-
infected nonimmune travellers returning to Europe from sub-Saharan Africa, found a 14.29% 
recrudescence rate (4 of 28 patients) with halofantrine treatment (250mg 6-hourly for 3 doses) . 
Of the 4 recrudescences, poor absorption of the drug was responsible for two and in vitro 
resistance was found in isolates from the other two (Bouchaud et al, 1994). 
Halofantrine is only of use in treating mild-to-moderate uncomplicated malaria. Due to its poor 
and highly variable bioavailability, standard doses may be subtherapeutic in some individuals 
and toxic in others (White, 1996; ter Kuile et al, 1993). This interindividual variability has led to 
the adoption of a micronized formulation for some studies. An adult treatment course is six 
250mg tablets, 2 tablets every 6 hours. If no cure occurs, the course is to be repeated one week 
afterward (Half an package insert). 
SmithKiine Beecham markets the drug in South Africa as Halfan, and its December 1997 
recommended retail price was R39.79 per six 250mg tablets, or one adult treatment course. 
Other endoperoxide antimalarials in use include pefloxin, a fluoroquinolone antibiotic which 
has been shown to inhibit P. Jalciparum in vitro, and pentoxifylline, a methylxanthine which may 
prevent the onset of cerebral malaria (Tester-Dalderup, 1996). 
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1.4.9. Sesquiterpene lactones 
These compounds have blood schizontocidal activity, and consist chiefly of the artemisinin 
derivatives. 







The artemisinin derivatives arose from an ancient Chinese remedy for fever, the herb 
Qinghaosu (Artemisia annua L). Chinese researchers extracted the herb's active principle, a 
sesquiterpene lactone peroxide which they named artemisinin. As well as artemisinin, three 
semi-synthetic preparations exist, based upon the compound dihydroartemisinin (DHA). At 
the time of writing (early 1999), artemisinin is subject to stringent World Health Organisation 
guidelines designed to prevent the development of resistance. According to these, artemisinin 
may only be used in treatment (not prophylaxis), and then only in multi-drug resistant malaria 
not responding to quinine treatment; may only be used in combination with mefloquine; and 
must be used for at least 3 days. At present, artemisinin is only available in South Africa on a 
named-patient basis, subject to clearance from the Department of Health (White, 1996; WHO, 
1993). 
There is evidence that artemisinin compounds may already be in significant use in Africa, in 
disregard of WHO guidelines, which may compromise their future usefulness on the continent. 
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Arteether is the ether ethyl derivative of DHA, and had been selected for further development 
by the WHO, but is no longer being pursued. Its Chinese discoverers have abandoned it as it is 
reportedly more toxic than the other derivatives. Artemether is the methyl ether derivative of 
DHA. Its action is thought to be faster than that of the other two primary derivatives, and has 
been used successfully in the treatment of both severe and complicated malaria. 
Artesunate is a water-soluble hemisuccinate variant of DHA. A 3-day course in combination 
with mefloquine has been shown to be effective against multidrug-resistant P. falciparum. 
(White, 1996; Nosten & Price, 1995). However, strains of P. falciparum resistant to mefloquine 
have been noted to be less sensitive to artemisinin, perhaps due to the synergistic relationship 
between the two drugs (WHO, 1998). 
The World Health Organisation has recommended that the 3-day course with mefloquine be 
adopted preferentially due to the high recrudescence rate found in short-course monotherapy, 
the problem of compliance in longer-duration monotherapy, and to delay the emergence of 
resistance (WHO, 1998). 
All three derivatives are rapidly metabolised to the biologically active form of the drug, DHA. 
Clinical and parasitological response is faster than with other antimalarials, and little resistance 
has as yet been reported. Its mode of action is not clear at this time. Animal testing suggests 
that there is a signilicant risk of neurotoxicity, but little evidence has appeared in human 
subjects (Nosten & Price, 1995; Hoffman, 1996). 
Resistance to the artemisinin derivatives is rare in Southeast Asia, and has been reported in one 
West African isolate (Gay et al, 1994). Treatment failures have been reported in Thailand 
(Luxemburger et al, 1998). 
Artesunate is produced in Vietnam at US$ 1.00 per twelve 250mg tablets, but in Thailand, 
where it is also a first-line antimalarial, twelve 250mg tablets cost US$ 3.60. South African 
prices may not be similar to Thai prices when the drug is introduced. 
1.4.10. Sulphonamides 
Sulphonamides inhibit dihydropteroate and folate synthesis, and have blood schizontocidal 
activity. They are generally given in combination with pyrimethamine (see section 1.4.13). 
1.4.11. Sulphones 
Sulphones are folate synthesis inhibitors with a blood schizontocidal action. They are often 
given in combination with pyrimethamine or chlorproguanil (see section 1.4.13). 
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1.4.12. Antibiotics 
The tetracyclines are the principal drugs in this category, and have blood and some tissue 
schizontocidal activity. 
1.4.12.1. Azithromycin 
Azithromycin, an azalide antibiotic, is presently under consideration for the treatment and 
prophylaxis of malaria. It is reportedly effective in parasite clearance, but its value in 
prophylaxis is controversial. Evidence currently does not support its use as an antimalarial 
agent (Sadiq et al, 1995). 
Pfizer have made the drug commercially available in South Africa as Zithromax. In December 
1997, its recommended retail price was R80.32 for three 500mg tablets. 
1.4.12.2. Doxycycline 
0 OH 0 0 
Although generally used as an antibacterial agent, the tetracycline antibiotic doxycycline is 
often used as prophylaxis against Plasmodium infections. Its side effect profile is markedly 
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different from most other antimalarials, including skin photosensitivity, gastrointestinal upset, 
and Candida superinfection of the gut and vagina (Chanterie, 1997). 
In combination with quinine, a 7-day treatment regimen is generally effective in 85% of cases, 
but compliance is poor due to quinine's cinchonistic side effects (Smith et al, 1997). 
Doxycycline is indicated in individuals visiting high-risk areas that are unable to use other 
prophylactic agents, as well as travellers to regions of high mefloquine resistance. Dosage of 
100 mg per day should begin 1-2 days before entering the area, and end four weeks after 
departure. Dosage in children over 8 years of age is 2 mg/kg body weight, not exceeding 100 
mg per day. Doxycyclinf' cannot be used for longer than 4 months without medical advice, and 
is contraindicated in pregnancy and in children younger than 8 years (Chanterie et al, 1997). 
In South Africa, doxycycline is available as Doxycyl from Lennon Meds at a December 1997 
recommended retail price of R159.54 per hundred 100mg capsules. 
1.4.13. Combinations 
1.4.13.1 . Sulfadoxine-pyrimethamine ('Fansidar') 
Cl 
Sulfadoxine Pyrimethamine 
The sulfadoxine-pyrimethamine combination was introduced as first-line therapy in KwaZulu-
Natal in 1990, replacing chloroquine, and has proved effective (Freese et al, -in press). 
Pyrimethamine is the most active of the 2-4-diaminopyrimidines against malaria-causing 
plasmodia, and is well absorbed, reaching peak plasma levels in 2-6 hours. Its half-life is in the 
order of 80-95 hours, and its effectiveness is enhanced when used in combination with a 
sulfonamide antibiotic, as in the formulation of Fansidar (25 mg pyrimethamine + 500 mg 
sulfadoxine). 
Sulfadoxine-pyrimethamine treatment is associated with a considerable number of side effects. 
Haematological symptoms including leukopenia, agranulocytosis, thrombocytopenia and 
pancytopenia occur occasionally during treatment for malaria, as well as severe cutaneous 
adverse reactions. The high frequency of adverse event prevents its use as a prophylactic drug 
(Tester-Dalderup, 1996). A review conducted by Roche (Sti.irchler et al, 1993) claimed that the 
frequency of severe cutaneous adverse reactions was 0.1 per million in developing countries, 
where the drug was administered as a single dose. 
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The sulfadoxine-pyrimethamine therapy option has come to the fore in areas severely affected 
by chloroquine resistance, where it is somewhat more effective (White, 1992). However, 
substantial resistance in P. Jalciparum has developed in Southeast Asia, Central America and 
parts of tropical Africa, such that its usefulness is becoming increasingly limited. The drug is, 
however, well-tolerated, and may be given in a single dose, making it a useful first-line therapy 
(White, 1992; Wemsdorfer, 1991). It has been used in KwaZulu-Natal since January 1988; 1990 
isolates showed reduced parasite sensitivity to the drug in the area (Freese et al, 1994). The drug 
was introduced recently as first-line treatment in Mpumalanga Province. 
Some problems have emerged in the sub-Saharan African milieu recently. Paediatric dosage 
inconsistencies were recently detected in Kenya, where age-specific differences in routine 
prescription practice resulted in subtherapeutic drug levels in some age groups. The switch 
from chloroquine's 3-day regimen to a single dose has created suspicion regarding sulfadoxine-
pyrimethamine efficacy among patients, resulting in increased self-medication. This problem is 
further complicated by sulfadoxine-pyrimethamine's seeming 'delay in effect' stemming from 
its stage-specificity, and it's lack of significant antipyretic and anti-inflammatory effect. Repeat 
prescription has been found to be common in Kenya (Phillips-Howard, 1998). 
Fansidar is made available in South Africa by Roche at R34.13 per pack of 3 tablets (December 
1997). Tender price to the Department of Health was somewhat lower, at about R18.50 per adult 
course. 
Other combination therapies using pyrimethamine include 'Maloprim' (12.5 mg 
pyrimethamine + 100 mg dapsone), 'Deltaprim' (25 mg pyrimethamine + 100 mg dapsone), 
'Fansimef' (25 mg pyrimethamine + 500 mg sulfadoxine + 250 mg mefloquine), pyrimethamine-
trimethoprim, pyrimethamine-clindamycin, and pyrimethamine-clarithromycin (Tester-
Dalderup, 1996). 
1.4.13.2. Artemether-benfiumetol ('Co-artemether') 
Cl 
Benflumetol (lumefantrine) is a new antimalarial originating in China. It is presently being 
developed by Novartis as CGP 56697, in combination with artemether. The combination is 
commonly known as co-artemether. Several in vitro clinical trials testing its efficacy have been 
conducted. 
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In Thailand, co-artemether was compared with artesunate-mefloquine in 617 acute patients 
with multidrug-resistant falciparum malaria; there was no difference in initial therapeutic 
response, but cure rate was significantly different at day 63 (81 % in co-artemether vs. 94% in 
artesunate-mefloquine, P<0.001) (van Vugt et al, 1998). A Gambian study in 287 children found 
co-artemether to be 100% effective in clearing gametocytes when compared with sulfadoxine-
pyrimethamine (71.1 %, P<0.0001). However, the day 15 cure rate was better in sulfadoxine-
pyrimethamine (97.7%) than in co-artemether (93.3%, P<0.003) (van Seidlein et al, 1998). Van 
Vugt et al conducted a double-blind trial with 359 patients at Mae Sot, Thailand, comparing a 
six-dose regimen of artemether-benflumetol (a total dosage of 480mg artemether + 2 880mg 
benflumetol) to the four-day regimen used previously at the same study site. The 28-day cure 
rate among the 6-dose groups were 96.9% and 99.1 %, while that of the 4-dose group was 83% 
(van Vugt et al, 1999). 
A further trial in Kilombero, Tanzania, found an overall parasitological cure rate of 86.4% in 260 
children, in comparison to 10.3% with the chloroquine group (Hatz et al, 1998). An in vitro study 
investigating the susceptibility of 158 Senegalese P. falcipanmz isolates to benflumetol found 
reduced efficacy in 6% of patients. No cross-resistance was detected (Pradines, 1999). 
Novartis will market co-artemether in South Africa as Riamet. It will be composed of 20mg 
artemether in combination with 120mg benflumetol. So far, the combination has only been 
registered in Switzerland, where it is available at 58.80 SFr for 16 tablets, and 78.75 SFr for 24 
(personal communication, C Ford, Novartis South Africa). 
1.4.13.3. Chlorproguanil-dapsone ('LapDap') 
Chlorproguanil Dapsone 
LapDap, as it is known, represents a potential 'salvage therapy' in the case of sulfadoxine-
pyrimethamine failure. Its short half-life and antifolate mode of action make it a viable 
alternative. 
A trial of chlorproguanil-dapsone efficacy was conducted by Keuter et al in Kakamega, Kenya, 
in 1990. It concluded that the combination was effective in clearing parasitemia by day 7 in 
comparison with chloroquine and sulfadoxine-pyrimethamine, but also found a 67% 
recrudescence rate by day 28. Another study was conducted by Amukoye et al in Kilifi, Kenya, 
in 1997. It showed that a three-dose regimen was effective in the treabnent of P. falciparum 
malaria, although not as effective as sulfadoxine-pyrimetharnine (SP). The authors concluded 
that chlorproguanil-dapsone should be developed in order to slow the emergence of antifolate 
resistance in Africa, as well as for a salvage role in the event of SP treabnent failure. 
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The dosage used in both studies was 1.2 mg/kg chlorproguanil and 2.4 mg/kg dapsone per 
dose. However, final recommended dosages for LapDap have not been finalised. 
1.5. Summary of First-Line Antimalarial Treatments 
Agent Resistance in Cost per Adult Analysis 
Sub-Saharan Course 
Africa 
Arnodiaquine Moderate R12.57 Subject of renewed interest, but moderate resistance 
levels. Cross resistant with chloroquine. 
Artesw1ate Low to Absent RS.06' Effective, but subject to stringent WHO guidelines for 
prevention of resistance 
Atovaquone/ Low R168.00 Results to date inconclusive 
Proguanil 
Otloroquine Very High R0.99 Ineffective 
Halofantrine Low to R79.58 Risk of serious cardiac complications, poor 
Moderate bioavai!ability 
Mefloquine Low to R96.so- Risk of adverse events, risk of encouraging quinine 
Moderate resistance 
Pyronaridine Low to Absent R9.02- Effective 
Quinine (0) Low R38.01 Risk of adverse events and low compliance preclude use 
as first-line agent 
Quinine (0)/ Low R52.37 Risk of adverse events and low compliance cast doubts 
Doxycycline on use as first-line treatment 
Sulfadoxine- Moderate RlS.50 Risk of adverse events; single-dose regimen enhances 
pyrimethan1ine compliance 
• Based on Thai market prices in 1997, and a mean 1997 US$/ZAR exchange rate of 4.6072. 
- Assuming average adult weight >70kg. 




1.6. Treatment of Malaria in the Shongwe and Tonga 
Districts of Mpumalanga, South Africa 
The Shongwe and Tonga districts of Mpumalanga use the following malaria treatment protocol: 
l 
Stable 
Give Fansidar according to 
protocol 
Observe for 1 hour to ensure 
vomiting does not occur 
Review daily, encourage fluids 
'--
1 
Suspected Malaria Case 
Confirm by 
immunochromatographic test 




Unwell, low BP. 





Stat dose of quinine, transfer 
immediately to hospital by 
whatever available means. 














CQ SP Q(IM) Q(7d/O) Mef Q(lOd/0) Art HF 
Drug or Combination 
Figure 1.6. Relative costs of antimalarial drugs in 1990, based upon WHO estimates (Phillips & 
Phillips-Howard, 1996; Schapira et al, 1993) (CQ•chloroquine, SP=sulfadoxine-pyrimethamine, 
Q(IM)=intramuscular quinine, Q(7d/O)=oral quinine for 7 days, Mef=mefloquine, Q(10d/O)•oral 
quinine for 10 days, Art=artemisinin, HF=halofantrine.) These prices are not consistent with South 
African market prices. 
1.7. Economic Implications of Resistance to 
Antimalarial Drugs 
The World Bank and the World Health Organiz.ation determined that a single malaria case costs 
the equivalent of 10 working days in Africa (World Bank, 1993). If this figure is multiplied by a 
million cases (in working adults between the ages of 18 and 45) a year, the result is about 10 
million working days lost per annum (Murray, 1994). Added to this, drug treatment costs 
between US$ 0.08 and US$ 5.30 per case depending on the drug used, which is in turn 
dependent on the resistance profile of the parasite. Since resistance is becoming more 
widespread, drug costs are rising proportionately. The projected cost of malaria in Sub-Saharan 
Africa in 1995 was US$1800-million (Murray, 1994; Velasquez & Boulet, 1997). 
Chloroquine was the drug of choice for the treatment of P. falciparum malaria until the mid-
Eighties. It was inexpensive (US$ 0.12 per treatment course, 1990) and widely available. 
However, once resistance emerged it became clear that cost-effective alternatives were needed. 
The first of these to be introduced was sulfadoxine-pyrimethamine, which was introduced at a 
cost of US$ 0.20 per treatment course, or 1.67 times the cost of its predecessor. However, the 
appearance of sulfadoxine-pyrimethamine resistance forced the introduction of more expensive 
drug therapies, mefloquine chief among them (Phillips & Phillips-Howard, 1996). 
24 
Poorer malaria-endemic nations faced with the problem of rapidly-increasing drug resistance 
are ill-equipped to make the switch to more effective therapy, often suffering from already-
strained health budgets. According to a WHO survey in 1990, the switch from chloroquine to 
sulfadoxine-pyrimethamine may increase first-line drug costs by between 67% and 1800%, 
depending on the country and the source of the import (Phillips & Phillips-Howard, 1996; 
Schapira, 1993). South Africa was, until recently, in the unique position in Africa of having to 
purchase sulfadoxine-pyrimethamine ('Fansidar') from Switzerland at the price charged to 
developed Western customers, while other sub-Saharan nations are able to obtain the drug 
from France at substantially-discounted prices. This remains the case for several other patented 
~timalarials. 
The switch from sulfadoxine-pyrimethamine to mefloquine would lead to an elevenfold 
increase in drug costs; changing from mefloquine to artemisinin would increase drug costs by a 
further 150%, a total increase of more than 5700% over the cost of chloroquine treatment. 
Another problem area is compliance. Sulfadoxine-pyrimethamine is convenient in this regard, 
since it is administered in a single dose, and the patient can be monitored by nursing or clinic 
staff to ensure that the drug is not vomited up before it is absorbed. Chloroquine, and all other 
antimalarials, requires a multi-dose regimen, and it is consequently far more difficult to ensure 
that the drug or combination in question is correctly and effectively used. 
1.8. Pharmacoeconomics 
Pharmacoeconomics is a relatively new field. It is a branch of outcomes research, which is 
defined as research that attempts to identify, measure, and evaluate the end results of health 
care services. These include clinical effects, functional status, wellbeing, and satisfaction with 
care. This field is generally subdivided into evaluation of variations in clinical practice patterns, 
effectiveness of treatments and other interventions, appropriateness of therapeutic alternatives, 
tools for the identification of patient preferences regarding treatment options, and methods for 
evaluating changes in health status and patient satisfaction with health care (Bootman, 1995). 
The first published work in the field of pharmacoeconomics appeared in 1978. 
1.8.1. Pharmacoeconomics Methodology 
In order to qualify as full economic evaluation, all studies must satisfy two criteria: two or more 
alternatives must be compared, and both inputs (costs) and outcomes (consequences) must be 
fully investigated. The choice of one drug therapy over others must include a comparison of 
that therapy with the most frequently used alternatives in routine clinical practice, which might 
also include 'do nothing' . 
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In addition, any evaluation must address hidden costs associated with the drug therapies under 
consideration: these might include hospital stays, clinical staff time, use of consumables, and 
travel costs. Costs in pharmacoeconomic studies are generally divided into two types: direct 
costs, which deal with short-term expenses associated with a particular therapy, such as drug 
costs and salaries of health professionals, and indirect costs. 
Indirect costs, or hidden costs, are the subject of some controversy. They have, in the past been 
estimated by means of the human capital method, whereby the potential value of lost 
production through disease is measured. Recently, Koopmanschap and Rutten pioneered the 
friction cost method, an alternative approach that measures the amount of production lost to 
disease by means of the time necessary for an affected organization to return production to 
initial levels (Koopmanschap & Rutten, 1996). Since then the topic has been the source of some 
debate Gohannesson & Karlsson, 1997; Koopmanschap et al, 1997). 
All costs involved in drug therapy must be considered in a complete economic analysis, taking 
into account the resource use falling on all parties: the health system, patients, caregivers, 
employers, and society. 
Finally, it is important to report on the evaluation of all identified costs and outcomes clearly 
and unequivocally. This transparency demonstrates the soundness of the approach and allows 
other researchers to adapt the methodology employed to other circumstances. 
1.8.2. Controversies of Outcomes Research 
Besides the disagreements over indirect costs, outcomes research and pharmacoeconomics in 
particular have inspired lively discussion. 
Bradley et al reported in 1995 that, while 73 % of 90 medical and health care journal articles 
published between January 1989 and December 1993 were rated as adequate in terms of quality, 
24%-33% of publications failed to address the issue of perspective correctly. In addition, an 
enormous 71 %-87% of papers dealt inadequately with ethics (Boatman, 1995). Perhaps more 
importantly, statistical aspects have been neglected in some cases (Bradley et al, 1995). 
The prospect of cost containment taking precedence over effective treatment is disturbing. In 
the case of malaria, this approach to management of the disease can only lead to increased 
resistance, increased morbidity and mortality, and a subsequent increase in economic damage 
to a country that overwhelms any saving in drug or treatment costs that might have been 
achieved. The true value of pharmacoeconomic research is that it seeks to associate outcomes 
with costs and thus can indicate potential value for money. 
Current opinion on standards for outcomes research is mixed, and the subject matter highly 
controversial. The American Food and Drug Administration (FDA), while having no official 
policy on pharmacoeconomic studies, has taken the position that only those studies based on 
' truthful and non-misleading information' are acceptable. By implication, this includes only the 
results of randomized clinical trials. 
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1.8.3. Cost-Effectiveness Analyses 
Reeder describes the health care system as an 'interrelationship of the budgetary (payment) and 
delivery system', a 'production process' in which resources such as pharmaceuticals, attention 
from medical professionals, inpatient hospital care, and outpatient services are combined to 
create a medical outcome, measured in 'natural units'. The most efficient combination of these 
resources to achieve an acceptable, defined patient outcome is the final goal of any 
pharmacoeconomic study (Reeder, 1995). 
The specific method of pharmacoeconomic research used here is cost-effectiveness analysis, a 
technique used to compare the costs and consequences of alternative approaches to addressing 
a health-care issue, in this case the effective treatment of malaria (Reeder, 1995). 
In cost-effectiveness analyses (CEA), costs are measured as monetary values, while outcomes 
are described in natural units common to all comparators. Outcomes are measured in terms of 
a specific therapeutic objective. A cost-effective alternative may not necessarily be a less 
expensive one: drug therapies are deemed to be cost-effective if one of three criteria is met: 
• The cost-effective alternative is less expensive and as effective as its comparators; 
• The cost-effective alternative is the same cost but more effective than its comparators; 
or 
• The cost-effective alternative is more expensive than its comparators, but delivers a 
greater benefit that is deemed worth the additional cost. 
CEA provides the means to identify the optimal health care outcome per monetary unit spent 
from a number of alternative drug therapies. Results may be expressed in one of two ways: 
• The Average Cost-Effectiveness Ratio (ACER): This is a measure of the average cost of 
obtaining a specific therapeutic outcome, spread over a large population. 
• The Incremental Cost-Effectiveness Ration (ICER): This approach reflects the 
additional cost and additional benefit gained when an optimal alternative is compared 
to the next-best option. 
1.8.4. Sensitivity Analysis and Discounting 
Pharmacoeconomic analyses contain an unavoidable degree of uncertainty: assumptions must 
often be made concerning compliance and choice of discount rate, and data invariably contains 
uncertainties and biases. Precision is limited by these factors, necessitating the use of sensitivity 
analysis to show the impact of variations in important values on the overall results. 
Discounting is the process whereby the effect of time passing is incorporated into 
pharmacoeconomic analysis. Costs and values change with the passage of time, and it is 
therefore necessary to compensate to allow for this. Discounting converts currency units to 
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their projected future values by applying a 'discount rate', generally accepted as being 5% per 
annum on costs and 0%, 5% or 6% on benefits. The process reflects society's preference for 
current benefits over future gains, and results in an annual increase in costs equal to the 
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Figure 1.7. A typical pharmacoeconomic decision matrix. Each alternative option must be balanced 
in terms of cost and outcome. In order to be accepted an option must be of equal or lower cost, and 
preferably equal or greater effectiveness. If an alternative is lower in both cost and effectiveness, it 
may be implemented if budgetary constraints are significant; if greater in both cost and 
effectiveness, it may be implemented in the interests of improving patient outcomes (Reeder, 1995). 
1.8.5. Cost of Death 
An important issue is the cost to the state of the malaria-related death of a patient. Direct 
costs may involve funerals and a number of other factors . Indirect costs are manifold, and 
include non-remunerated household work (e.g. cooking, collecting wood), as well as the 
impact of a shortened life expectancy on productive society (e.g. the cost to business of an 
escalating crime rate) . Employed individuals would lose the present value of their lifetime 
income, although this does not affect the state. It can also be argued that the above indirect 
costs are offset by the savings made in future healthcare services and unemployment benefits 
unused by the deceased, but this may perpetuate higher mortality and a lower per capita 
income, and discourage policy development. 
In the case of child mortality, another factor comes into play: the cost to households and 
society of higher birth rates, which increase concomitantly with increasing infant and child 
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mortality. Costs invested in education, healthcare and women's health will be written off 
with every death, as potentially productive individuals are lost before maturity. 
While a comprehensive analysis of costs related to death was well beyond the scope of this 
study, its importance cannot be underestimated. It should also be noted that cost of death has 
little impact on the costs incurred by the public healthcare provider (Donaldson & Shackley, 
1997; Kobelt, 1996). 
1.8.6. Ethics 
There are two opposing schools of thought regarding ethics in pharmacoeconomics. The first 
proposes that attaching a financial figure to clinical decision-making is potentially unethical. 
The second puts forward the idea that all clinical decisions have costs associated with them, and 
to ignore that fact is unethical, because resources are limited. The use of resources associated 
with a clinical decision implies that they will no longer be available elsewhere, thus denying 
them to others. 
The argument has been presented (Williams, 1998) that disregarding costs in clinical decision-
making is akin to fanaticism. 
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Chapter 2 
AIMS, OBJECTIVES & 
METHODOLOGY 
2.1. Justification for the study 
The cost-effectiveness of the treatment of uncomplicated P. Jalciparum malaria with 
sulfadoxine-pyrimethamine in Mpumalanga was evaluated, giving a crucial measure of the 
advisability of the change from chloroquine as a first-line therapy. Further, several other 
alternatives were modelled to assess their suitability for use as first-line treatment. 
The basic conceptual framework developed for this study may potentially be applied 
generally to other infectious diseases, such as HIV/ AIDS, sexually-transmitted diseases 
(STDs), tuberculosis, and cholera. 
This information is vital to a number of stakeholders, including the provincial Malaria 
Control Programme, the provincial and national Departments of Health and Welfare, the 
World Health Organization, and other researchers. 
2.2. Study Design 
This is a cost-effectiveness analysis (CEA) of sulfadoxine-pyrimethamine as first-line 
treatment for P. Jalcipanm1 malaria in Mpumalanga, compared with chloroquine. The direct 
and, to a limited extent, the indirect costs of treating the disease with sulfadoxine-
pyrimethamine and/ or chloroquine in Mpumalanga were evaluated. Additionally, the costs 
of employing other alternative therapies, including the artemisinin derivatives, atovaquone-
proguanil, and pyronaridine were modelled. 
Resistance to sulfadoxine-pyrimethamine in the South African milieu is thought to be lower 
than resistance to chloroquine, the first-line agent of choice until the beginning of 1997. The 
artemisinin derivatives and pyronaridine are presently undergoing clinical trials, and may 
become available for widespread use soon. Preliminary results are encouraging. 
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The study was observational in nature, and was located in the Tonga district of Mpumalanga, 
due to its high malaria transmission between October and April. It was both retrospective 
and prospective, with data gathered from both hospital and rural clinical settings. Data 
collected from malaria notifications and an in vivo chloroquine effectiveness study conducted 
in 1997 by the Mpumalanga Malaria Control Programme was used retrospectively. 
Information was collected from patients regarding income and expenses incurred in travel. 
Subjects were recruited from two 24-hour district clinics located respectively at Naas and 
Mangweni. These subjects also participated in a study of sulfadoxine-pyrimethamine 
effectiveness being carried out by the Malaria Control Programme, similar to the chloroquine 
investigation conducted in 1996-1997. Information was shared between this study and the 
effectiveness study; the latter provided follow-up data conforming to WHO guidelines. 
Mpumalanga Department of Health and Welfare (DOHW) databases containing malaria 
notification data were extensively used. 
The study has been designed to provide information to governmental and health care system 
decision-makers. 
The study was passed by the University of Cape Town Medical School Ethics Committee, as 
well as the equivalent authority in Mpumalanga. Written informed consent was obtained 
from all patients participating in the study, under the auspices of the sulfadoxine-
pyrimethamine in vivo study. 
2.3. Aim 
The project had the overall goal of estimating the total direct costs of malaria to the public 
health system and afflicted patients in the Shongwe and Tonga districts of Mpumalanga, in 
terms of fixed and variable costs, from the perspective of the public health care system. 
2.4. Objectives 
• Analyse the baseline malaria situation in the area to provide background 
information, primarily concerning malaria case frequency at clinic and hospital level, 
in order to justify choice of sentinel sites, and in order to gauge the efficiency of the 
active surveillance programme in the region. 
• Determine the variable and fixed direct costs of treating uncomplicated P. falciparnm 
malaria in Mpumalanga province (Shongwe Hospital and district clinics) per malaria 
case, with respect to the health care system and the individual patient, at primary and 
secondary health care levels, by means of a model. 
• Relate all data to determine the costs and cost-effectiveness of the treatment of 
uncomplicated P. Jalcipanan malaria with a single dose of sulfadoxine-pyrimethamine 
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with respect to both patient and health care system, compared with treatment of the 
same class of patient with chloroquine. The average cost-effectiveness ratio (ACER) 
analysis technique was used. 
+ Model other treatment approaches, based on effectiveness data obtained from the 
literature, to evaluate their projected cost-effectiveness. 
+ Determine the costs of treatment to malaria patients, including travel expenses. 
• Determine mean road distances from the sentinel clinics (Naas and Mangweni) to 
the communities from which their patients are drawn. 
• Determine mean cost per kilometre travelled per patient, based on information 
collected by means of the questionnaire. 
2.5. Methodology 
2.5.1. Sentinel Sites 
The clinics at Naas and Mangweni were chosen as sentinel sites owing to their 24-hour status, 
as well as their use as sentinel sites for a study evaluating the in vivo resistance of P. falciparum 
to sulfadoxine-pyrimethamine in the district. The latter study was conducted jointly by the 
South African Medical Research Council's National Malaria Research Programme and the 
Mpumalanga Department of Health and Welfare's Malaria Control Programme, and assisted 
with some data gathering for this work. 
2.5.2. Baseline Study of Malaria in the Nkomazi Region 
2.5.2.1 . Thick smear records for assessment of distribution and 
positivity 
The laboratory based at Shongwe Hospital was, until 1997, responsible for confirming the 
diagnosis of all malaria cases presenting at any health facility in the Tonga and Shongwe 
districts . This was done by microscopic examination of blood specimens obtained from 
patients suspected of having malaria; a droplet of blood was placed on a glass slide as a thick 
smear and inspected for trophozoites by a skilled microscopist. The presence of trophozoites 
was taken as confirmation of malaria in the patient. The test was accurate enough to 
distinguish between species of Plasmodium, but diagnostic accuracy was impossible to 
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evaluate and depended heavily on microscopist skill, a serious limitation since skill levels 
were reportedly low (Durrheirn et al, 1997). 
Records kept at the laboratory covered a period of time between 1991 and 1996. These were 
analysed to determine: 
• The presentation rate of positive cases among public health facilities in the district, in 
order to identify regions of high transmission; 
+ The positivity rate at these public health facilities (the proportion of malaria cases 
positively identified as against the total number of thick smears analysed), to provide 
an estimate of the ratio of malaria cases to tests performed; 
+ The relationship between positivity rate at public health care facilities and time of 
year, in order to assess whether the time of year influenced diagnosis patterns in 
primary health care staff; 
+ The positivity rate of thick smears analysed for the active surveillance programme in 
the region, to assess the usefulness of the programme. 
2.5.2.2. The 1997 malaria notifications database for validation of the 
thick smear approach 
The Mpumalanga Department of Health and Welfare (DHW) began keeping a more detailed 
database of malaria notifications in the province in 1997; the 1997 revision contains fields for 
date, name, race, age, gender, plasmodial species, address, source of infection, notification 
location and method of detection (both actively and passively detected cases were included). 
Prior to that year, no information on the site at which the malaria case was detected was kept. 
A copy of the database was obtained from the DHW and analysed to assess the distribution 
of notifications among public health care facilities in the Shongwe and Tonga districts. This 
served as a means of validating the laboratory data on thick smear analysis as a tool for 
assessing cases that presented at district health care facilities from 1991 to 1996. 
The 1997 database was also analysed to determine the proportion of the total number of 
malaria cases notified in the province made up by notifications from the Nkomazi region. 
The suitability of the sentinel sites was evaluated by examining the relative malaria caseload 
at each of the two locations. 
2.5.2.3. Analysis of demographic data 
In addition to the 1997 revision of the DHW's malaria notifications database, a copy of an 
earlier version of the database, covering 1987 to 1996, was obtained. 
The database was analysed with a view to determining the distribution of patients in the 
Nkomazi region, as well as the entire province, by age, gender, and species of Plasmodium 
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from January 1987 to December 1996. The analysis was repeated using data from the revised 
database, covering January 1997 to December 1997. 
2.5.3. Development of the Model: Comparing Chloroquine and 
Sulf adoxine-pyrimethamine 
One malaria-related clinic 
visit 
- First-line drug cost 
- Clinical staff time 
- Consumables 
- Maintenance 
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Figure 2.1. Flowchart illustrating the philosophy behind the costing methodology used in this work. 
South Africans have a lower level of herd immunity in comparison to the populations of other 
African countries in which malaria is endemic because of seasonal malaria transmission. First-line 
treatment failure may therefore be more serious, which the Mpumalanga Department of Health and 
Welfare felt justified their policy of mandatory hospitalisation of treatment failures. 
2.5.3.1. The Resistance Variable (R) 
In order for the direct fixed and variable costs for a first-line drug therapy to be assessed, a 
model was necessary for each category of cost. The model was in tum developed to be 
dependent on the concept of a resistance variable (R), which is defined as follows: 
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R = pl/ x (Pp ± 0.15) 1 
R describes the proportion of those patients for whom first-line therapy was ineffective that 
return to the same clinic for further treatment. 
PR, the rate of resistance, was the in vivo resistance rate for the drug, including RI, RII and RIil 
resistance. Pr was the estimated proportion of resistant patients (in whom first-line treatment 
was a clinical failure) who would return to clinics for further treatment. Pr was taken as 0.70 
throughout the region, based upon expert interviews with regional and frontline health 
professionals (personal communications, D Diirrheim & S Donohue). For sensitivity 
assessment, it was assumed that a normal distribution was present, with a standard deviation 
of 0.15. The remainder of the resistant subset of patients were presumed to seek help from the 
private sector or traditional healers, or not at all. Residents of the district typically have little 
access to formal private medicine. R is derived under the assumption that there is no 
resistance bias in those who return to the clinics. 
PR for chloroquine and sulfadoxine-pyrimethamine was obtained from in vivo studies of each 
drug in the Nkomazi district of Mpumalanga in 1996 and 1998 respectively. Both studies 
made use of a 42-day follow-up period and were strictly controlled. PCR validation was used 
to control for recrudescence (Govere et al, in press). 
2.5.3.2. Modelling Approach 
A system of equations was developed to implement the model, one equation for every 
category. In order to circumvent the problem of point estimates, a risk-analysis package was 
used to generate uncertainty in the resistance variable R as well as in the variable describing 
the proportion of hospital malaria admissions receiving intravenous quinine (Riv). Both 
variables were described by a normal distribution with a mean of 0.7 and a standard 
deviation of 0.15. 
All the data for all categories was entered into a spreadsheet according to the model. A Monte 
Carlo simulation consisting of 1 000 iterations was run, using random values for R and R1v 
that were generated in accordance with the normal distribution. The mean and standard 
deviations in each category of costs were recorded for each drug, and taken as the best 
possible estimates of the real costs of each category. 
2.5.3.3. Modelling of Variable Costs 
Variable costs, defined as costs that are subject to change depending on the choice of first-line 
therapy, include drug costs, the costs of clinical staff time used in malaria treatment, the costs 
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of consumables associated with malaria treatment, and the costs of transporting malaria 
patients to and from hospital. Equations were developed, using the work of Kirigia et al 
(1997) on the pharmacoeconomics of schistosomiasis treatment as a starting point, for each 
category of variable cost. 
+ Dnigs 
Drug costs include the costs of the first-line agent itself, as well as the cost of quinine used in 
treating hospitalised resistant patients. Details of costs were obtained from the Shongwe 
Hospital pharmacy (personal communications, S Swanepoel, Pharmacist, Shongwe Hospital) 
in the case of chloroquine, sulfadoxine-pyrimethamine and quinine. Other drugs were valued 
at the tender prices at which they were available to public health in 1997 (personal 
communication, M Kiessig, Financial Pharmacist, Groote Schuur Hospital). Those drugs not 
on tender were valued according to 1997 retail prices (MiMS, 1997). Drugs not registered in 
South Africa were evaluated either at their international selling price (in the case of 
artesunate and co-artemether) or at World Health Organisation projected cost (in the case of 
pyronaridine). Costs of administration were included with staff costs. 
The equation for the calculation of drug costs is derived as follows: 
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Coston is the total annual cost of using a specific first-line antimalarial drug for the treatment 
of patients falling within a certain age group (as an indicator of weight, and hence of dose 
used) at a single site. Cd is the cost of a treatment course at the necessary dosage for the age 
group, and n,,,0 is the number of patients within the age group treated with the drug during 
the year. Riv is the proportion of referred patients within the age group receiving intravenous 
quinine upon hospital admission, and is equal to 70% ± 15% (personal communications, S 
Donahue & E Athan, Shongwe Hospital; M Young, Bethesda Hospital, KwaZulu-Natal) . R is 
the rate of resistance to the first-line antimalarial. C1 vQJ, CroQ4, and CroQ7 refer to the costs of 
quinine given intravenously for 3 days, orally for 4 days, and orally for 7 days, respectively. 
Gender differences were incorporated via the NCHS Growth Charts (see Fig. 3). 
This simplifies to 
3 
So total cost of the drug across all age groups is 
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for all the age/ dosage differences for a particular first-line drug. 
For the calculation of cumulative costs, the resistance variable was used to estimate the 
number of referrals to Shongwe Hospital from each of the two study clinics. After 
consultation with senior clinical staff at the hospital, the assumption was made that 70% ± 
15% of those referrals were severe enough to require 3 days of intravenous treatment 
followed by 4 days of oral quinine. The remaining 30% ± 15% of referrals were assumed to be 
treated with 7 days of oral quinine, but admitted for observation for the first 3 days. 
CostQ = (Weight NcHs x Dose per kg x Cost per mg) 6 
WeiglztNcHs is weight extrapolated from age using the NCHS Growth Charts. Dose per kg is (for 
intravenous quinine therapy) 20 for loading dose and 10 for all subsequent doses. Cost per mg 
is R5.428/300mg, which is R0.018/mg. For oral quinine, Cost per mg becomes R0.003/mg. 
Wastage of intravenous quinine was not considered; it was felt to be negligible, as costs 
incurred by resiting were assumed to be confined to replacement of the IV apparatus and not 
the bag. 
• Clinical Staff Time 
Clinical staff time refers to the value of time spent by clinical staff in treating and interacting 
with malaria patients, both at clinic level and at the district hospital. Clinical staff include 
doctors and nurses, those who are directly involved with patient treatment. The value of their 
time was calculated by estimating the amount of time spent on patients and valuing that time 
based upon their 1997 annual salaries and benefits, as supplied by the Mpumalanga 
Department of Health and Welfare (personal communication, R Raubenheimer). 
Clinical staff time costs are made up of two primary components: staff time at clinic level and 
staff time at hospital level. 
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Castes; is the contribution to costs made by clinical staff time. n,,,; is the number of malaria 
notifications at the clinic, R is the resistance variable for the study drug, Timea is the time per 
malaria consultation (10 min), and S,,; is the salary per minute of the consulting clinic nurse. 
CostHs; is the clinical staff cost of referred malaria at Shongwe Hospital in 1997. R is the 
resistance variable, n,,,; is the total number of malaria notifications for 1997, R,v is the 
proportion of referred patients receiving intravenous quinine therapy, DTiv is the amount of 
time spent daily (in minutes) on each malaria patient by medical officers, Sd; is the salary per 
minute of a medical officer, NTiv is the amount of time spent daily (in minutes) on each 
malaria patient by nursing staff, and S,,; is the salary per minute of an average nursing staff 
member at Shongwe Hospital. Dm is the time spent daily (in minutes) on a malaria patient 
requiring oral quinine by medical officers, and Nm is the time spent by nursing staff on the 
same type of patient. 
Total costs are described by equation (9): 
Cost rs, = Cost cs; + Cost Hs; 91 
• Consumables 
Consumables describe items with a lifespan of less than one year; items such as disposable 
gloves, syringes, IV bags, canulas, and ICT kits . Malaria cases were monitored for the 
duration of their stay in hospital to determine what consumables were used on a standard 
malaria admission. Costs were based on those quoted by the Shongwe Hospital pharmacy (S 
Swanepoel) . ICT kits are used systematically for the diagnosis of malaria, owing to the poor 
reliability and delay associated with microscopy (Durrheim et al, 1997), and were valued 
according to their South African tender price. 
Costs were calculated with the aid of equation (10): 
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Coste is the total consumables cost stemming from malaria cases initially treated with the 
first-line agent under investigation during a single year. The number of malaria patients 
presenting at a study clinic (11111;) is extrapolated upwards to estimate the total number of 
malaria tests carried out at the clinic. This estimation is obtained by dividing llmi by Rp, the 
positivity rate for the clinic, determined from Shongwe Hospital laboratory records of smears 
conducted between 1991 and 1996. The quotient is multiplied by Ct, the average consumables 
cost of a single !CT-based malaria test, to generate the total cost of consumables used in 
malaria testing at the clinic. Since no other malaria-related activity is carried out at clinic 
level, this is the total malaria-related cost of consumables at the clinic for the year. 
The second term of the equation refers to the contribution made to the cost of consumables by 
hospital admissions. R is the resistance variable, Ri v is the proportion of clinic malaria 
referrals that receive 3 days of intravenous quinine upon admission, and C1 v3 is the average 
cost of consumables used during 3 days of IV quinine therapy. All referred patients are 
routinely re-tested upon admission, and therefore use another ICT and other test-related 
items included in Ct- Patients admitted for oral therapy are assumed to use no other 
consumables, except food. Glucose monitoring is not routinely done in rural hospitals. 
Consumables used at clinic level in the first-line treatment of malaria include 
immunochromatographic testing (ICT) kits, cotton wool swabs, lancets, alcohol swabs, and 
non-sterile pairs of gloves. Each patient tested for malaria is assumed to use one of each of 
these. While laboratory-based blood tests were used for part of 1997, it is assumed for the 
purposes of modeling that ICTs were used throughout. 
Since patients are not admitted to the clinics, no other consumables are used, with the 
exception of stationery, which for the purposes of this study are assumed to be negligible. 
Once admitted to hospital for intravenous quinine therapy, consumables used would include 
IV kits, drip bags, disposable gloves, cotton wool swabs, and meals. Patients receiving oral 
quinine are assumed to use no consumables apart from food and an ICT upon discharge. 
Food, however, as is the case with linen, was common to all patients (Coyle, 1996). 
• Transport 
Transport costs are those incurred in the process of transporting patients from clinic to 
hospital. These costs applied only to hospital admissions, and were mainly limited to fuel 
costs. Vehicles were taken to be capital items, and vehicle maintenance was not considered. 
The transport costs of first-line treatment of malaria are confined to the costs involved in 
transporting referred patients from the outlying clinics to Shongwe Hospital. The informal 
ambulance service is composed of a number of four-wheel-drive vehicles that run between 
39 
several clinics each and Shongwe Hospital. Transport costs involved in training have been 
incorporated in the in-service training component. The equation is: 
Cost ,. = R.nm, X Dist; X co 11 
Costr is the total transport cost generated by patients originating at a study clinic i, Rn,,,; is the 
number of malaria patients referred for hospital treatment by clinic i, Dist; is the distance that 
must be covered by an ambulance vehicle while collecting referred patients and transferring 
them to the hospital, and Co is the mean operating cost per kilometre of the vehicles 
performing the function. 
2.5.3.4. Modelling of Fixed Costs 
Fixed costs describe those costs that do not change when a new first-line therapy is 
introduced. Change in costs of this kind may only be reasonably expected when a threshold 
number of patients is reached and existing infrastructure can no longer cope with demand. 
They include capital costs, maintenance of equipment and facilities, time of administrative 
and support personnel, in-service training of staff, and utilities such as water, electricity, 
postage and telephone calls. In all cases, it was assumed that the proportion of each cost per 
clinic assigned to malaria would be equal to the proportion of malaria patients to total 
patients at each study clinic. 
Due to inherent difficulties in the adaptation of a ratio approach to fixed costs -- adoption of a 
more effective therapy would reduce patient load, and hence increase the proportion of each 
fixed cost allocated to malaria, rather than reducing it -- fixed costs were also examined in 
terms of savings in clinic visits and hospital days. 
• Adjustment of n; and n,, 
Since sulfadoxine-pyrimethamine was used from the beginning of 1997 onwards, it was 
assumed that the hospital and clinic totals (total patients seen for the clinics and total 
admissions for the hospital) included patients returning for further treatment upon the failure 
of sulfadoxine-pyrimethamine. Therefore, the clinic and hospital total patient loads (n; and 111, 
respectively) were moderated as follows for drug x: 
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+ Capital 
Capital items are fixed items required by a health facility, including buildings, furniture, and 
equipment. Acquisition of new equipment or replacement of existing assets is not envisaged 
to occur when a new first-line drug is adopted; hence, capital costs are disregarded for the 
purposes of this study. 
+ In-service Training 
In-service training in malaria-related matters occurs annually in the Nkomazi region. It is not 
directly dependent on first-line drug therapy. Details of costs (which included salaries of 
involved staff and transport costs) were estimated based upon information obtained from the 
Mpumalanga Department of Health and Welfare (D Di.irrheim) on training courses 
conducted annually in the district. However, since this cost is identical no matter the choice of 
first-line therapy, it is largely irrelevant to cost-effectiveness. 
The equation for this aspect of costs is as follows: 
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In-service training in malaria management for private doctors, provincial doctors and nurses 
is provided every year (D Di.irrheim). Variables used include the number of staff of type i 
involved (Qr;), length of the training sessions (Dayr; ), average cost of training per trainee per 
day (made up from salary cost per day (Sa/365.25) and cost of training-related consumables 
per day of training (Cr;)) and proportion of training allocated to malaria (Rr;) are assumed to 
be independent of the drug therapy selected. 
+ Maintenance 
Maintenance costs are those related to the upkeep of equipment and facilities; examples 
include replacement of broken windows and repairs to facilities. Responsibility for 
maintenance of public health facilities lies with the Department of Public Works, but records 
are kept at district level by the Department of Health and Welfare (S Mabuza, Eerstehoek-
Carolina District) . 
The equation for maintenance costs is as follows: 
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CostM = (1 + R)(nm, JMc, + R(nm, JM" 
n, n1, 
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CostM is the total annual maintenance cost of treating malaria cases detected at a study clinic 
with a first-line antimalarial drug. R is the drug's resistance variable, n111; is the number of 
malaria cases presenting at the clinic during one year, n; is the total number of patients 
visiting the clinic during the same year, and Ma is the annual maintenance cost for clinic i. n,, 
is the total number of hospital admissions during the year, and M,, is the annual cost of 
maintenance at this district hospital. 
+ Administrative & Support Staff Time 
Administrative and support staff are those cadres not directly involved in the treatment of 
malaria, including clerks, cooks and sanitation staff. In contrast to clinical staff time, the 
overall contribution of administrative and support staff to total costs was assessed by 
applying the same malaria case ratio used in the calculation of the otl1er fixed costs to their 
cumulative annual salary including benefits. Details of annual salaries and benefits were 
obtained from the Department of Health and Welfare (R Raubenheimer) . 
The equation for this aspect of fixed costs follows a similar pattern to equation (14): 
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Costs is the total annual administrative and support staff cost of treating malaria cases 
detected at clinic level with a first-line antimalarial drug. R is the drug's resistance variable, 
n,,,; is the number of malaria cases presenting at the clinic during one year, n; is the total 
number of patients visiting the clinic during the same year, and Sa is the combined annual 
salary of all staff in the support and administrative categories. n,, is the total number of 
hospital admissions during the year, and s,, is the combined annual salary of all hospital 
support and administrative staff. 
It was assumed that all support and administrative staff at both clinic and hospital level 
contributed to the treatment of malaria, regardless of specific job description, in equal 
proportion to the ratio of malaria cases to non-malaria cases. This is justified if one considers 
that the overall aim of any healthcare facility is to treat patients: all staff ultimately contribute 
towards this, regardless of the degree with which they are directly involved with patients. 
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• Utilities 
Utility costs include annual totals for water, electricity, postage, and telephone calls at each of 
the two study clinics, also taking those of the district hospital into account. No public health 
care facility is responsible for the payment of water accounts. Cost information was provided 
by the Tonga and Shongwe district offices (A Khoza, Tonga; D Nkosi, Shongwe). 
The equation is based upon the number of patients serviced by the clinics as a proportion of 
the total number of patients visiting the clinics. 
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Costu is the total cost of utilities at 24-hour clinic i. R is the resistance variable, nm; is the 
number of notified malaria patients presenting at the clinic during a period of 1 year, Ud is 
the cost of utilities at clinic i, n; is the total number of patients seen per annum at clinic i, u,. is 
the total utilities cost at hospital h, and n,, is the total number of admissions at hospital h. 
Structurally, the equation is identical to equation (14). 
2.5.4. Modelled Costs of Alternative First-line Antimalarial Drugs 
Probability of resistance for the other modelled drugs was estimated from data on their in 
vivo efficacy in Sub-Saharan Africa obtained from a thorough literature search using 
MEDLINE. Inclusion criteria were somewhat relaxed: randomised controlled trials (RCTs) 
conducted in sub-Saharan Africa were preferred, followed by in vitro sensitivity studies, 
followed by RCTs conducted elsewhere in the world. Large sample sizes were also desirable. 
An R value was then calculated for each from equation (1) and each drug was modelled in the 
same manner as chloroquine and sulfadoxine-pyrimethamine, using chloroquine as a 
comparator. 
Drugs and drug combinations modelled included amodiaquine, artesunate, artesunate-
mefloquine, atovaquone-proguanil, co-artemether, halofantrine, mefloquine and 
pyronaridine. Quinine combinations were also considered, but their cinchonistic side effects 
and long treatment courses were thought to make them unsuitable for first-line treatment in a 
rural African setting. 
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2.5.5. Assessing cost-effectiveness of alternative antimalarial drugs 
The average cost-effectiveness ratio (ACER) for drug i was assessed by means of equation 
(17). For chloroquine, the ACER will always be equal to 1.0. This will be true as long as an 
identical outcome-in this case patient cure-is obtained. 
Mean Total Cost per Patient of Baseline Drug (Chloroquine) ACER= 
Mean Total Cost per Patient of Modelled Drug 
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The drug and dosage cost data were related to the number of recrudescences detected among 
the study group by the follow-up personnel, in order to draw conclusions regarding the 
effectiveness of each drug. 
2.5.6. Treatment Costs Incurred by Patients 
2.5.6.1. Data Collection 
Mpumalanga Malaria Control Programme staff at the 24-hour clinics at Naas and Mangweni 
assisted patients with the completion of forms, in co-operation with clinic personnel, under 
the auspices of the in vivo sulfadoxine-pyrimethamine resistance study. 
2.5.6.2. Patient Information 
Patients were recruited according to the inclusion and exclusion criteria specified by the 
Mpumalanga Malaria Control Programme's protocol for the in vivo study of sulfadoxine-
pyrimethamine resistance in South Africa's malaria areas (la Grange et al, 1998). Each 
recruited malaria patient (or their legal guardian) was issued with a questionnaire designed 
to gather data regarding the patient's personal details and travel information. These data 
were used to assess the direct financial impact of malaria on patients. 
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2.5.6.3. On-site Evaluation of Data 
Diagnosis was carried out according to usual clinical procedure at the sentinel site, which was 
and is by means of a P. Jalcipantm imrnuno-chromatographic test (ICT), a method of high 
specificity and sensitivity (Diirrheim et al, 1998). This was the case for all patients enrolled in 
the in vivo study; notified patients included in the database before 1998, however, were 
detected by thick smear analysis at the Shongwe Hospital laboratory in the overwhelming 
majority of cases. 
2.5.6.4. Determination of Travel Costs per Kilometre 
Patient address information in the malaria notification databases assembled by the 
Mpurnalanga Department of Health and Welfare between 1991 and 1997 was retrieved and 
analysed by clinic to determine numbers of patients from each community visiting the clinics 
for antimalarial treatment. Mean distances travelled per patient were calculated using the 
resultant data on feeder areas for the clinics. 
Using questionnaires (Appendix B) filled out by clinic assistants during the course of the 
study, data was collected regarding the costs of travel to each of the 125 participants in the in 
vivo sulfadoxine-pyrimethamine study conducted by the Department of Health and Welfare. 
The patient group was broken down according to mode of travel (e.g. walking, hired vehicles, 
private vehicles). A mean travel cost per kilometre was calculated for the group. 
Finally, the mean cost of treatment per patient was calculated, comparing chloroquine and 
sulfadoxine-pyrimethamine as first-line treatments for malaria. 
2.5. 7. Statistical Design 
Since much of the work relied on the calculation of point estimates, normal statistical 
techniques did not apply. Instead, a rigorous sensitivity analysis was conducted, including a 
risk-based simulation of each drug (Briggs et al, 1994; Doubilet et al, 1985). A parametric 
approach was used to evaluate and compare those sections of the collected data for which 
orthodox analysis was possible. Nonparametric tests are not ideal in economic analysis; the 
relative values of each observation, and specifically a comparison of the mean values for each 
alternative, are of primary interest. This is necessary to compensate for patients consuming a 
disproportionate quantity of resources (Drummond et al, 1994). 
Probabilistic sensitivity analysis was conducted on each modelled drug, using the Monte 
Carlo simulation approach. The Monte Carlo simulation selects random values from a 
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specified distribution and records the modelled result for large numbers of hypothetical 
patients (Briggs et al, 1994). 
A risk analysis package was used as an alternative to the generation of point estimates. 
Instead of using a static R value, R was modelled using a normal distribution for estimating 
the number of returning patients (µ=0.7, cr=0.15). Further, R,v was similarly modelled using 
the same mean and standard deviation parameters. The simulation was run 1 000 times for 
each drug, generating a range of values for R and R,v along their respective (and separately 
modelled) distributions. This resulted in the generation of mean values for each cost category, 
along with standard deviations and variances. 
Individual resource items and effectiveness values are not independent. When analysing 
pharmacoeconomic data, statistical testing of differences in costs should be primarily 
focussed on the total costs of the alternatives being compared. The only exceptions to this rule 
are costs common to all regimens, those that exhibit no variation between patients (Coyle, 
1996). 
Testing for statistical significance of incremental cost per outcome should only be done if 
differences between both costs and outcomes are statistically significant (O'Brien & 
Drummond, 1994). 
Recently, suggestions have been made that confidence intervals should be used in preference 
to simple hypothesis testing in medical research, since the latter provides only a fundamental 
'yes/no' result where more detailed information on the imprecision of study estimates is 
desirable. The main focus in studies of this kind would hence be on precision of measurement 
rather than statistical significance. This is equally true in economic studies, in which the 
magnitude of differences between compared interventions is often more important than 
simply knowing that one intervention is more effective and/ or costly than another (Coyle, 
1996). 
2.5.8. Appropriateness of the Approaches Used 
2.5.8.1. Patient Information and Recruitment 
A narrow, highly focused approach was used throughout the areas of the study in which 
patient information was gathered. Only patients admitted to the Mpumalanga section of the 
study of in vivo sulfadoxine-pyrimethamine resistance were used, due to a number of reasons. 
The most important was the extreme shortage of clinical staff at the two sentinel clinics; extra 
clerical work required of the nursing staff was deemed an unacceptable burden by local 
district management. Additionally, there was considerable opposition to the idea of a second 
study from the clinical staff themselves, as it was perceived as a further disruption of their 
normal activities. However, the in vivo study was conducted with full district and staff 
cooperation, and therefore it is unlikely that personnel dissatisfaction was a source of bias. 
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Chapter 3 
BASELINE STUDY OF MALARIA 
IN THE NKOMAZI REGION OF 
MPUMALANGA 
3.1. 1991-1996 by Thick Smear 
The prevalence of malaria in South Africa increased dramatically between January 1991 and 
December 1996 (Fig. 1.2, p 3). All the smears collected for routine malaria diagnosis at clinics 
and Shongwe Hospital found to be positive for malaria were listed in laboratory records as 
Plasmodium falciparum infections. The seasonality of malaria in the Mpumalanga Lowveld 
region was confirmed, with peak transmission being found between December and April (see 
Figure 1 ). A substantial increase was found in positive smears in 1996, corresponding with 
the malaria epidemic experienced by the region in that year (personal communication, Dr D 
Diirrheim, Infectious Diseases Consultant for the Mpumalanga Department of Health). 
Thick smears found to be positive for malaria were categorised by site, and these results 
appear in Figure 2. Shongwe Hospital showed the largest proportion of positive smears, 
accounting for an annual mean of 57.69% ± 2.43%. The 24-hour clinics at Naas and 
Mangweni accounted for mean proportions of the annual total of 7.71 % ± 1.24% and 6.66% ± 
1.11 % respectively. Of the day clinics, Block B, Mbuzini, Steenbok, Sihlangu, Mzinti, and 
Block C showed the highest proportions of positive smears, ranging between 6.15% ± 1.39% at 
Block B to 1.03% ± 0.36% at Block C. All the other day clinics had less than 1 % of the mean 
annual total. 
1n terms of absolute numbers within the six-year period, Shongwe Hospital accounted for 
53.63% (2363 positive smears), Naas for 10.10% (445 positive smears), Steenbok for 7.74% (341 
positive smears), Mbuzini for 6.42% (283 positive smears), Mangweni for 6.22% (274 positive 
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Figure 3.1. Increase in number of malaria cases in the Shongwe and Tonga districts of Mpumalanga 
between January 1991 and December 1996, based upon blood smear records at the laboratory at 
Shongwe Hospital. 
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Figure 3.2. Mean frequency of positive malaria diagnoses at clinic level in the Shongwe and Tonga 
districts of Mpumalanga between 1991 and 1996. Radii of the red shaded areas represent proportion 
of malaria cases: the 24-hour clinics at Naas and Mangweni have the greatest number of new cases. 
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Figure 3.3. The distributions of (a) thick smears found to be positive for Plasmodium trophozoites, 
and (b) total numbers of thick smears submitted for analysis, including both positives and 
negatives. 
3.2. Positivity of Blood Smears 
The efficiency of the blood smear analysis technique was found to be low in most cases, as 
illustrated in Table 3.1. 
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Facility Total smears Total positives Proportion of malaria Mean positivity rate 
cases 
Shongwe nC117 2363 53.63% 11.21% 
Naas 5560 445 10.10% 8.00% 
Steenbok 5817 341 7.74% 5.86% 
Mbuzini 6162 283 6.42% 4.59% 
Mangweni 5777 274 6.22% 4.74% 
BlockB 5996 169 3.84% 282% 
Sihlangu 3425 84 1.91% 245% 
Mzinti 4065 59 1.34% 1.45% 
BlockC 3855 55 1.25% 1.43% 
Masiliekela 2060 54 1.23% 2.62% 
Fig-Tree 2872 48 1.09% 1.67% 
Phiva 1458 45 1 .02% 3.09% 
Mbangwane 168 42 0.95% 25.00% 
Mgobozi 4325 42 0.95% 0.97% 
Sikwahlane 1359 28 0.64% 2.06% 
Middelplaas 2550 22 0.50% 0.86% 
Sc:hoemansdal 2583 13 0.30% 0.50% 
Langeloop 2259 12 0.27% 0.53% 
I<amhlushwa 1406 11 0.25% 0.78% 
JeppesRust 4239 9 0.20% 0.21% 
Boschfontein 1096 5 0.11% 0.46% 
Driekoppies 1246 1 0.02% 0.08% 
JeppesReef 248 1 0.02% 0.40% 
Krombraai 24 0 0.00% 0.00% 
Makoko 24 0 0.00% 0.00% 
Mooiplaas 120 0 0.00% 0.00% 
Tjakastad 24 0 0.00% 0.00% 
Vlakplaas 144 0 0.00% 0.00% 
Total 89939 4406 100% 4.90% 
Total (without 68862 2043 46.37% 2.97% 
Shongwe) 
Table 3.1. Diagnosis of malaria by blood smear at primary health care facilities in the Shongwe and 
Tonga districts of Mpumalanga. These are the total number of thick smears analysed at the 
laboratory at Shongwe Hospital from January 1991 to December 1996. Data for October 1991, 
February 1994, April 1994 and January 1996 were not available and have been omitted from the 
analysis above. 
Year Months available Total smears Total positives Mean positivity 
1991 11 53878 534 0.991% 
1992 12 86280 324 0.376% 
1993 12 77635 156 0.201% 
1994 10 51985 106 0.204% 
1995 12 64101 130 0.203% 
1996 11 70957 389 0.548% 
Total 68 404836 1639 0.405% 
Table 3.2. Efficiency of the active surveillance programme in the Shongwe region of Mpumalanga, 
1991-1996. These data are basfd on thick smears evaluated at Shongwe Hospital during this period, 
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Figure 3.4. Positivity of thick smears obtained from Shongwe Hospital and the 24-hour clinics at 
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Figure 3.5. Positivity of thick smears analysed at Shongwe Hospital, under the auspices of the active 
surveillance programme, between January 1991 and December 1996. 
51 
3.3. The Malaria Notifications Databases 
Results obtained from searching the database for 1997 indicated that the use of clinic thick 
smear results as a measure of numbers of malaria cases was justified, as results fit within the 
standard deviations of the figures determined from the 1991-1996 data (fable 3). The primary 
exception to this is Shongwe Hospital, which accounted for 26.19% (642) of the 2451 
notifications recorded among the Tonga and Shongwe clinics in 1997, in contrast to the 
53.63% found for the thick smear approach used for evaluating 1991 to 1996. This is partially 
explained by the routine re-testing of hospital referrals at Shongwe, due to poor 
communication between the hospital and the referring clinic, as well as slow smear analysis 
at the laboratory (personal communication, Dr E Athan). 
Mbuzini Clinic was the largest single source of notifications in the subregion (after Shongwe 
Hospital) in 1997, with 22.36 % of the total (548 malaria cases). The day clinics at Steenbok and 
Mbangwane accounted for higher-than-average numbers of notifications, with 7.14% (175 
cases) and 7.06 % (173 cases) of the total, respectively. Malaria cases among the sites included 
amounted to 2451, which constituted 41.31 % of the absolute number of cases reported in 
Mpumalanga in 1997 (5933). However, of these, 23.68% (1405) database entries did not specify 
location of notification. Although this substantial dataset undoubtedly contains data 
belonging to the study group, it was necessary to omit it from analysis. 
c;? 
Facility Proportion of malaria Proportion of malari.> Difference in Standard Deviation 
cuea by blood smear, casea by notification proportion 
1991-1996 database, 1997 
Shongwe 53.63% 26.19% (27.44%) 19.40% 
BlockB 3.84% 2.12% (1.72%) 1.22% 
BlockC 1.25% 151% 026% 0.18% 
Boschfontcin 0.11% 0.04% (0.CY7%) 0.05% 
Driekoppies 0.02% 1.57% 1.55% 1 .10% 
Fig-Tree 1.09% 4.24% 3.15% 2.23% 
JeppesReef 0.02% 0.08% 0.06% 0.04% 
JeppesRust 0.20% 0.04% (0.16%) 0.11% 
Kamhlushwa 0.25% 0.04% (0.21 %) 0.15% 
Krombraai 0.00% 0.00% 
Langeloop 0.27% 0.29% 0.02% 0.01% 
Magudu 0.00% 0.12% 0.12% 0.08% 
Makoko 0.00% 0.00% 
Mangweni 6.22% 11.06% 4.84% 3.42% 
Masibek.ela 1.23% 4.08% 2.85% 2.02% 
Mbangwane 0.95% 7.06% 6.11% 4.32% 
Mbuzini 6.42% 22.36% 15.94% 11.27% 
Mgobodi 0.95% 0.41% (0.54%) 0.38% 
Middelplaas 0.50% 0.61% 0.11% 0.08% 
Mooiplaas 0.00% 0.00% 
Mzinti 1.34% 0.78% (0.56%) 0.40% 
Naas 10.10% 9.63% (0.47%) 0.33% 
Phiva 1.02% 0.20% (0.82%) 0.58% 
Schoemansdal 0.30% 0.33% 0.03% 0.02% 
Sihlangu 1.91% 0.86% (1.05%) 0.74% 
Sikwahlane 0.64% 0.20% (0.44%) 0.31% 
Steenbok 7.74% 7.14% (0.60%) 0.42% 
T)<lkastad 0.00% 0.00% N/A N/A 
Vlakplaas 0.00% 0.00% N/A N/A 
Total 100% 100% 
Total (withont 46.37% 73.81% 
Shongwe) 
Table 3.3. Comparison of malaria caseload proportions using (a) thick smears between 1991 and 1996 
and (b) using data retrieved from the 1997 malaria notifications database maintained by the 
Mpumalanga Department of Health and Welfare. 
3.4. Suitability of Sentinel Sites 
The day clinics at Mbuzini and Steenbok receive the highest numbers of malaria patients in 
relation to other clinics in the Shongwe and Tonga districts. Their malaria caseloads were 
compared with those of Naas and Mangweni to confirm the suitability of the latter 24-hour 
clinics as sentinel sites (Fig. 6). Total caseload for Mbuzini in 1997 was 3.91 % of total cases, 
which translates to 5.79% when adjusted for a 47.92% chloroquine resistance rate. Steenbok 
showed a corrected malaria caseload of 2.29% in 1997. 
In comparison, Naas and Mangweni Oinics showed corrected malaria caseloads of 0.78% and 
1.10% respectively. While Mbuzini and Steenbok both have higher percentages of malaria 
cases, they are open only 8 hours a day and lack the infrastructure for hosting studies of this 
magnitude. 
3.5. Demographics 
The Mpumalanga Department of Health and Welfare's malaria notifications database, 
covering January 1987 to December 1996, was searched for details regarding the ages and 
gender of malaria notifications. Notifications from the entire Nkomazi region of 
Mpumalanga were included, rather than the clinics considered in the analysis of thick smears, 
because notification site was only recorded from 1997. A smaller, separate analysis was made 







3.5.1. Malaria in the Nkomazi Region, 1987-1996 
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Figure 3.6. Mean ages of malaria patients in the districts of Nkomazi, Barberton, Nelspruit and 
White River. The analysis was split into tluee time segments, 1987-89, 1990-93, and 1994-96. 
The mean age of the 9 196 notified malaria patients in the Nkomazi district was significantly 
lower than mean age in other districts in the province (P < 0.0001) during the period 1987-
1996 (Fig 3.6). The overall mean for this ten-year period was 18.82 ± 0.16 years. Ages ranged 
between O and 101 years, and median age was 15 years. There was a significant increase in 
age of malaria patients between 1987 and 1996 (Fig 7); slope_was significantly different from 
zero (m=0.594 ± 0.166, P=0.0073) but was not linear (r2=0.614). 
4 811 (52.32%) of the notifications during this time were female, while 4 385 (47.68%) were 
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Figure 3.7. Change in mean age of malaria notifications in the Nkomazi region of Mpumalanga 
between 1987 and 1996. 
3.5.2. Malaria in the Shongwe and Tonga Districts, January 1997--
March 1998 
More than hall of the 3 303 usable malaria notifications in the Nkomazi region were under the 
age of 17 years (53.77%, 1 776 cases). 240 (7.27%) were younger than 3 years, while 69 (2.15%) 
were 65 or older. 
The mean age was 20.21 ± 0.27 years, the median age was 16, and all ages fell between O and 
95 years. The 1 414 unclassified cases had a mean age of 21 .41 ± 0.36 years, and ranged 
between O and 78 years. Male patients made up 50.20% of the Shongwe/Tonga group. 
Female patients accounted for 49.80%. 15 patients (0.45%) died. Virtually all the patients 
(3298, 99.85%) were African. 
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Figure 3.8. Breakdown of malaria notifications in the Nkomazi district by age, during the time 
period 1987-1996. 
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Figure 3.9. Differences in the distribution of malaria cases among age categories between 1987 and 
1996. The proportion of notifications in the under-17 group was generally higher from 1987 to 1992, 
but from 1993 to 1996 the proportion was approximately equal. There seems to be no transitional 
step between the two extremes. 
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Chapter 4 : Results 
DEVELOPMENT OF THE MODEL 
A model was developed to estimate the direct costs of first-line malaria treatment. At its core 
were the resistance variable, R, and the cost of the drug to the State. Other relevant costs, such 
as staff time, transport, maintenance, utilities and consumables were included, although R 
ultimately governed all to an extent. 
4.1. Derivation of the Resistance Variable (R) 
The resistance variable, R, describes the proportion of patients initially treated for malaria that 
return to the public health system for treatment if first line therapy fails . R is unique for every 
drug included in the study, and is a reflection of the effect resistance has on costs. It is defined 
as the product of PR, the in vivo prevalence of drug resistance, and Pp± 0.15, the proportion of 
patients not cured by the first line drug that return to a clinic for further treatment. Please note 
that after sections 4.1.1 and 4.1.2, R will be represented by 2 decimal places only; calculated 
figures in tables may therefore appear to be slightly inaccurate, due to the use of the full 4 
decimal places in spreadsheet calculations. 
R is expressed by equation (1), as derived in section 2.5.3.1. 
4.1.1. Chloroquine 
RcQ =0.4792x(0.7±0.15) 
RcQ = 0.3354 ± 0.0719 
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PR for chloroquine is 47.92%, extrapolated from data collected during the recent i11 vivo study 
of chloroquine resistance conducted in Mpumalanga by the Department of Health and 
Welfare and the SA Medical Research Council's National Malaria Control Programme. Pr is an 
estimate (70% ), considered appropriate by public health care professionals working in the 
district (personal communication, S Donahue, Shongwe Hospital). 
4.1.2. Sulfadoxine-pyrimethamine 
R sP = 0.0550 x (0. 7 ± 0.15) 
R.\·r = 0.0385 ± 0.0083 
PR for sulfadoxine-pyrimethamine is 5.50%, and represents the total proportion of RI, RII and 
RIIl1 patients participating in the 1998 in vivo study of sulfadoxine-pyrimethamine resistance 
in Mpumalanga (Govere et al, in press). 
4.2. Variable Costs 
4.2.1. Drug Costs 
4.2.1.1. Chloroquine 
Adult 
1.Sg over 3 days: 
• 600mg upon presentation 
• 300mg 6-8 hours later 
• 300mg after 24 hours 
• 300mg after 48 hours 
Paediatric 
25 mg/kg over 3 days: 
• 10 mg/kg upon presentation (up to maximum of 
600mg) 
• 5 mg/kg (up to 300mg) repeated 6, 24 and 48 hours 
after initial dose. 
Table 4.1. Chloroquine dosage regimen for the first-line treatment of malaria. 
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Category Total Dosage (mg) Cost per 150mg Tablet Total Cost per 
(ZAR) (December Treatment Course 
1997) (ZAR/US$) 
Adult >65 kg 1800 0.08 0.99/0.22 
Adult 1500 0.08 0.83/0.18 
Child 13-16 yrs 1050 0.08 0.58/0.13 
Child 10-12 yrs 750 0.08 0.41/0.09 
Child 4-9 yrs 600 0.08 0.33/0.07 
Child <4 yrs* 375 0.08 0.21/0.04 
Table 4.2. Cost per chloroquine treatment course. *Children under 4 years of age were assumed to 
have a mean weight of 15kg. Other figures are based upon district treatment protocols. Costs 
supplied by S Swanepoel, pharmacist at Shongwe Hospital. ZAR 1.00 was equivalent to a mean of 
US$ 0.217in 1997. 
Category Total Malaria Patients Cost per Treatment Total Cost of Category 
Treated at Naas Clinic Course (ZAR) (ZAR) 
in 1997 
Adult >65 1 0.99 0.99 
Adult17-65 108 0.83 89.21 
Child 13-16 51 0.58 29.49 
Child 10-12 32 0.41 13.22 
Child 4-9 39 0.33 12.89 
Child <4 5 0.21 1.03 
Total 236 146.82 
Table 4.3. Total 1997 projected cost of chloroquine at Naas Clinic. ZAR 1.00 = US$ 0.217. 
Category Total Malaria Patients Cost per Treatment Total Cost of Category 
Treated at Mangweni Course (ZAR) (ZAR) 
Clinic in 1997 
Adult >65 4 0.99 3.% 
Adult17-65 127 0.83 104.90 
Child 13-16 45 0.58 26.02 
Child 10-12 29 0.41 11.98 
1 RI, RII and RIii resistance categories were originally developed for use in the amino-4-quinolines, but 
they are commonly used by the South African Department of Health as indicators of resistance in other 
antimalarial drug families. 
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Child4-9 51 0.33 16.85 
Child <4 15 0.21 3.10 
Total 271 166.81 
Table 4.4. Total 1997 projected cost of chloroquine at Mangweni Clinic. ZAR 1.00 = US$ 0.217. 
4.2.1.2. Sulfadoxine-pyrimethamine 
Adult Paediatric 
1500mg sulfadoxine + 75mg pyrimethamine • < 1 yr: 125mg sulfadoxine + 6.25mg 
as a single dose* pyrimethamine single dose 
• 1-3 yrs: 250mg sulfadoxine + 12.5mg 
pyrimetharnine single dose 
• 4-8 yrs: 500mg sulfadoxine + 25mg 
pyrimethamine single dose 
• 9-14 yrs: 1000mg sulfadoxine + 50mg 
pyrimetharnine single dose 
Table 4.5. Sulfadoxine-pyrimethamine dosage regimen for the first-line treatment of malaria. 
•Doses have recently been revised to address underdosing issues; the doses above reflect these 
changes. 
Category Total Malaria Patients Cost per Treatment Total Cost of Category 
Treated at Naas Clinic Course (ZAR/US$) (ZAR) 
in 1997 
Adult >14 143 18.50/i02 2 645.50 
Child 9-14 56 12.33/2.68 690.67 
Child 4-8 32 6.17 /1 .34 197.33 
Child 1-3 3 3.08/0.67 9.25 
Child <1 2 1.54/0.33 3.08 
Total 236 3 545.83 
Table 4.6. Total 1997 projected cost of sulfadoxine-pyrimethamine at Naas Clinic. ZAR 1.00 = US$ 
0.217. 
61 
Category Total Malaria Patients Cost per Treatment Total Cost of Category 
Treated at Mangweni Course (ZAR) (ZAR) 
Clinic in 1997 
Adult >14 156 18.50 2886.00 
Child 9-14 58 12.33 715.33 
Child 4-8 42 6.17 259.00 
Child 1-3 14 3.08 43.17 
Child <1 1 1.54 1.54 
Total 271 3 903.04 
Table 4.7. Total 1997 projected cost of sulfadoxine-pyrimethamine at Mangweni Clinic. ZAR 1.00 = 
US$ 0.217. 
4.2.1.3. Quinine 
According to standard operating procedure in the public health system in the Shongwe and 
Tonga districts of Mpumalanga, patients who have not responded adequately to first-line 
drug therapy (typically, those who present a few days later and show no improvement) are 
referred to Shongwe Hospital. Once there, they are admitted, either to receive intravenous 
quinine treatment or to ensure compliance with oral quinine. The average length of a hospital 
stay was 3 days, and it was estimated that it was necessary to treat 70% of clinic-referred 
malaria patients with IV quinine for the duration of their stay (S Donahue, Shongwe Hospital). 
Loading dose: 
Maintenance dose: 
Adult & Paediatric 
Quinine dihydrochloride 20mg/kg by IV infusion, over 4 hours in 5% 
dextrose saline. No loading dose to . be given if patient has taken 
mefloquine, quinine or halofantrine in preceding 24 hours. It was 
assumed that this situation did not apply to any of the study patients. 
Quinine hydrochloride lOmg/kg by IV infusion, over 4 hours in 5% 
dextrose saline, starting 8 hours after loading dose and repeated 8 
hourly until patient is able to tolerate quinine administered orally. 
Table 4.8. Intravenous quinine dosage regimen for the treatment of severe and/or complicated 
malaria (Smith et al, 1997; White, 1996). 
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Adult 
Quinine sulphate 600mg 8-hourly for 7 days 
Paediatric 
Quinine sulphate 10mg/kg body weight 8-
hourly for 7 days 
Table 4.9. Oral quinine dosage regimen for the treatment of non-severe malaria resistant to first-
ine treatment (Smith et al, 1997). l 
Description 
Quinine sulphate IV, 300mg per 10ml 
ampoule 
Quinine dihydrochloride, 300mg per tablet 
Cost (ZAR, 1997) 
5.43 per ampoule (US$1.78) 
0.91 per tablet (US$ 0.20) 
Table 4.10. Quinine drug costs in 1997. (Prices observed at Shongwe Hospital pharmacy.) ZAR 1.00 
= US$ 0.217 in 1997. 
The weight of each malaria notification was estimated from the patient's age using NCHS 
Growth Charts (National Center for Health Statistics, 1976). Quinine dosage, and hence cost of 
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Figure 4.1. Typical decision tree for patients referred to Shongwe Hospital from clinics with 
resistant malaria. 70°/i, ± 15% of admitted referrals are sufficiently severe to warrant treatment with 
a 3 day course of intravenous quinine, whereas the remaining 30% ± 15% receive oral quinine and 
remain under observation for 3 days. Upon release, both IV and PO patients receive a prescription 
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Figure 4.2. Differences in cost of intravenous and oral quinine therapy, by age, in the Tonga 
District of Mpumalanga in 1997. Age/weight relationships are estimated from NCHS Growth 
Charts (National Center for Health Statistics, 1976). Differences in gender were factored into the 
calculations. ZAR 1.00 = US$ 0.217 in 1997. 
The formula for calculating first-line drug cost for each age group is represented by equation 3 
(p 33). Cumulative drug costs may be calculated by adding CostQ (equation (6), p 34) to Costoa, 
yielding Costa; for drug i. 
For example, a female patient aged 7 years would weigh 22kg, according to the NCHS charts. 
If the case were severe, an IV course would be used. A loading dose of IV quinine for this 
patient would cost 22 x 20 x R0.018, or R7.96. After the loading dose, using the default IV 
course over 3 days, 8 doses of 10 mg/kg would be administered, a total cost of 8 x 22 x 10 x 
R0.018, or R31 .44. After the 3 days of intravenous therapy, a further 4 days of oral therapy is 
administered: 12 x 22 x 10 x R0.003, or R7.94. Adding the loading dose, the remainder of the 
intravenous quinine course, and the oral quinine course, the total cost for this patient would 
beR47.34. 
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If she were admitted with mild, but resistant, malaria, she would be treated orally for 7 days: 
the cost would be 21 x 22 x 10 x R0.003, or R13.94. 
The cost of both IV and PO quinine therapy was calculated for each patient, and totalled for 
each clinic. The total was then divided by the number of malaria notifications at each clinic, to 
yield the cost-per-patient of IV and PO quinine therapy at Naas (R112.10 and R30.50, 
respectively) and Mangweni {R108.95 and R29.66, respectively). 
Chloroquine 
Clinic No.of R Est. Cost to treat with IV Cost to treat with PO 
patients no. of Quinine (ZAR) Quinine (ZAR) 
in 1997 referrals 
Per Adj. Per Adj. 
patient (Referrals patient (Referrals 
x0.7± x0.3± 
0.15) 0.15) 
Naas 236 0.3354± 79.15± 112.10 6 211 .25 ± 30.50 724.26± 
0.07188 16.96 2 947.37 594.% 
Total for Naas (IV+ PO) 6 935.51 ± 
3542.32 
Mangweni 271 0.3354± 90.89± 108.95 6931.99± 29.66 808.77± 
0.07188 19.48 3 289.37 664.38 
Total for Mangweni (IV+ PO) 7740.76± 
3953.75 
Table 4.11. Calculation of quinine costs per clinic, assuming first-line drug is chloroquine (R=0.3354 
± 0.07188). Quinine costs are dependent on the number of referred patients, hence the resistance 
variable R, and hence drug. ZAR 1.00 = US$ 0.217. 
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S ulf adoxi 11e-pyri nze tlzanz i ne 
Clinic No. of R Est. Cost to treat with IV Cost to treat with PO 
patients no.of Quinine (ZAR) Quinine (ZAR) 
in 1997 referrals 
Per Adj. Per Adj. 
patient (Referrals patient (Referrals 
x0.7± x0.3± 
0.15) 0.15) 
Naas 236 0.0385 ± 9.09± 112.10 712.98 ± 30.50 83.14± 
0.0083 1.96 339.43 68.45 
Total for Naas (IV+ PO) 796.12 
±407.88 
Mangweni 271 0.0385 ± 10.43± 108.95 795.71 ± 29.66 92.84 ± 
0.0083 2.25 378.81 76.44 
Total for Mangweni (IV + PO) 888.55 
±455.25 
Table 4.12. Calculation of quinine costs per clinic, assuming first-line drug is sulfadoxine-
pyrimethamine (R=0.0385 ± 0.0083). ZAR 1.00 = US$ 0.217. 
Summan; 
Study Clinic Chloroquine Cost (ZAR) Sulfadoxine-pyrimetharnine (ZAR) 
CQCost Quinine Total Cost SP Cost Quinine Total Cost 
(Clinic Cost (Clinic Cost 
Cost) (Hospital Cost) (Hospital 
Cost) Cost) 
Naas 145.79 6 935.51 ± 7081.30 ± 3 545.83 796.12 4341.95 ± 
3542.32 3542.32 ±407.88 407.88 
Mangweni 163.71 7740.76 ± 7 904.47 ± 3 903.04 888.55 4 791.59 ± 
3953.75 3953.75 ±455.25 455.25 
Table 4.13. Total projected 1997 drug costs for the treatment of patients originating at the study 
clinics. ZAR 1.00 = US$ 0.217. 
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Total Drugs Cost (Per Patient) of Malaria in 1997 Difference in Cost per 




Naas 30.01 ± 15.01 18.40± 1.73 11.61 ± 13.28 
Mangweni 28.56 ± 14.59 17.68 ± 1.68 11.49 ± 12.91 
Mean 29.29 ± 14.80 18.04 ±1.71 11.55 ± 13.10 
Table 4.14. Summary of drug costs of malaria cases originating at Naas (236 cases) and Mangweni 
(271 cases) Clinics in 1997, using chloroquine and sulfadoxine-pyrimethamine as first-line agents. 
ZAR 1.00 = US$ 0.217. 
Simulntio11 Results 
Clinic Total Drugs Cost (Per Patient) of Malaria in 1997 
(µ ±cr/ZAR) 
Chloroquine Sulfadoxine-Pyrimethamine 
Naas 31.12 ± 10.57 18.48 ±1.25 
Mangweni 29.96 ± 10.65 17.80±1.17 
Mean 30.54 ± 10.61 18.14±1.21 
Table 4.15. Results of the Monte Carlo simulation for drug costs. ZAR 1.00 = US$ 0.217. 
4.2.2. Clinical Staff Costs 
4.2.2.1. Clinical Staff Makeup and Salaries 
Naas Clinic 
Naas employs a total of 22 clinical employees, as detailed in Table 2, accounting for a total 
annual clinical staff cost (as at 1997) of R 1107191.40 (US$ 240 317.33). At present there is one 
vacant Emergency Care Practitioner post, which has been frozen. A more detailed description 
of these data is presented in Appendix 1. 
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Position Category Number of staff (Q;) Monthly wage or Annual fringe Total annual cost of 
salary (ZAR) (W;) benefits (ZAR) (FB;) position including 
benefits (ZAR) 
((Q; X [(T; X W;) + 
FB;))) 
Prof. nurse 11 3 709.50 17805.60 685515.60 
Staff nurse 1 2533.00 12158.40 42554.40 
Emerg. care 3 (1 vacan..:y) 2533.00 12158.40 127663.20 
practitioner 
Nursing assts 7 2138.55 10 263.60 251458.20 
Total 22 1107191.40 
Table 4.16. Total salaries and benefits paid to nursing staff at the clinic at Naas in 1997, as well as 
numbers of staff per job category. ZAR 1.00 = US$ 0.217. 
Mangweni Clinic 
Mangweni Clinic maintains a permanent clinical staff of 23, with no vacancies at present. 
Total clinical staff cost amounted to ZAR 1 149 745.80 (US$ 249 554.13) in 1997. A description 
of this information appears as Table 4.17, and a more detailed summary of the data is 
contained in Appendix 1. 
Position Category Number of staff (Q;) Monthly wage or Annual fringe Total annual cost of 
salary (ZAR) (W;) benefits (ZAR) (FB;) position including 
benefits (ZAR) 
((Q; X [(T; X W;) + 
FB;))) 
Prof. nurse 11 3 709.50 17 805.60 685515.60 
Staff nurse 1 2533.00 12158.40 42554.40 
Emerg. care 4 2533.00 12158.40 127 663.20 
practitioner 
Nursing assts 7 2138.55 10 263.60 251458.20 
Total 23 1149745.80 
Table 4.17. Total salaries and benefits paid to clinical staff at the clinic at Mangweni in 1997, as well 















Figure 4.3. Proportional breakdown of job types at Naas and Mangweni Clinics, as percentages of 
















Figure 4.4. Proportional breakdown of salaries by job type at Naas and Mangweni Clinics, 
assuming all posts are filled. ZAR 1.00 = US$ 0.217. 
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Shongwe Hospital 
The largest category of staff employed at Shongwe Hospital is nursing (278, 43.2% ), and a 
similar proportion of the annual staff cost at the hospital (ZAR 12 890 043.60, US$ 2 797 804.22, 
46.9%) is attributable to nurses. Descriptions of the other categories appear as Table 1, as well 
as Figure 4.5 and Figure 4.6. A detailed description of the staff and salary makeup of the 
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General & Domestic 
22.84% 
Figure 4.6. Proportional breakdown of salaries by job type at Shongwe Hospital. ZAR 1.00 = US$ 
0.217. 
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.Position Category Number of staff Monthly wage or Annual fringe Total annual cost 
(Q;) salary (ZAR) (W;) benefits (ZAR) of position 
(FB;) including benefits 
(ZAR) 
((Q; X [(T; X W;) + 
FB;])) 
Medical 19 3 374 232.24 
Nursing 278 12 890 043.60 
<( <( 
.:!$ X 
1265048.40 Suppl Health 34 -a :a 




747066.24 Primary Health 8 ] <l) 
Care ~ 
Total 644 18 276 390.48 
Table 4.18. Total salaries and benefits paid to clinical staff at Shongwe Hospital in 1997, as well as 
numbers of staff per category. Subcategories and details of wages and benefits appear in Appendix 
A. 
4.2.2.2. Calculation of costs 
Equations 7, 8 and 9 (pp 34-5) were used for the calculation of costs. 
Naas & Mangweni Clinics 
Since three categories of nursing staff are employed by the clinics - professional nurses, staff 
nurses and nursing assistants, all with differing salaries, with interchangeable duties -- it was 
necessary to calculate a mean salary. Average salary, including benefits, among the 19 staff 
belonging to these three categories was R51 544.12 (US$11187.73) per annum. Emergency care 
practitioners, although clinical staff, were omitted since malaria cases rarely, if ever, require 
this kind of attention, regardless of the severity of their condition. 
All malaria notifications originating at the clinic are assumed to have been consultations. The 
number of returning patients is estimated by R; each returning patient is assumed to need 
another consultation. Consultations for malaria by nursing staff at both clinics were observed 
to take an average of ten minutes, during which a brief history would be taken, and an ICT 
used for diagnosis. 
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Nursing staff work 40 hours a week, with 45 days' leave per annum, giving a total of 
109 371.43 minutes worked per annum. Therefore, the salary of an average nursing staff 
member would be R0.47 /min, or US$ 0.10/min (D Nkosi, Shongwe District Manager, 
Department of Health and Welfare, Mpumalanga). This figure makes provision for leave. 
Chloroquine 
Clinic Resistance Adjusted Time per Mean Total Clinical 
Variable Number of Consultation Salary per Clinical Staff Cost 
(1 + R) Malaria (Timeci) (min) Minute Staff Cost per Notified 
Patients (S,,;) (Castes;) Patient 
(11,,,; X (ZAR/min) (ZAR) (Costcs/11,,,;) 
(1 + R)) (ZAR) 
Naas 1.34 ±0.072 315.15 10 0.47 1485.25 ± 6.29±0.25 
79.95 
Mangweni 1.34±0.072 361.89 10 0.47 1705.52± 6.29±0.25 
91.80 
Table 4.19. Clinical staff costs at Naas & Mangweni Clinics for chloroquine in 1997. All posts were 
assumed to be filled. ZAR 1.00 = US$ 0.217. 
Sulfadoxine-pyrimethamine 
Clinic Resistance Adjusted Time per Mean Total Clinical 
Variable Number of Consultation Salary per Clinical Staff Cost 
(1 + R) Malaria (Timeci) (min) Minute Staff Cost per Notified 
Patients (S,,;) (Costcs;) Patient 
(1tmi X (ZAR/min) (ZAR) (Costcs/n,,.;) 
(1 + R)) (ZAR) 
Naas 1.04 ± 0.0083 245.09 ± 1.96 10 0.47 1155.03± 4.89±0.04 
9.23 
Mangweni 1.04 ± 0.0083 281.43 ± 2.25 10 0.47 1326.33 ± 4.89±0.04 
10.60 
Table 4.20. Clinical staff costs at Naas & Mangweni Clinics in 1997, assuming first-line therapy was 
sulfadoxine-pyrimethamine. All posts were assumed to be filled. ZAR 1.00 = US$ 0.217. 
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Slwngwe Hospital 
Referred patients at Shongwe Hospital would be seen by two types of clinical staff: nursing 
staff, at least once, who would attend to such matters as intravenous infusions, and medical 
staff, who would see them daily (during the routine ward round) . 
Mean annual salary including benefits for the 18 frontline medical staff was R170 534.46 (US$ 
37 014.77) per annum, including benefits. This included interns, specialist physicians, etc, all of 
whom were classified and paid as Medical Officers. The hospital superintendent was not 
included in the assessment of costs, because his position entailed no patient contact. Mean 
annual salary including benefits for the 278 nurses was R46 367.06 (US$ 10 064.04). The same 
shifts were assumed to apply. 
Medical staff worked an average of 50 hours per week with 45 days' leave per annum. 
Therefore, each staff member worked 137 250 minutes on site per annum, resulting in a total 
salary of Rl.24 (US$ 0.27) per minute. Medical and nursing staff time were the only cadres 
taken into account. 
Expert interviews were conducted with a number of health professionals at various malaria-
endemic sites around the country to assess the amount of staff tin1e spent on each of the two 
types of admitted patient. The results are summarised in Table 20 below. 
Type Medical Nursing 
Moderately severe (3 days of 5 minutes per 24 hours, 60 minutes per 24 hours (180 
oral quinine, followed by during ward round; 25 min total for 3 days) 
release) minutes on admission (45 
min total over 3 days) 
Severe and/ or complicated 25 minutes per 24 hours; 30 180 minutes per 24 hours (540 
minutes on admission (105 min total for 3 days) 
min total over 3 days) 
Table 4.21. Estimates of time spent daily by clinical staff on hospitalised malaria patients. 
(Compiled from expert interviews with Dr S Donohue, Shongwe Hospital, Mpumalanga; Dr H 
Born-Williams & K Dlamini, Mosveld Hospital, KwaZulu-Natal; Dr H Mcllleron, Department of 
Pharmacology, University of Cape Town.) 
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Chloroquine 
Clinic of Resistance Patients Patients Cost of Cost of Total Cost 
Origin Variable admitted admitted for Medical Nursing of Clinical 
(R) for IV Oral Quinine Staff Time Staff Time Staff Time 
Quinine {(1-Rrv) x (ZAR) (ZAR) (ZAR) 
(Rrv x R11,,,;) R11 ... ;) 
Naas 0.3354 ± 55.41 ± 19.51 23.75 ± 19.51 8 556.46 ± 16115.14 ± 24 671.60 ± 10 
0.07188 3 635.88 6 619.51 255.38 
Mangweni 0.3354 ± 63.63 ± 22.40 27.27 ± 22.40 9 825.43 ± 18 505.10 ± 28 330.50 ± 11 
0.07188 4175.09 7601.21 736.31 
Table 4.22. Estimated clinical staff costs at Shongwe Hospital for chloroquine in 1997. ZAR 1.00 = 
US$ 0.217. 
Sulfadoxine-pyrin1etha111ine 
Clinic of Resistance Patients Patients Cost of Cost of Total Cost 
Origin Variable admitted admitted for Medical Nursing of Clinical 
(R) for IV Oral Quinine Staff Time Staff Time Staff Time 
Quinine {(1-Rrv) x (ZAR) (ZAR) (ZAR) 
(Rrv x Ru,,.;) R11,,.;) 
Naas 0.0385 ± 6.36 ±2.25 2.73 ±2.25 982.18 ± 1849.43 ± 2832.01 ± 
0.0083 
419.84 764.36 1184.19 
Mangweni 0.0385 ± 7.30 ± 2.59 3.13 ± 2.59 1127.84± 2124.17± 3 25201 ± 
0.0083 
48210 877.71 1359.81 
Table 4.23. Clinical staff costs at Naas & Mangweni Clinics in 1997, assuming first-line therapy was 
sulfadoxine-pyrimethamine. ZAR 1.00 = US$ 0.217. 
Summan; 
Clinic Total Clinical Staff Cost (ZAR) 
Chloroquine Sulfadoxine-pyrimethamine 
Naas 26 156.85 ± 10 335.33 3 987.04 ± 1193.42 
Mangweni 30 036.04 ± 11 868.11 4 578.34 ± 1 370.41 
Table 4.24. Total clinical staff costs of malaria notifications originating at the study clinics. ZAR 
1.00 = US$ 0.217. 
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Total Clinical Staff Cost (Per Patient) of Difference in Cost 
Clinic Malaria in 1997 (ZAR) per Patient (ZAR) 
Chloroquine Sulfadoxine-
Pyrimethamine 
Naas 110.83 ± 43.79 16.89 ± 5.06 93.94 ± 38.74 
Mangweni 110.83 ± 43.79 16.89 ± 5.06 93.94 ± 38.74 
Mean 110.83 ± 43.79 16.89 ± 5.06 93.94 ± 38.74 
Table 4.25. Summary of clinical staff costs of malaria cases originating at Naas and Mangweni 
Clinics in 1997, using chloroquine and sulfadoxine-pyrimethamine as first-line agents. ZAR 1.00 = 
US$ 0.217. 
Si111ulatio11 Results 
Clinic Total Clinical Staff Cost (Per Patient) of Malaria in 1997 
(µ ± cr/ZAR) 
Chloroquine Sulfadoxine-Pyrimethamine 
Naas 112.09 ± 26.44 16.89 ± 3.19 
Mangweni 110.45 ± 27.19 16.92 ± 3.00 
Mean 111.27 ± 26.82 16.91 ± 3.10 
Table 4.26. Results of the Monte Carlo simulation for clinical staff costs. ZAR 1.00 = US$ 0.217. 
4.2.3. Consumables 
The consumables cost equation 10 (p 35) was used for the calculation of costs. 
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4.2.3.1. Naas & Mangweni Clinics (First-line treatment) 
Item Unit Cost 
(ZAR) 
ICT Malaria P.f. Kits 0.80* 






Non-Sterile Pairs of Gloves 0.17 
Total Consumables Cost per First-Line Malaria 1.08 (US$ 0.23) 
Test (C1) 
Table 4.27. The costs of consumables used in first-line malaria treatment at clinic level. .. Figure obtained from R+R Marketing, South African distributors for ICT. ZAR 1.00 = US$ 0.217. 
The malaria blood smear positivity rate at the Shongwe Hospital laboratory for Naas and 
Mangweni Clinics was used in the estimation of the number of patients tested for malaria at 
these sites in 1997. 
Clinic 1997 1991-1996 Estimated Total cost of Cost per 
Notifications Positivity Rate Malaria malaria Notified 
(Rp) Tests in 1997 testing in Patient in 
1997 (ZAR) 1997 (ZAR) 
Naas 236 7.45% 3168 3 405.60 14.43 
Mangweni 271 4.78% 5669 6094.18 22.49 
Table 4.28. Total consumables costs of malaria testing at Naas and Mangweni Clinics in 1997. ZAR 1.00 = US$ 0.217. 
4.2.3.2. Shongwe Hospital (referred patients) 
Referred patients make use of a much wider range of consumables at Shongwe Hospital, although this is dependent on the prevalence of resistance to the modelled drug. These items include IV kits, saline, glucose and dextrose drips, and other items of this type. A standard list 
of consumables used by a typical severe and/ or complicated case of malaria was prepared to assess costs. 
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Item Quantity (Q;) Unit Cost (P;) Total Cost (CM) 
(ZAR) (ZAR) 
IV Set 1 2.02 2.02 
Cannula needle 1 1.41 1.41 
Cannula tape (Webcol) 1 0.05 0.05 
Cotton swab (1g) 1 0.02 0.02 
Dextrose NaCl (500ml) 9 7.92 71.28 
Meals (3 per day) 3 days 30.19 90.57 
Total consumables cost per 3-day IV quinine course (CM) 165.35 (US$ 35.88) 
Table 4.29. Consumables cost per patient receiving a standard 3-day course of IV quinine at hospital 
level, based on observed consumables use in individual hospital malaria patients. Costs of meals 
implicitly included staff meals, since costs were calculated as a proportion of the hospital's annual 
meals budget. Laboratory costs were generally not incurred, and so have been omitted. ZAR 1.00 = 
US$ 0.217. 
4.2.3.3. Calculation of Consumables Costs 
Naas Clinic 
From equation 10 (p 35), assuming the use of chloroquine as first-line agent, we have: 
Coste = (3168 x 1.075)+ {(79. 15 ± 16.96) x [co.7 ± 0.15) x (74.774 + 1.075)]+ [(0.3 ± 0.15) x 1.075 ll 
:. Cost, = 7633.54 ± 1999. 72) 
where I!,,,; = 236, Rp= 0.0745, Ci = 1.075, Rll111; = 79.15 ± 16.96, R,v= 0.7 ± 0.15, and C1 v3 = 165.34. 
The estimated total cost of consumables used in the treatment of malaria cases originating at 
Naas Clinic, assuming use of chloroquine as first-line agent, was R12 651 .63 ± R4 380.90 (US$ 2 
745.40 ± US$ 950.66) in 1997. 
Substituting sulfadoxine-pyrimethamine for chloroquine (involving a change in the resistance 




Similarly, the cost of consumables used in the treatment of malaria cases originating at 
Mangweni Clinic for each of the two first-line antimalarials was calculated as: 
Drug Coste 
Chloroquine R16 712.20 ± RS 030.61 
(US$ 3 626.55 ± US$ 1 091.64) 
Sulfadoxine-pyrimethamine R7 313.43 ± R579.34 
(US$ 1587.01 ± US$125 .72) 
4.2.3.4. Summan; 
Clinic Total Consumables Cost (Per Notified Difference in Cost per 
Patient) of Malaria in 1997 (ZAR) Patient (ZAR) 
Chloroquine Sulfadoxine-
Pyrimethamine 
Naas 53.61 ± 18.56 18.93 ± 2.14 34.68 ± 16.42 
Mangweni 61.67 ± 18.56 26.99± 2.14 34.68 ± 16.42 
Mean 57.64 ± 18.56 22.96 ± 2.14 34.68 ± 16.42 
Table 4.30. Summary of consumable costs of malaria cases originating at Naas and Mangweni 
Clinics in 1997, using chloroquine and sulfadoxine-pyrimethamine as first-line agents. A mean 1997 
exchange rate of R4.6072 to the US dollar was used. 
Simulation Results 
Clinic Total Consumables Cost (Per Patient) of Malaria in 1997 
(µ±er/ZAR) 
Chloroquine Sulfadoxine-Pyrimethamine 
Naas 63.18 ± 11.20 19.96 ± 1.35 
Mangweni 70.62 ± 11.60 28.05 ± 1.28 
Mean 66.90 ± 11.40 24.01 ±1.32 
Table 4.31. Results of the Monte Carlo simulation for consumables costs. ZAR 1.00 = US$ 0.217. 
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4.2.4. Transport 
While Shongwe Hospital itself has no vehicles assigned to ambulance duty, two were 
borrowed from other facilities for this purpose: 
• a 1991 Isuzu KB pickup truck from Themba Hospital, valued at approximately R 21 000, 
with a fuel consumption of 10.7 litres per 100 km (estimated by Reeds Delta); and 
• a 1988 Toyota Hiace minibus from Ermelo Hospital, with a fuel consumption of 13.3 litres 
per 100 km (estimated by Market Toyota). 
The vehicles followed no set routine, but were dispatched to and from clinics as necessary. 
Both were no longer operational at the time of writing. The mean fuel price of 93% octane in 
1997 was R 2.20 per litre in Mpumalanga (personal communication, J Smalberger, Shell Cape 
Town). Distance covered by the vehicles was dependent on the number of malaria cases 
referred by the clinics, which was in turn dependent on the in vivo resistance of P. Jalcipantm to 
each particular drug. 
Clinic Number of Noof Combined Total Operating '"" ITRC, Vehicles patients road Kilometres Cost per i a: I 
(NV;) distance per Covered for Kilometre 
trip to clinic All Malaria (q (ZAR) 
Cases in 
1997 (KM;) 
Naas 2 79.15 ± 16.96 80.0 6332.35 ± 0.264 1671.74 ± 
1357.09 358.27 
Mangweni 2 90.89 ± 19.48 77.0 6998.79 ± 0.264 1847.68± 
1499.92 395.98 
Table 4.32. Transport costs of first-line malaria treatment with chloroquine at Naas and Mangweni 
Clinics. Operating cost per kilometre was taken as the mean of the two vehicles' fuel consumption 
(12.0 1 per 100 km). KM; was calculated by multiplying the estimated number of recrudescent 
patients from each clinic by the total distance that would have to be covered by a vehicle travelling 
from Shongwe Hospital to the clinic and back again. It was assumed that each vehicle handled 
exactly 50% of the load, and that each patient was conveyed separately. ZAR 1.00 = US$ 0.217. 
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Clinic Number of Noof Combined Total Operating ... Irnc, Vehicles patients road Kilometres Cost per l•I 
(NV;) distance per Covered for Kilometre 
trip to clinic Malaria (C;) (ZAR) 
Cases in 
1997 (KM;) 
Naas 2 9.09± 1.96 80.0 726.88 ± 0.264 191.90± 
156.70 41.37 
Mangweni 2 10.43 ± 2.25 77.0 803.38 ± 0.264 212.09± 
173.20 45.72 
Table 4.33. Transport costs of first-line malaria treatment with sulfadoxine-pyrimetharnine. 
Total Transport Cost (Per Patient) of Malaria in Difference in Cost per 
Clinic 1997 (ZAR) Patient (ZAR) 
Chloroquine Sulfadoxine-
Pyrimetharnine 
Naas 7.08 ± 1.52 0.81 ± 0.18 6.271 ± 1.343 
Mangweni 6.82±1.46 0.78 ±0.17 6.035 ± 1.292 
Mean 6.95 ±1.49 0.80 ± 0.18 6.153 ± 1.318 
Table 4.34. Summary of transport costs of malaria cases originating at Naas and Mangweni Clinics 
in 1997, using chloroquine and sulfadoxine-pyrimethamine as first-line agents. ZAR 1.00 = US$ 
0.217. 
Since distance from the hospital is an important determinant of costs, and varies from clinic to 
clinic, a distance ratio, R,1, was derived from the Naas and Mangweni patient data. 
Cost Tp = Rd x Dist; 
R,1 was calculated to be 0.0784, where CostT11 is the total transport cost per patient at a specific 
clinic, and Dist; is the road distance covered by a vehicle travelling from the hospital to the 
clinic and back again. 
This allows the difference in 1997 transport costs per patient to be calculated for any clinic 
within the district for a given drug. 
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Si11wlatio11 Results 
Clinic Total Transport Cost (Per Patient) of Malaria in 1997 
(µ ±er/ZAR) 
Chloroquine Sulfadoxine-Pyrimetharnine 
Per Patient Per Patient per Per Patient Per Patient per 
km km 
Naas 7.12± 1.52 8.90 X 10-2 ± 0.809 ± 0.181 1.01 X 10-2 ± 
1.90 X 10-2 2.27 X 10-3 
Mangweni 6.80 ± 1.53 8.83 X 10-2 ± 0.786 ± 0.170 1.02 X 10-2 ± 
1.99 X 10-2 2.21 X 10-3 
Mean 6.96 ±1.53 8.86 X 10-2 ± 0.798 ± 0.176 1.02x 10-2± 
1.95 X 10-2 2.24 X lQ-3 
Table 4.35. Results of the Monte Carlo simulation for transport costs. ZAR 1.00 = US$ 0.217. 
4.3. Fixed Costs 
4.3.1. In-service Training 
4.3.1.1. Calculation of Costs 
During 1997, one training session for clinicians and nurs_ing staff was held at Shongwe 
Hospital (in tandem with three others at Themba, Barberton and Rob Ferreira Hospitals). 
Another session was held for clinic nursing staff in the Tonga district (supplying training for 
staff at Mangweni and Naas Clinics, among others). Another clinic training session was held 
in the Shongwe district, but is not relevant to this study. Consumable costs were negligible. 
Staff attendance at the training session in Tonga was assumed to be 2 nurses per clinic, of 
which there are 11 in the district, for a total of 22 attendees (D Di.irrheim, Communicable 
Diseases Consultant for the Mpumalanga Department of Health and Welfare). Consumable 
costs in the form of petrol were calculated for 93% octane at an estimated fuel consumption of 
10 litres per 100 kilometres, at a mean 1997 fuel price of R 2.20 per litre O Smalberger, Shell 
Cape Town). Consumable costs were assessed only for the Communicable Diseases 
Consultant, who made the trip from Nelspruit to Tonga and back. The total distance covered 
was 246 kilometres. 
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The post of Communicable Diseases Consultant carried a 1997 remuneration package of 
R304611 .96 p.a. including benefits. The post of Communicable Disease Control Coordinator 
accounted for an annual salary of R 50 341.20 including benefits. (personal communication, R 
Raubenheimer, Personnel, Mpumalanga Department of Health and Welfare.) Other salary 
information is presented in Appendix A and sections 4.2.2 and 4.3.3. 
Some ad hoc malaria training was also given to clinical staff by doctors based at Shongwe 
Hospital, but since this training occurred during the completion of the normal duties assigned 
to the trainers and trainees, and no consumables were used, costs were assumed to be 
negligible. 
Equation 13 (p 38) was used in calculations. 
Position Noof Training Pro- Total Cost Con- Cost per Total 
Staff (Qr,) Days portion. per Type sumable Trainee Training 
{Dayn) {Rr,) (ZAR) Cost {Cn) per Day Cost {ITC,) 
(ZAR) {ZAR) 
Prof. nurse 2 1 1.00 121.87 0.00 121.87 243.74 
Communicable 1 1 0.09· 833.98 54.1r 40.37 80.74 
Diseases 
Consultant 





Table 4.36. Training costs for Naas and Mangweni Clinic staff in 1997. Both clinics contributed an 
equal number of staff (2) to the training sessions. ZAR 1.00 = US$ 0.217. 
• 2 staff from each of Naas and Mangweni Clinics, of 22 total attendees. 
•• Fuel costs, assessed as R 2.20/1, 246 km at a fuel consumption of 10 1 per 100 km. 
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Position No of Training Pro- Total Cost Con- Cost per Total 
Staff (Qr;) Days portion. per Type sumable Trainee Training 
(Dayn) (Rr;) (ZAR) Cost (Cn) per Day Cost(ITC1) 
(ZAR) (ZAR) 
Medical Officer 12 1 1.00 462.28 0.00 462.28 5547.36 
Nurse, Prof. 11 1 1.00 243.75 0.00 243.75 2681.25 
Nurse, Prof, Sen 1 1 1.00 303.62 0.00 303.62 303.62 
Staff Nurse 6 1 1.00 166.44 0.00 166.44 998.64 
Staff Nurse, Sen 2 1 1.00 196.90 0.00 196.90 393.80 
Communicable 1 1 1.00 833.98 39.71 27.30 873.69 
Diseases 
Consultant 




Table 4.37. Training costs for Shongwe Hospital staff in 1997. ZAR 1.00 = US$ 0.217. 
'It was estimated that 12 doctors (Medical Officers) and 20 nurses attended the Shongwe course (D 
Diirrheim). 20 nurses represent 13.61 % of the hospital's total nursing complement; this percentage 
was used to estimate the numbers of each nursing pay class attending the course. 
"Fuel costs, assessed as R 2.20/l, 190 km at a fuel consumption of 10 l per 100 km. 
4.3.1.2. Shongwe Hospital Training Costs: Proportion Attributable to 
the Study Clinics in 1997 
The proportion of in-service training costs at Shongwe Hospital applicable to patients 
presenting at the study clinics in 1997 was calculated using the ratios derived in Section 4.2.3 
('Proportion of Total Shongwe Admissions') . 
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Study Clinic Total Cost of In-Service Proportion of Total Total Cost of In-Service 
Malaria Training at Shongwe Malaria Training Attributable 
Shongwe in 1997 (ZAR) Cases (est 10354.13) to Clinic Patients 
(ZAR) 
Naas 11520.85 3.61 % 415.90 
Mangweni 11520.85 4.15% 478.12 
Table 4.38. In-service training costs at Shongwe Hospital attributable to study clinic patients. 
Assuming R=0.3354 ± 0.07188, the total number of patients referred to Shongwe Hospital by all the 
clinics within its feeder district was 2 191.84 ± 468.74. A total of 6 535 malaria cases were ntoified in 
the Nkomazi region, encompassing Shongwe and Tonga. ZAR 1.00 = US$ 0.217. 
The number of malaria referrals from each clinic is dependent on R, and the total number of 
hospital admissions for malaria received from all sources in the feeder region is also 
dependent on R. All sources with the hospital's feeder district are assumed to be using the 
same agent. By this reasoning, it follows that the proportion of study clinic referrals in relation 
to the hospital's total malaria admissions will remain constant, regardless of the first-line 
antimalarial agent. Therefore, costs for in-service training are constant and do not vary 
according to the choice of drug. 
It is assumed that each drug or combination requires equal training. 
4.3.1.3. Summan; 
Clinic Total In-Service Training Cost of Malaria in 1997 Difference in Cost per 
(ZAR) Patient (ZAR) 
Chloroquine Sulfadoxine-
Pyrimethamine 
Naas 3.24 3.24 0.00 
Mangweni 3.05 3.05 0.00 
Mean 3.15 3.15 0.00 
Table 4.39. Summary of in-service training costs of malaria cases originating at Naas and 
Mangweni Clinics in 1997, using chloroquine and sulfadoxine-pyrimethamine as first-line agents. 
The per-clinic staff costs (R349.54) have been added to referral costs in all of the above figures. ZAR 
1.00 = US$ 0.217. 
84 
4.3.2. Maintenance 
Total annual maintenance costs for each of the 24-hour clinics at Naas and Mangweni was 
estimated to be R4 000.00 by the Department of Health and Welfare (S Mabuza, Eerstehoek-
Carolina District, Mpumalanga). Total expenditure at Shongwe Hospital in this category in 
1997 was R88 378.67 (D Nkosi, Shongwe District). Costs were estimated by means of equation 
(13). 
Naas Cli11ic 
Drug Resistance Adjusted Adjusted Est. Proportion Shongwe Total 1997 
Adjustment Number of Maintenance Total ofTotal Main- Cost(ZAR) 
(R) Malaria Cost of Naas Shongwe tenance 
Patients Malaria in Malaria Admissions Cost of 
1997(ZAR) Referrals Referred 
in 1997 Malaria 
(ZAR) 
CQ 1.34± 315.15 ± 28.11 ± 1.51 79.15 ± 0.563% ± 497.55 ± 525.66 ± 
0.072 16.96 16.96 0.121 % 106.63 108.14 
SP 1.04± 245.09± 21.90±0.18 9.09± 0.065% ± 57.40± 79.30± 
0.008 1.96 1.96 0.014% 12.57 12.55 
Table 4.40. Total maintenance costs due to malaria at Naas Clinic in 1997, based upon a chloroquine 
resistance prevalence of 47.92%, a sulfadoxine-pyrimethamine resistance prevalence of 5.50% and a 
patient return rate of 70'Yo ± 15%. ZAR 1.00 = US$ 0.217. 
Mangweni Clinic 
Drug Resistance Adjusted Adjusted Est. Total Proportion Shongwe Total 1997 
Adjustment Number of Main- Naas ofTotal Main- Cost(ZAR) 
(R) Malaria tenance Malaria Shongwe tenance 
Patients Cost of Referrals in Admissions Cost of 
Malaria in 1997 Referred 
1997(ZAR) Malaria 
(ZAR) 
CQ 1.34± 361.89± 39.50 ± 90.89± 0.646% ± 570.92± 610.41 ± 
0.072 19.48 2.13 19.48 0.138% 122.35 124.48 
SP 1.04± 281.43 ± 30.78 ± 10.43 ± 0.075% ± 65.91 ± 96.70± 
0.008 2.25 0.25 2.25 0.016% 14.21 14.46 
Table 4.41. Total maintenance costs due to malaria at Mangweni Clinic in 1997, based upon an 
incidence of chloroquine resistance of 47.92%, a. sulfadoxine-pyrimethamine resistance prevalence 
of 5.50% and a patient return rate of 70% ± 15%. ZAR 1.00 = US$ 0.217. 
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Total Maintenance Cost (Per Patient) of Malaria Difference in Cost per 
Clinic in 1997 (ZAR) Patient (ZAR) 
Chloroquine Sulfadoxine-
Pyrimethamine 
Naas 2.23 ±0.46 0.34±0.05 1.89±0.41 
Mangweni 2.25 ±0.46 0.36± 0.05 1.90±0.41 
Mean Difference 2.24±0.46 0.35 ± 0.05 1.89±0.41 
Table 4.42. Summary of maintenance costs of malaria cases originating at Naas and Mangweni 
Clinics in 1997, comparing chloroquine and sulfadoxine-pyrimethamine as first-line agents. ZAR 
1.00 = US$ 0.217. 
Simulation Results 
Clinic Total Maintenance Cost (Per Patient) of Malaria in 1997 
(µ ± cr/ZAR) 
Chloroquine Sulfadoxine-Pyrimethamine 
Naas 2.24 ± 0.45 0.335 ± 0.055 
Mangweni 2.22±0.48 0.337 ± 0.054 
Mean 2.23±0.46 0.336 ± 0.054 
Table 4.43. Results of the Monte Carlo simulation for maintenance costs. ZAR 1.00 = US$ 0.217. 
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4.3.3. Administrative & Support Staff 
4.3.3.1. Administrative & Support Staff Makeup and Salaries 
Naas & Mangweni Clinics 
Position Category Number of staff per Monthly wage or Annual fringe Total annual cost of 
clinic (Q;) salary (ZAR) (W;) benefits (ZAR) (FB;) position including 
benefits (ZAR) 
((Q; X [(f; X W;) + 
FB;])) 
Admin. clerk 1 2138.55 10 263.60 35 922.60 
Cleaner 5 1583.50 7 600.80 13 3014.00 
Groundsman 1 1583.50 7 600.80 26602.80 
Total 7 195 539.40 
Table 4.44. Total salaries and benefits paid to support and administrative staff at each of the clinics 
at Naas and Mangweni in 1997, as well as numbers of staff per job description. ZAR 1.00 = US$ 
0.217. 
Slwngwe Hospital 
Position Category Number of staff (Q;) Monthly wage or Annual fringe Total annual cost of 
salary (ZAR) (W;) benefits (ZAR) (FB;) position including 
benefits (ZAR) 
((Q; X [(f; X W;) + 
FB;])) 
Admin 46 1859 827.20 
General & 230 <( <( 6 271 801 .20 
X X Domestic :a :a 
C: C: <lJ <lJ 
Maintenance 21 0.. 0.. 558 658.80 0.. 0.. <( -< 
Lab Services 8 Jl Jl 498 556.80 
Total 305 9188 844.00 
Table 4.45. Total salaries and benefits paid to administrative and support staff cadres at Shongwe 
Hospital in 1997, as well as numbers of staff per category. Subcategories and details of wages and 
benefits appear in Appendix A. ZAR 1.00 = US$ 0.217. 
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4.3.3.2. Proportion of Costs due to Malaria 
Naas Clinic 
Drug CQ Adjusted Adjusted Est. Total Proportion Shongwe Total 1997 
Resistance Number of Clinic Staff Naas ofTotal Staff Cost of Cost(ZAR) 
Adjustment Malaria Cost of Malaria Shongwe Referred 
(R) Patients Malaria in Referrals in Admissions Malaria 
1997(ZAR) 1997 (ZAR) 
CQ 1.3354± 315.15 ± 1374.39 ± 79.15 ± 0.563% ± 51730.72± 53105.11 ± 
0.07188 16.96 73.98 16.96 0.121% 11086.48 11160.45 
SP 1.0385 ± 245.09 ± 1070.50 ± 9.09± 1.96 0.065% ± 5 967.82±1 7038.32±1 
0.0083 1.96 8.56 0.014% 286.57 295.13 
Table 4.46. Total support and administrative staff costs due to malaria at Naas Clinic in 1997, based 
upon a chloroquine resistance prevalence of 47.92%, a sulfadoxine-pyrimethamine resistance 
prevalence of 5.50%, and a patient return rate of 70% ± 15%. ZAR 1.00 = US$ 0.217. 
Mangweni Clinic 
Drug CQ Adjusted Adjusted Est. Total Proportion Shongwe Total 1997 
Resistance Number of Clinic Staff Naas of Total Staff Cost of Cost(ZAR) 
Adjustment Malaria Cost of Malaria Shongwe Referred 
(R) Patients Malaria in Referrals in Admissions Malaria 
1997(ZAR) 1997 (ZAR) 
CQ 1.3354 ± 361.89 ± 1930.90 ± 90.89± 0.646% ± 59 358.78± 61 289.67± 
0.07188 19.48 103.93 19.48 0.138% 12 721.25 12 825.19 
SP 1.0385 ± 281.43 ± 1504.90± 10.43 ± 2.25 0.075% ± 6852.88± 8357.79± 
0.0083 2.25 12.03 0.016% 1477.37 1489.40 
Table 4.47. Total support and administrative staff costs due to malaria at Mangweni Clinic in 1997, 
based upon a chloroquine resistance prevalence of 47.92%, a sulfadoxine-pyrimethamine resistance 
prevalence of 5.50%, and a patient return rate of 70% ± 15%. ZAR 1.00 = US$ 0.217. 
Shongwe Hospital 
Staff costs related to malaria referrals from the two study clinics were relevant, and were thus 
calculated. 
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Adjustments for Chloroq11i11e Resista11ce: Chloroquine 
47.92% of the malaria cases detected at Naas and Mangweni, based upon the results of the in 
vivo study of chloroquine resistance in the region (summarized in Section 4.2), are assumed to 
have been resistant to chloroquine. Assuming that all recrudescent patients returned to the 
same clinic where they were treated, and were referred to Shongwe Hospital as per protocol, 
staff costs are adjusted accordingly by applying the R modifier (see Section 4.2.1). 
During the period January to December 1997, Shongwe Hospital recorded an estimated 13990 
admissions and 53 083 outpatient visits.' For the purposes of this study, only admissions 
arising from clinic referrals are considered. 
4.3.3.3. SummnnJ 
Total Staff Cost (Per Patient) of Malaria in 1997 Difference in Cost per 
Clinic (ZAR) Patient (ZAR) 
Chloroquine Sulfadoxine-
Pyrimethamine 
Naas 225.02 ± 47.29 29.82± 5.49 195.20 ± 41.80 
Mangweni 226.16 ± 47.33 30.84 ± 5.50 195.32 ± 41 .83 
Mean Difference 225.59 ± 47.31 30.33 ±5.49 195.26 ± 41.82 
Table 4.48. Summary of support & administrative staff costs of malaria cases originating at Naas 
and Mangweni Clinics in 1997, using chloroquine and sulfadoxine-pyrimethamine as first-line 
agents. ZAR 1.00 = US$ 0.217. 
• Owing to the permanent non-availability of the inpatient and outpatient totals for August 1997, the 
mean of the other 11 months was substituted as the total for that month in all calculations, including 
the determination of the year's total. Seasonal fluctuations were assumed to be insignificant. 
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Simulation Results 
Clinic Total Administrative & Support Staff Cost (Per Patient) of Malaria 
in 1997 (µ ± cr/ZAR) 
Chloroquine Sulfadmcine-Pyrimethamine 
Naas 226.04 ± 47.09 29.69±5.68 
Mangweni 224.09 ± 49.19 29.92±5.52 
Mean 225.07 ± 48.14 29.81 ±5.60 
Table 4.49. Results of the Monte Carlo simulation for administrative and support staff costs. ZAR 
1.00 = US$ 0.217. 
4.3.4. lltilities 
Naas & Mangwe11i 
Utility Mean Cost per month per clinic Cost per clinic per annum 
(ZAR) (ZAR) 
Electricity 1200.00 14400.00 
Postage 12.82 153.85 
Telephone 2000.00 24000.00 
Water Free Free 
Total 3212.82 38553.84 
Table 4.50. Mean utilities costs for each of the 24-hour clinics at Naas and Mangweni in the Tonga 
district (A Khoza, Administrative Officer, Tonga District). The costs are those for the 1997-1998 
financial year; since they are mean costs, they are assumed to be relevant for the 1997 calendar year 
also. ZAR 1.00 = US$ 0.217. 
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5/wngwe Hospital 
Utility 1997 Expenditure 
Electricity 418 954.06 
Postage 2000.00 
Telephone 235 813.25 
Water Free 
Total 656 767.31 
Table 4.51. Utilities costs for Shongwe Hospital in 1997 (figures courtesy of Shongwe District 
administration). ZAR 1.00 = US$ 0.217. 
4.3.4.1. Proportion of U tilihJ Costs due to Malaria 
Naas Clinic 
Drug CQ Adjusted Adjusted Est. Total Proportion Shongwe Total 1997 
Resistance Number of Clinic Staff Naas ofTotal Staff Cost of Cost(ZAR) 
Adjustment Malaria Cost of Malaria Shongwe Referred 
(R) Patients Malaria in Referrals in Admissions Malaria 
1997(ZAR) 1997 (ZAR) 
CQ 1.34±0.072 315.15 ± 270.98 ± 79.15 ± 0.563% ± 3 697.42± 3 968.41 ± 
16.96 14.59 16.96 0.121% 792.40 806.99 
SP 1.04 ±0.008 245.09± 211.07± 9.09± 1.96 0.065% ± 426.55 ± 637.61 ± 
1.96 1.69 0.014% 91.96 93.64 
Table 4.52. Total utility costs due to malaria at Naas Clinic in 1997, based upon a chloroquine 
resistance prevalence of 47.92%, a sulfadoxine-pyrimethamine resistance prevalence of 5.50%, and a 
patient return rate of 70'V., ± 15%. ZAR 1.00 = US$ 0.217. 
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Ma11gwe11i Clinic 
Drug CQ Adjusted Adjusted Est. Total Proportion Shongwe Total 1997 
Resistance Number of Clinic Staff Naas ofTotal Staff Cost of Cost (ZAR) 
Adjustment Malaria Cost of Malaria Shongwe Referred 
(R) Patients Malaria in Referrals in Admissions Malaria 
1997(ZAR) 1997 (ZAR) 
CQ 1.34± 361.89 ± 380.71 ± 90.89± 0.646% ± 4 242.63± 4623.34± 
0.072 19.48 20.49 19.48 0.138% 909.24 929.74 
SP 1.04± 281 .43 ± 296.72 ± 10.43 ± 0.075% ± 489.81 ± 786.52± 
0.008 2.25 2.37 2.25 0.016% 105.59 107.97 
Table 4.53. Total utility costs due to malaria at Mangweni Clinic in 1997, based upon a chloroquine 
resistance prevalence of 47.92%, a sulfadoxine-pyrimethamine resistance prevalence of 5.50%, and a 
patient return rate of 70% ± 15%. ZAR 1.00 = US$ 0.217. 
4.3.4.2. Summan; 
Total Utility Cost (Per Patient) of Malaria in 1997 Difference in Cost per 
Clinic (ZAR) Patient (ZAR) 
Chloroquine Sulfadoxine-
Pyrimethamine 
Naas 16.82±3.42 2.70 ±0.40 14.11±3.02 
Mangweni 17.06±3.43 2.90±0.40 14.16±3.03 
Mean Difference 16.94± 3.43 280±0.40 14.14±3.03 
Table 4.54. Summary of utility costs of malaria cases originating at Naas and Mangweni Clinics in 




Clinic Total Utility Cost (Per Patient) of Malaria in 1997 
(µ±er/ZAR) 
Chloroquine Sulfado,<lne-Pyrimethamine 
Naas 16.89 ± 3.41 2.69±0.41 
Mangweni 16.75 ± 3.56 2.71 ±0.40 
Mean 16.82±3.49 2.70±0.40 
Table 4.55. Results of the Monte Carlo simulation for utility costs. ZAR 1.00 = US$ 0.217. 
4.4. Summary 
4.4.1. Variable Costs 
Cost Category Costs Arising from Malaria Cases Presenting at the Study Clinics of Naas 
and Mangweni during 1997 
CQ SP Difference 
Drug Costs 29.29 ± 14.80 18.04 ± 1.71 11.55 ± 13.10 
Clinical Staff Costs 110.83 ± 43.79 16.89 ± 5.06 93.94 ± 38.74 
Consumables 36.38 ±8.47 20.52± 0.98 15.859 ± 7.498 
Transport 6.95 ±1.49 0.80 ±0.18 6.153 ± 1.318 
Total 183.45 ± 68.55 56.25 ±7.93 127.20 ± 60.62 
Table 4.56. Summary of differences in modelled variable costs per patient during 1997, when 
comparing chloroquine to sulfadoxine-pyrimethamine. ZAR 1.00 = US$ 0.217. 
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Cost Category Costs Arising from Malaria Cases Presenting at the Study Clinics of 
Naas and Mangweni during 1997 
CQ SP 
Drug Costs 30.54 ± 10.61 18.14 ± 1.21 
Clinical Staff Costs 111.27 ± 26.82 16.91 ±3.10 
Consumables 66.90 ± 11.40 24.01 ±1.32 
Transport 6.96±1.53 0.798 ± 0.176 
Total 215.67 ± 50.36 59.86±5.81 
Table 4.57. Summary of differences in modelled variable costs per patient during 1997, when 
comparing chloroquine to sulfadoxine-pyrimethamine. These data were a product of the Monte 
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Figure 4.7. Comparison of variable costs per notified patient involved when comparing chloroquine 
to sulfadoxine-pyrimethamine as first-line therapy for mild malaria. Use of sulfadoxine-
pyrimethamine results in a 72.24% ± 20.66% reduction in costs, a total of R155.81 ± R44.55 per 
notified patient. ZAR 1.00 = US$ 0.217. 
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Figure 4.8. Comparison of variable costs between CQ and SP regimen models. 
4.4.2. Fixed Costs 
Cost Category Costs Arising from Malaria Cases Presenting at the Study Clinics of Naas 
and Mangweni during 1997 
CQ SP Difference 
In-service Training 3.15 3.15 0.00 
Maintenance 2.24±0.46 0.35±0.05 1.89±0.41 
Administrative & 225.59 ± 47.31 30.33 ±5.49 195.26 ± 41.82 
Support Staff Time 
Utility Costs 16.94±3.43 280±0.40 14.14±3.03 
Total 247.92 ± 51.20 36.63±5.94 211.29 ± 45.26 
Table 4.58. Summary of differences in mean fixed costs per patient during 1997, when comparing 
chloroquine to sulfadoxine-pyrimethamine. ZAR 1.00 = US$ 0.217. 
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Cost Category Costs Arising from Malaria Cases Presenting at the Study Oinics of 
Naas and Mangweni during 1997 
CQ SP 
In-service Training 3.15 3.15 
Maintenance 2.23± 0.46 0.336 ± 0.054 
Administrative & Support Staff 225.07 ± 48.14 29.81 ±5.60 
Time 
Utility Costs 16.82±3.49 2.70±0.40 
Total 247.27 ± 52.09 36.00±6.05 
Table 4.59. Summary of differences in modelled fixed costs per patient during 1997, when 
comparing chloroquine to sulfadoxine-pyrimethamine. These data were a product of the Monte 
Carlo simulation process. ZAR 1.00 = US$ 0.217. 
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Figure 4.9. Comparison of fixed costs between CQ and SP regimen models. 
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Figure 4.10. Combination of variable and fixed costs produces a final result: the use of chloroquine 
as first line agent against malaria in the Tonga district in 1997 was estimated to cost the health care 
system R462.94 ± R102.45 per notified patient. Sulfadoxine-pyrimethamine, in comparison, cost 
R95.86 ± Rll.86 per notified patient, representing a saving of 79.29% ± 19.57% per notified patient. 
ZAR 1.00 = US$ 0.217. 
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4.4.4. Differences in Benefits Determined by Choice of First-line Drug 
Clinic Benefits 
Chloroquine Sulfadoxine-pyrimethamine 
Clinic Visits Hospital Clinic Visits Hospital 
Patient Days Patient Days 
Naas 79.15 ± 16.96 237.46 ± 50.89 9.09±1.96 27.26±5.88 
Mangweni 90.89 ± 19.48 272.68 ± 58.44 10.43±2.25 31.30± 6.75 
Table 4.60. Differences in benefits, as influenced by choice of first-line drug. Using SP as first-line 
therapy at the study clinics would result in an 88.S'Yo ± 21.5% mean drop in clinic visits and patient 
days at hospital level. 
4.4.5. Cost-effectiveness 





Table 4.61. ACERs of the study drugs, compared in terms of modelled fixed and variable costs. 
Drug Average Benefits Ratio 
Chloroquine 1.000 
Sulfadoxine-pyrimethamine 8.707 
Table 4.62. Average benefits ratios of the study drugs, comparing benefits in terms of clinic visits 
and hospital patient days saved. 
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Chapter 5: Results 
MODELLING OF ALTERNATIVE 
DRUGS 
Apart from sulfadoxine-pyrimethamine and chloroquine, several other antimalarial drugs are 
potentially suitable as first-line therapy for mild malaria. These include halofantrine, 
pyronaridine, mefloquine, artesunate, co-artemether and the atovaquone-proguanil 
combination. 
As before, the number of decimal places used in the presentation of R-values for the various 
drug models has been limited to two for the sake of clarity, although the full number was 
used in all calculations. 
5.1. Amodiaquine 
Recently, a case has been made for amodiaquine to be brought back into use as an 
antimalarial agent (White, 1996; Olliaro, 1996). 
A systematic review of amodiaquine treatment in uncomplicated malaria published by 
Olliaro et al in 1996 indicated that, by day 14 of treatment, 85.44% (657 of 769) of patients 
treated with amodiaquine showed parasitological success. The review covered a total of 15 
studies, 9 of which compared amodiaquine with chloroquine, and the remaining 6 of which 
compared amodiaquine with sulfadoxine-pyrimethamine. The overwhelming majority of 
studies were conducted in Africa. 
However, in results from the 4 studies that evaluated patients to day 28, all of which 
compared amodiaquine to sulfadoxine-pyrimethamine, the mean parasitological success rate 
fell to 63.21 %. 
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5.1.1. Derivation of R 
Using the review published by Olliaro et al, and applying the principles developed in Section 
5.2.1, R AM was derived as follows: 
RAM =0.3679x(0.7±0.15) 
RAM = 0.2575 ± 0.05519 
It was decided to use the 28-day parasitological failure rate of 36.79% as an estimate of 
resistance, bearing in mind the 76% resistance prevalence found in Mozambique (Schapira & 
Schwalbach, 1988). Freese et al found an in vitro resistance prevalence of 40% (2 of 5 isolates) 
to amodiaquine in P. falcipantm isolates collected in the then-Transvaal, now Northern 
Province and Mpumalanga (Freese et al, 1993). This lends credibility to the results found by 
the Olliaro review. 
5.1.2. Variable Costs 
5.1.2.1. Drug Costs 
Amodiaquine is not currently registered in South Africa . The export price for the Parke-Davis 
product is ca US$ 22.00, for a box of 500 200mg tablets (personal communication, P Olliaro). 
This, using a mean 1997 ZAR/US$ exchange rate of 4.6072 (Olsen & Associates, 
http:/ /www.oanda.com), gives us an estimated South African price of RlOl.36 per 500 
tablets. 
Dosage is 10 mg/kg once daily for 3 days. 
Estimation of Dntg Cost per Patient: Amodiaquine 
Drug dosages, and hence costs, for patients of different ages and gender were estimated by 
means of the National Center for Health Statistics data used in the estimation of quinine 
dosage (see Section 5.2.2.3). These data allowed weights to be inferred from ages. Weight 
allowed dose, and hence cost, to be estimated. 
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Clinic No. of Malaria Total AM Cost (ZAR) Mean AM cost per 
Notifications in 1997 Patient (ZAR) 
Naas 236 408.02 1.73 
Mangweni 271 455.28 1.68 
Mean 1.70 (US$ 0.37) 
Table 5.1. Modelled cost of amodiaquine first-line therapy at the study clinics in 1997. US$1.00 = 
ZAR4.6072. 
Estimation of Dnig Cost per Patient: Quinine 
Clinic No. of R Est. Cost to treat with IV Cost to treat with PO 
patients no. of Quinine (ZAR) Quinine (ZAR) 
in 1997 referrals 
Per Adj. Per Adj. 
patient (Referrals patient (Referrals x 
x0.7± 0.3 ± 0.15) 
0.15) 
Naas 236 0.26± 60.77 ± 112.10 4768.62± 30.50 556.05 ± 
0.06 13.02 2262.92 456.79 
Total for Naas (IV+ PO) 5324.67± 
2719.71 
Mangweni 271 0.26± 69.78 ± 108.95 5321 .96 ± 29.66 620.92± 
0.06 14.96 2525.50 510.09 
Total for Mangweni (IV + PO) 5942.97± 
3035.59 
Table 5.2. Calculation of quinine costs per clinic, assuming first-line drug is amodiaquine (R=0.26 ± 
0.06). US$1.00 = ZAR 4.6072. 
Summan; 
Study Clinic Amodiaquine Cost (ZAR) 
AM Cost Quinine Cost Total Cost 
Naas 408.02 5 324.67 ± 2 719.71 5 732.69 ± 2 719.71 
Mangweni 455.28 5 942.97 ± 3 035.59 6 398.17 ± 3 035.59 
Table 5.3. Total projected 1997 drug costs for the treatment of patients originating at the study clinics; 
amodiaquine is used as study drug. US$1.00 = ZAR 4.6072. 
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Total Drugs Cost (Per Patient) of Malaria in 1997 (Amodiaquine) (ZAR) 
Clinic 
Point Estimate Monte Carlo Simulation 
Naas 24.29 ± 11.52 25.61 ± 8.47 
Mangweni 23.61 ± 11.20 24.86 ± 8.29 
Mean 23.95 ± 11.36 25.24 ± 8.38 
Table 5.4. Summary of drug costs of malaria cases originating at Naas (236 cases) and Mangweni (271 
cases) Clink:. in 1997, using chloroquine and amodiaquine as first-line agents. US$1.00 = ZAR 4.6072. 
5.1.2.2. Clinical Staff Costs 
Clinical staff costs were assessed according to the model developed in section 4.2.2.2. 
Clinic Total Clinical Staff Cost (Per Patient) of Malaria in 1997 (Amodiaquine) 
(ZAR) 
Point Estimate Simulation 
Naas 86.19 ± 33.63 86.62 ± 20.11 
Mangweni 86.19 ± 33.63 86.13 ± 21 .02 
Mean 86.19 ± 33.63 86.38 ± 20.57 
Table 5.5. Summary of clinical staff costs of malaria cases originating at Naas and Mangweni Clinics 
in 1997, using amodiaquine as first-line agent. US$1.00 = ZAR 4.6072. 
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5.1.2.3. Consumables 
R is the only factor to change in the estimation of Coste in amodiaquine. Otherwise, costs are 
calculated as in section 4.2.3. 
Clinic Total Consumables Cost of Malaria in 1997 (Amodiaquine) (ZAR) 
Point Estimate Monte Carlo Simulation 
Naas 44.51 ± 14.25 51.72 ± 8.62 
Mangweni 52.57 ± 14.25 59.61 ± 8.98 
Mean 48.54 ± 14.25 55.67 ± 8.80 
Table 5.6. Summary of consumable costs of malaria cases originating at Naas and Mangweni Clinics 
in 1997, using chloroquine and amodiaquine as first-line agents. US$1.00 = ZAR 4.6072. 
5.1.2.4. Transport 
Since the equation for transport costs is a product, Cosh may be estimated for amodiaquine 
simply by substituting R. Where CostrcQ is the transport cost for chloroquine and CostrAM is 
the transport cost for amodiaquine, we have 
CostrcQ is R1671 .74 ± R358.27 at Naas Clinic, RcQ=0.3354 ± 0.07188, and RAM=0.2575 ± 0.05519. 
Therefore, CostrAM for Naas is Rl 283.46 ± R275.08 (US$ 278.51 ± US$ 59.69). 
Similarly, CostrAM for Mangweni Clinic was estimated to be Rl 418.54 ± R304.04 (US$ 307.82 ± 
US$ 65.98). 
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Clinic Total Per-Patient Transport Costs of Malaria in 1997, using Amodiaquine 
(ZAR/km) 
Point Estimate Monte Carlo Simulation 
Per Patient Per Patient per Per Patient Per Patient per 
km km 
Naas 5.44 ± 1.17 6.80 X lQ-2 5.48 ± 1.20 6.84 X 10-2 
± 1.46 X 10-2 ± 1.50 X 10-2 
Mangweni 5.23 ± 1.29 7.81 X lQ-2 5.26 ± 1.19 6.83 X lQ-2 
± 1.67 X lQ-2 ± 1.55 X lQ-2 
Mean 5.34 ± 1.23 7.30 X 10-2 5.37 ± 1.20 6.84 X 10-2 
± 1.57 X 10-2 ± 1.53 X 10-2 
Table 5.7. Summary of transport costs of malaria cases originating at Naas and Mangweni Clinics in 
1997, using chloroquine and amodiaquine as first-line agents. US$1.00 = ZAR 4.6072. 
5.1.3. Fixed Costs 
In-service training and capital are not affected by the choice of first-line drug, and are 
therefore not reflected as separate sections . In-service training, however, appears in the 
summaries for completeness. The point estimates for each category were calculated similarly 
to those in Section 4.3. 
5.1.3.1 . Administrative & Support Staff 
Clinic Per-Patient Staff Time Cost of Malaria in 1997 (Amodiaquine) (ZAR) 
Point Estimate Monte Carlo Simulation 
Naas 173.99 ± 36.36 175.11 ± 37.36 
Mangweni 175.13 ± 36.39 174.68 ± 38.40 
Mean 174.56 ± 36.37 174.90 ± 37.88 
Table 5.8. Summary of administrative & support staff costs of malaria cases originating at Naas and 
Mangweni Clinics in 1997, using amodiaquine as first-line agent. US$1.00 = ZAR 4.6072. 
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5.1.3 .2. Maintenance 
Total Maintenance Cost (Per Patient) of Malaria in 1997 (Amodiaquine) 
Clinic (ZAR) 
Point Estimate Monte Carlo Simulation 
Naas 1.73 ± 0.35 1.74 ± 0.362 
Mangweni 1.76 ± 0.35 1.74 ± 0.372 
Mean Difference 1.75 ± 0.35 1.74 ± 0.367 
Table 5.9. Summary of maintenance costs of malaria cases originating at Naas and Mangweni Clinics 
in 1997, comparing chloroquine and amodiaquine as first-line agents. US$1.00 = ZAR 4.6072. 
5.1.3.3. Utilities 
Clinic Per-Patient Utility Cost of Malaria in 1997 (Amodiaquine) 
(ZAR) 
Point Estimate Monte Carlo Simulation 
Naas 13.13 ± 2.63 13.21 ± 2.70 
Mangweni 13.36 ± 2.64 13.18 ± 2.78 
Mean 13.24 ± 2.63 13.20 ± 2.74 
Table 5.10. Summary of utility costs of malaria cases originating at Naas and Mangweni Clinics in 
1997, using chloroquine and amodiaquine as first-line agents. US$1.00 = ZAR 4.6072. 
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5.1.4. Total Costs for Amodiaquine 
5.1.4.1. Variable Costs 
Category of Cost Naas (Per Patient) Mangweni (Per Patient) (ZAR) 
(ZAR) 
Point Estimate Monte Carlo Point Estimate Monte Carlo 
Simulation Simulation 
Drug Costs 24.29 ± 11.52 25.61 ± 8.47 23.61 ± 11.20 24.86 ± 8.29 
Clinical Staff Costs 86.19 ± 33.63 86.62 ± 20.11 86.19 ± 33.63 86.13 ± 21 .02 
Consumables Costs 44.51 ± 14.25 51.72 ± 8.62 52.57 ± 14.25 59.61 ± 8.98 
Transport Costs 5.44 ± 1.17 5.48 ± 1.20 5.23 ± 1.29 5.26 ± 1.19 
Total 160.43 ± 60.57 169.43 ± 38.40 167.60 ± 60.37 175.86 ± 39.48 
Table 5.11. Summary of variable costs at Naas and Mangweni Clinics in the event of amodiaquine 
being adopted as first-line therapy. US$1.00 = ZAR 4.6072. 
5.1.4.2. Fixed Costs 
Category of Cost Naas (Per Patient) Mangweni (Per Patient) (ZAR) 
(ZAR) 
Point Estimate Monte Carlo Point Estimate Monte Carlo 
Simulation Simulation 
In-service Training 3.24 3.24* 3.05 3.05* 
Maintenance 1.73 ± 0.35 1.74 ± 0.362 1.76 ± 0.35 1.74 ± 0.372 
Administrative & Support Staff 173.99 ± 36.36 175.11 ± 37.36 175.13 ± 36.39 174.68 ± 38.40 
Costs 
Utility Costs 13.13 ± 2.63 13.21 ± 2.70 13.36 ± 2.64 13.18 ± 2.78 
Total 192.09 ± 39.34 193.30 ± 40.42 193.30 ± 39.38 192.65 ± 41.55 
Table 5.12. Summary of fixed costs at Naas and Mangweni Clinics in the event of amodiaquine being 
adopted as first-line therapy. US$1.00 = ZAR 4.6072. *Not modelled. 
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5.1.4.3 . Cost-effectiveness 
Clinic Total Combined Fixed and ACER 
Variable Cost per Patient 
Naas 362.73 ± 78.82 1.267 
(US$ 78.71 ± US$17.10) 
Mangweni 368.51 ± 81.03 1.266 
(US$ 79.97 ± US$ 17.58) 
Mean 365.62 ± 79.93 1.266 
(US$ 79.34 ± US$ 17.34) 
Table 5.13. The cost-effectiveness of amodiaquine at the study clinics in 1997, compared with 
chloroquine. A mean total cost per notified patient of R462.94 ± R102.45 (US$100.46 ± US$ 22.23) was 
used for the chloroquine, the baseline. (ACER: average cost-effectiveness ratio.) US$1.00 = ZAR 
4.6072. 
5.2. Arternether-benflurnetol (Co-arternether) 
Two trials in children in Sub-Saharan Africa showed resistance to CGP 56697 in P. falciparum . 
A 15-day cure rate of 93.3% was recorded in The Gambia (van Seidlein et al, 1998), and in 
Kilombero, Tanzania, a 14-day cure rate of 86.4% was recorded (Hatz et al, 1998). 
5.2.1. Derivation of R 
Co-artemether has been in use for only a very short time, and has been tested by clinical trial 
in Sub-Saharan Africa and Southeast Asia, with mixed results. For the derivation of R, it was 
decided to use the cure rate of 93.3% reported by van Seidlein et al in the Gambia in 1998. The 
only other useful study, published in Tanzania, reports a higher level of resistance, but South 
Africa has not used artemisinin derivatives for the treatment of malaria, and so resistance in 
vivo is thought to be lower. 
R AB =0.067x(0.7±0.15) 
R AB = 0.0469 ± 0.01005 
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5.2.2. Variable Costs 
5.2.2.1. Drug Costs 
For the purposes of this study, the 6-dose schedule used by Looareesuwan et al in 1998 was 
modelled: an adult course was composed of a total of 480mg artemether combined with 
2880mg benflumetol, or 6.86 mg/kg artemether plus 41 .14 mg/kg benflumetol (assuming a 
mean adult weight of 70 kg). 
The cost of a package of 16 tablets of Riamet from Novartis is 58.80 Swiss francs, which 
translates to R186.91 (at a mean 1997 exchange rate of 0.3146 Rands to the Swiss franc). A 
pack of 24 tablets costs 78.75 CHF, or R250.33 in mean 1997 Rands. (Exchange rates obtained 
from the website of Olsen & Associates, http:/ /www.oanda.com.) Therefore, an adult course 
of 24 tablets (each containing 20mg artemether and 120mg benflumetol) would cost R250.33 
(US$ 54.32). 
Estimation of Dntg Cost per Patient: Artemether-benjlumetol 
Clinic No. of Malaria Total AB Cost (ZAR) Mean AP cost per 
Notifications in 1997 Patient (ZAR) 
Naas 236 44162.52 187.13 
Mangweni 271 49 276.76 208.80 
Mean 197.96 (US$ 42.96) 
Table 5.14. Modelled cost of artemether-benflumetol first-line therapy at the study clinics in 1997. 
US$1.00 = ZAR 4.6072. 
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Estimation of Drug Cost per Patient: Q11ini11e 
Clinic No. of R Est. Cost to treat with IV Cost to treat with PO 
patient no. of Quinine (ZAR) Quinine (ZAR) 
sin referrals 
1997 
Per Adj. Per Adj. 
• ' L pa,1en, (Referrals patient (Referrals x 
x0.7± 0.3 ± 0.15) 
0.15) 
Naas 236 0.05± 11.07 ± 112.10 868.54 ± 30.50 101.28 ± 
0.01 2.37 412.11 83.19 
Total for Naas (IV+ PO) 969.81 ± 
495.30 
Mangweni 271 0.05± 12.71 ± 108.95 969.32 ± 29.66 113.09 ± 
0.01 2.72 459.93 92.90 
Total for Mangweni (IV + PO) 1082.41 ± 
552.83 
Table 5.15. Calculation of quinine costs per clinic, assuming first-line drug is artemther-benflumetol 
(R=0.0469 ± 0.01005). US$1.00 = ZAR 4.6072. 
Sum man; 
Study Clinic Co-artemether Cost (ZAR) 
AB Cost Quinine Cost Total Cost 
Naas 44162.52 969.81 ± 495.30 45 132.33 ± 495.30 
Mangweni 49 276.76 1 082.41 ± 552.83 50 359.17 ± 552.83 
Table 5.16. Total projected 1997 drug costs for the treatment of patients originating at the study 
clinics; a comparison of chloroquine and co-artemether. US$1.00 = ZAR 4.6072. 
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Total Drugs Cost (Per Patient) of Malaria in 1997 
Clinic (Co-artemether) (ZAR) 
Point Estimate Monte Carlo Simulation 
Naas 191.24 ± 2.10 191.38 ± 1.49 
Mangweni 185.83 ± 2.04 185.95 ± 1.41 
Mean 188.53 ± 2.07 188.67 ± 1.45 
Table 5.17. Summary of drug costs of malaria cases originating at Naas (236 cases) and Mangweni 
(271 cases) Clinics in 1997, comparing chloroquine and co-artemether as first-line agents. US$1.00 = 
ZAR4.6072. 
5.2.2.2. Clinical Staff Costs 
Total Clinical Staff Cost (Per Patient) of Malaria in 1997 
Clinic (Co-artemether) (ZAR) 
Point Estimate Monte Carlo Simulation 
Naas 19.55±6.12 19.57 ± 3.68 
Mangweni 19.55 ± 6.12 19.48 ± 3.59 
Mean 19.55 ± 6.12 19.53 ± 3.64 
Table 5.18. Summary of clinical staff costs of malaria cases originating at Naas and Mangweni 
Clinics in 1997, comparing chloroquine and co-artemether as first-line agents. US$1.00 = ZAR 4.6072. 
5.2.2.3. Consumables 
Clinic Total Consumables Cost per ·Patient of Malaria in 1997 
(Co-artemether) (ZAR) 
Point Estimate Monte Carlo Simulation 
Naas 19.91 ± 2.60 21.19 ± 1.56 
Mangweni 27.97 ± 2.60 29.22± 1.53 
Mean Difference 23.94 ± 2.60 25.21 ± 1.55 
Table 5.19. Summary of consumable costs of malaria cases originating at Naas and Mangweni 
Clinics in 1997, using co-artemether as first-line agent. US$1.00 = ZAR 4.6072. 
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5.2.2.4. Transport 
CostrcQ is Rl 671.74 ± R358.27 at Naas Clinic, RcQ=0.34 ± 0.072, and RAs=0.05 ± 0.01. Therefore, 
CostrHF for Naas is R233.76 ± R50.09 (US$ 50.73 ± US$10.87). 
Similarly, CostrHF for Mangweni Clinic was estimated to be R258.37 ± R55.36 (US$ 56.07 ± US$ 
12.01). 
Clinic Total Per-Patient Transport Costs of Malaria in 1997 
(Co-artemether) (ZAR/km) 
Point Estimate Monte Carlo Simulation 
Per Patient Per Patient per Per Patient Per Patient per 
km km 
Naas 0.99 ± 0.21 1.24 X lQ-2 0.993 ± 0.214 1.24 X lQ-2 
± 2.65 X lQ-3 ± 2.67 X lQ-3 
Mangweni 0.95 ± 0.23 1.24 X 10-2 0.953 ± 0.204 1.24 X 10-2 
± 3.05 X lQ-3 ± 2.66 X 10-3 
Mean 0.97 ± 0.22 1.24 X 10-2 0.973 ± 0.209 1.24 X lQ-2 
± 2.85 X lQ-3 ± 2.66 X 10-3 
Table 5.20. Summary of transport costs of malaria cases originating at Naas and Mangweni Clinics in 
1997, modelling co-artemether as first-line agent. US$1.00 = ZAR 4.6072. 
5.2.3. Fixed Costs 
5.2.3.1. Maintenance 
Total Maintenance Cost (Per Patient) of Malaria in 1997 
Clinic (Co-artemether) (ZAR) 
Point Estimate Monte Carlo Simulation 
Naas 0.39 ± 0.06 0.390 ± 6.47 X 10-2 
Mangweni 0.41 ± 0.07 0.390 ± 6.44 X lQ-2 
Mean Difference 0.40 ± 0.06 0.390 ± 6.46 X lQ-2 
Table 5.21. Summary of maintenance costs of malaria cases originating at Naas and Mangweni 
Clinics in 1997, modelling co-artemether as first-line agent. US$1.00 = ZAR 4.6072. 
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5.2.3.2. Administrrztiz,e & Support Staff Costs 
Clinic Per-Patient Administrative & Support Staff Cost of Malaria in 1997 (Co-
artemether) (ZAR) 
Point Estimate Monte Carlo Simulation 
Naas 35.37 ± 6.64 35.44 ± 6.68 
Mangweni 36.40 ± 6.65 35.37 ± 6.64 
Mean 35.88 ± 6.65 35.41 ± 6.66 
Table 5.22. Summary of administrative & support staff costs of malaria cases originating at Naas and 
Mangweni Clinics in 1997, comparing chloroquine and co-artemether as first-line agents. US$1.00 = 
ZAR4.6072. 
5.2.3.3. Utilities 
Clinic Per-Patient Utility Cost of Malaria in 1997 
(Co-artemether) (ZAR) 
Point Estimate Monte Carlo Simulation 
Naas 3.10 ± 0.48 3.11 ± 0.483 
Mangweni 3.31 ± 0.48 3.10 ± 0.480 
Mean 3.20 ± 0.48 3.11 ± 0.482 
Table 5.23. Summary of utility costs of malaria cases originating at Naas and Mangweni Clinics in 
1997, comparing chloroquine, artesunate and artesunate-mefloquine as first-line agents. US$1.00 = 
ZAR4.6072. 
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5.2.4. Total Costs for Co-artemether 
5.2.4.1. Variable Costs 
Category of Cost Naas (Per Patient) Mangweni (Per Patient) 
(ZAR) (ZAR) 
Point Estimate Monte Carlo Point Estimate Monte Carlo 
Simulation Simulation 
Drug Costs 191 .24 ± 2.10 191 .38 ± 1.49 185.83 ± 2.04 185.95 ± 1.41 
Clinical Staff Costs 19.55 ± 6.12 19.57 ± 3.68 19.55 ± 6.12 19.48 ± 3.59 
Consumables Costs 19.91 ± 2.60 21 .19 ± 1.56 27.97 ± 2.60 29.22 ± 1.53 
Transport Costs 0.99 ± 0.21 0.993 ± 0.214 0.95 ± 0.23 0.953 ± 0.204 
Total 228.71 ± 9.61 233.13 ± 6.94 234.30 ± 10.99 235.60 ± 6.73 
Table 5.24. Summary of variable costs at Naas and Mangweni Clinics in the event of co-artemether 
being adopted as first-line therapy. US$1.00 = ZAR 4.6072. 
5.2.4.2 . Fixed Costs 
Category of Cost Naas (Per Patient) Mangweni (Per Patient) 
(ZAR) (ZAR) 
Point Estimate Monte Carlo Point Estimate Monte Carlo 
Simulation Simulation 
In-service Training 3.24 3.24* 3.05 3.05* 
Maintenance 0.39 ± 0.06 0.390 ± 0.41 ± 0.07 0.390 ± 
6.47 X 10-2 6.44 X 10-2 
Administrative & Support Staff 35.37 ± 6.64 35.44 ± 6.68 36.40 ± 6.65 35.37 ± 6.64 
Costs 
Utility Costs 3.10 ± 0.48 3.11 ± 0.483 3.31 ± 0.48 3.10 ± 0.480 
Total 42.10 ± 7.18 42.18 ± 7.23 43.17 ± 7.20 41.91 ± 7.18 
Table 5.25. Summary of fixed costs at Naas and Mangweni Clinics in the event of co-artemether 
being adopted as first-line therapy. US$1.00 = ZAR 4.6072. *Not simulated. 
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5.2.4.3. Cost-effectiveness 
Clinic Total Combined Fixed and ACER 
Variable Cost per Patient 
Naas 275.31 ± 13.79 1.669 
Mangweni 277.51 ± 13.54 1.680 
Mean 276.41 ± 27.33 1.675 
(US$ 59.98 ± US$ 5.93) 
Table 5.26. The cost-effectiveness of co-artemether at the study clinics in 1997, compared with 
chloroquine. A mean total cost per notified patient of R462.94 ± R102.45 (US$100.46 ± US$ 22.23) was 
used for the chloroquine, the baseline. US$1.00 = ZAR 4.6072. 
5.3. Artesunate and Combinations 
Three variations on artesunate treatment were examined: artesunate monotherapy, artesunate 
in combination with mefloquine, and artesunate in combination with sulfadoxine-
pyrimethamine. 
5.3.1. Derivation of R 
Artesunate has been in almost constant use in Southeast Asia since the early 90s, with very 
little resistance thus far apparent. Resistance has been induced in vitro, but no reports of 
clinical resistance have appeared (WHO, 1998). Gay et al reported a single case of resistance to 
qinghaosu in West Africa in 1994. Furthermore, artesunate's gametocytocidal action may 
decrease incidence. 
Considering the total absence of drug pressure in sub-Saharan Africa in general and South 
Africa in particular, and the non-emergence of resistance in areas of high drug pressure at the 
time of writing, R was taken to be zero in both mono- and combined therapy. 
Furthermore, since there is no variation in R and R,v is irrelevant, no risk analysis could be 
done. 
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5.3.2. Variable Costs 
5.3.2.1. Drug Costs 
Artesunate is not yet registered in South Africa, but is sold in Thailand at US$ 3.60 per 12 
250mg tablets. This translates (at a mean 1997 US$/ZAR exchange rate of 4.6072) to R16.59 
per 12 250mg tablets. Information supplied by the WHO suggests that the drug will be made 
available to Africa at 75¢ US (personal communication, M Gomes), but in the light of the 
Thailand experience, it was decided to use Thai prices as a guide. 
Mefloquine is registered for malaria prophylaxis only. It is marketed as Lariam by Roche at 
R128.66 (US$ 27.92) per 8 250mg tablets. Costs of neuropsychiatric side effects incurred due to 
the use of mefloquine were not evaluated, though some risk of these is expected. 
Artesunate monotherapy Artesunate-mefloquine 
4 mg/kg in a divided loading dose on day 1, • 4 mg/kg artesunate daily for 3 days; 
followed by 2 mg/kg daily for 6 days • 15-25 mg mefloquine base/kg as 
single/ split dose on day 2 or 3 
Artesunate-SP 
Adult Paediatric 
• 4 mg/kg artesunate daily for 3 days; • 4 mg/kg artesunate daily for 3 days; 
• 1500mg sulfadoxine + 75mg S11lfadxoine-pyrimethamine: 
pyrimethamine as a single dose • < 1 yr: 125mg sulfadoxine + 6.25mg 
pyrimethamine single dose 
• 1-3 yrs: 250mg sulfadoxine + 12.5mg 
pyrimethamine single dose 
• 4-8 yrs: 500mg sulfadoxine + 25mg 
pyrimethamine single dose 
• 9-14 yrs: 1000mg sulfadoxine + 50mg 
pyrimethamine single dose 
Table 5.27. WHO recommended dosing schedule for artesunate and combinations. 
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Estimation of Drug Cost per Patient: Arteszmate 
Drug dosages, and hence costs, for patients of different ages and gender were estimated by 
means of the National Center for Health Statistics data used in the estimation of quinine 
dosage (see Section 5.2.2.3). 
Clinic No. of Total Mean Total As- Mean As- Total As- Mean As-
Malaria Arte- Arte- Mef Cost Mef cost SP Cost SP cost 
Notifi- sunate sunate (ZAR) per (ZAR) per 
cations in Cost cost per Patient Patient 
1997 (ZAR) Patient (ZAR) (ZAR) 
(ZAR) 
Naas 236 1 092.46 4.63 12443.65 52.73 4 612.80 19.55 
Mangweni 271 1 218.97 4.50 13 841.95 51.08 5 093.57 18.80 
Mean 4.56 51.90 19.17 
(US$ 0.99) (US$11.26) (US$ 4.16) 
Table 5.28. Modelled cost of artesunate and artesunate-mefloquine first-line therapy at the study 
clinics in 1997. For mefloquine costs, a dose of 15 mg base/kg was used. US$1.00 = ZAR 4.6072. 






Total Drugs Cost (Per Patient) of Malaria in 1997 
(Artesunate and combinations) (ZAR) 
Artesunate Artesunate-mefloq uine Artesunate-SP 
4.63 52.73 19.55 
4.50 51.08 18.80 
4.56 (US$ 0.99) 51.90 (US$ 11.26) 19.17 (US$ 4.16) 
Table 5.29. Summary of drug costs of malaria cases originating at Naas (236 cases) and Mangweni 
(271 cases) Clinics in 1997, modelling artesunate, artesunate-mefloquine and artesunate-SP as first-
line agents. US$1.00 = ZAR 4.6072. 
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5.3.2.2. Clinical Staff Costs 
Since R=O, no referrals are required, and therefore no hospital staff costs are incurred. 
Clinic Resistance Adjusted Time per Mean Total Clinical 
variable Number of Consultation Salary per Clinical Staff Cost 
(1 + R) Malaria (Time,;) Minute Staff Cost per 
Patients (min) (S,,;) (CostCSi) Notified 
(11 111 ; X (ZAR/min) (ZAR) Patient 
(1 + R)) (Costcs/n,,,;) 
(ZAR) 
Naas 1.0 236 10 0.471 1112.21 4.71 
Mangweni 1.0 271 10 0.471 1277.16 4.71 
Table 5.30. Clinical staff costs at Naas & Mangweni Clinics, assuming R=O.O, and using 




Total Per-Patient Consumables Cost of Malaria in 1997 





Table 5.31. Summary of consumable costs of malaria cases originating at Naas and Mangweni 
Clinics in 1997, using artesunate and artesunate combinations as first-line agents. US$1.00 = ZAR 
4.6072. 
5.3.2.4. Transport 
Costr may be estimated by the simple substitution of R. However, if R is zero, Costr is also 









Total Maintenance Cost (Per Patient) of Malaria in 1997 
(Artesunate and combinations) (ZAR) 
Point Estimate 
8.94 X 10·2 
0.109 
9.94 X 10-2 
Table 5.32. Summary of maintenance costs of malaria cases originating at Naas and Mangweni 






Support & Administrative Stnff Costs 
Per-Patient Staff Time Cost of Malaria in 1997 





Table 5 .33. Summary of administrative & support staff costs of malaria cases originating at Naas and 
gweni Clinics in 1997, using chloroquine and artesunate/artesunate-mefloquine as first-line 










Per-Patient Utility Cost of Malaria in 1997 





Table 5.34. Summary of utility costs of malaria cases originating at Naas and Mangweni Clinics in 
1997, comparing chloroquine, artesunate and artesunate-mefloquine as first-line agents. US$1.00 = 
ZAR4.6072. 
5.3.4. Total Costs for Artesunate and Artesunate Combinations 
5.3.4.1. Variable Costs 
Category of Cost Naas (ZAR) Mangweni (ZAR) 
As As-Me£ As-SP As As-Me£ As-SP 
Drug Costs 4.63 52.73 19.55 4.50 51.08 18.80 
Clinical Staff Costs 3.65 3.65 3.65 3.65 3.65 3.65 
Consumables Costs 14.43 14.43 14.43 22.49 22.49 22.49 
Transport Costs 0.00 0.00 0.00 0.00 0.00 0.00 
Total 22.71 70.81 37.63 30.64 77.22 44.94 
Table 5.35. Summary of variable costs of artesunate alone and artesunate in combination with 
mefloquine and SP when used as first-line malaria treatment. US$1.00 = ZAR 4.6072. 
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5.3.4.2. Fixed Costs 
Category of Cost Naas (ZAR) Mangweni (ZAR) 
As As-Me£ As-SP As As-Me£ As-SP 
In-service Training 3.24 3.24 3.24 3.05 3.05 3.05 
Maintenance 8.94 X 10~ G.94 X 10 2 8.94 X 10·2 0.109 0.109 0.109 
Administrative & 4.37 4.37 4.37 5.35 5.35 5.35 
Support Staff Costs 
Utility Costs 0.86 0.86 0.86 1.05 1.05 1.05 
Total 8.56 8.56 8.56 9.56 9.56 9.56 
Table 5.36. Summary of fixed costs of artesunate alone and artesunate in combination with 
mefloquine when used as first-line malaria treatment. US$1.00 = ZAR 4.6072. 
5.3.4.3. Cost-effectiveness 
Clinic Total Combined Fixed and Variable ACER 
Cost per Patient 
As As-Me£ As-SP As As-Mef As-SP 
Naas 31 .27 79.37 46.19 14.70 5.790 9.948 
Mangweni 40.20 86.78 54.50 -11 .60 5.374 8.557 
Mean 35.74 83.08 50.35 12.95 5.572 9.194 
(US$ 7.76) (US$18.03) (US$10.93) 
Table 5.37. The cost-effectiveness of artesunate monotherapy and combinations at the study clinics in 
1997, compared with chloroquine. A mean total cost per notified patient of R462.94 ± R102.45 was 
used for the chloroquine, the baseline. US$1.00 = ZAR 4.6072. 
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5.3.4.4. Cost-effectiveness with Resistance and Increasing Drug Costs 
Adjustment Mean Total Combined Fixed and ACER 
Variable Cost per Patient (ZAR) 
As As-Mef As-SP As As-Mef As-SP 
Cdx2 40.76 89.03 55.26 11.36 5.200 8.377 
PR=5% 81.34 ± 7.00 128.52 ± 96.02± 7.37 5.691 3.602 4.821 
7.20 
PR=5%, Cd x2 85.33 ± 7.18 134.01 ± 99.90 ± 7.27 5.425 3.455 4.634 
7.08 
PR=10% 125.43 ± 173.48 ± 140.81 ± 3.691 2.669 3.288 
14.22 14.59 14.49 
PR=10%, Cd x2 131.39± 179.32 ± 144.92 ± 3.523 2.582 3.194 
13.72 14.19 14.08 
Table 5.38. The effect of increasing resistance and drug cost on the ACER for artesunate and its 











Effect of Changing Resistance and Drug Cost on the Cost-Effectiveness of 




-----------------~ 5% Resistance+ Drug Costx2 
•10% Resistance 
• 10% Resistance+ Drug Costx2 
As As-SP As-Mef 
Drug or Combination 
Figure 5.1. Increases in i1l vivo resistance levels have a profound effect on the cost-effectiveness of 
artesunate and its combinations. The effect of alterations of artesunate costs are less marked. 
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5.4. Atovaquone-proguanil 
Radloff et al conducted a study in Lambarene, Gabon in 1996 to test the efficacy of a novel 
combination of atovaquone and proguanil. 142 adult patients were randomly allocated either 
1000mg atovaquone plus 400mg proguanil daily for 3 days, or amodiaquine 600mg on 
admission, 600mg at 24 hours, and 600mg at 48 hours. 126 of those patients were followed up 
until 28 days or recrudescence. Of 71 patients in the atovaquone-proguanil group, 62 (87.32%) 
were cured by day 28. Only 1 (1.41 %) cf the group recrudesced . However, 33% of the group 
complained of nausea, and 29% of vomiting. In contrast, the amodiaquine group showed a 
71.83% cure rate (51 of 71 patients). The authors concluded that the atovaquone-proguanil 
combination was a safe, highly effective antimalarial therapy in Gabon. 
A product monograph published by Glaxo Wellcome (Scott, 1998) claimed an overall efficacy 
of 99%, but this describes the results of trials conducted in South America, the Philippines, 
Southeast Asia, South America and Europe as well as Africa. The Lambarene estimate of 
87.32% is considered more valuable in the African context. 
5.4.1. Derivation of R 
The Gabon study carried out by Radloff et al in 1996 was chosen as the best indicator of 
resistance in sub-Saharan Africa. Their findings indicated an atovaquone-proguanil resistance 
prevalence of 12.676% in the region. Since very little work on atovaquone-proguanil has been 
done anywhere in the world, this was taken to be a fair estimate of resistance throughout the 
sub-continent. 
Applying the principles developed in Section 5.2.1, RAr was derived as follows: 
R AP =0.1268x(0.7±0.15) 
R AP = 0.08876±0.01902 
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5.4.2. Variable Costs 
5.4.2.1. Drug Costs 
Assuming that the drugs would be made available to the Department of Health and Welfare 
at retail prices, atovaquone would be available as Wellvone (Glaxo Wellcome, R2 348.86 per 
189 250mg tablets), and proguanil as Paludrine (Zeneca, R49.09 per 100 100mg tablets). If the 
combination were to be made available as Malarone (Glaxo Wellcome), the cost would be UK 
£21 .00 per adult course (Medical Advisor for Infectious Diseases, Glaxo Wellcome South 
Africa). Using a mean 1997 UK Pound/South African Rand exchange rate of 7.550 (Olsen & 
Associates, http:/ /www.oanda.com), this translates to R158.54 (US$ 34.40) per adult 
treatment course. 
It was decided to base the estimation of costs on a Wellvone-Paludrine combination rather 
than Malarone, since the latter's price was only fixed very recently, and was estimated to be 
roughly equivalent in any event. 
Adult 
1000mg atovaquone + 400mg proguanil, one 
dose daily for 3 days 
Paediatric 
+ ll-20kg: 250mg AQ + 100mg PG 
+ 21-30kg: 500mg AQ + 200mg PG 
+ 31-40kg: 750mg AQ + 300mg PG 
+ 41kg and over: 1000mg AQ + 400mg PG 
Table 5.39. Dosing for atovaquone-proguanil (Lell et al, 1998; Radloff et al, 1996). 
Estimation of Dntg Cost per Patient: Atovaquone-proguanil 
Drug dosages, and hence costs, for patients of different ages and gender were estimated by 
means of the National Center for Health Statistics data used in the estimation of quinine 
dosage (see Section 5.2.2.3). 
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Male Female 
Age (yrs) Est. Est. AP Est. Cost Age (yrs) Est. Est. AP Est. Cost 
Weight Dose (mg per Weight Dose (mg per 
(kg) AQ/mg Course (kg) AQ/mg Course 
PG) (1997 PG) (1997 
ZAR) ZAR) 
1-5 11-20 250/100 38.76 1-6 11-20 250/100 38.76 
6-9 21-30 500/200 77.51 7-9 21-30 500/200 77.51 
10-12 31-40 750/300 116.27 10-11 31-40 750/300 116.27 
13+ 41+ 1000/400 155.02 12+ 41+ 1000/400 155.02 
Table 5.40. Age/weight/dosage/cost relationships for paediatric treatment of malaria with 
atovaquone-proguanil. Atovaquone and proguanil costs are based upon December 1997 tender 





No. of Malaria 
Notifications in 1997 
236 
271 
Total AP Cost (ZAR) 
31508.78 
34648.04 




130.49 (US$ 28.32) 
Table 5.41. Modelled cost of atovaquone-proguanil first-line therapy at the study clinics in 1997. 
US$1.00 = ZAR 4.6072. 
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Esti111ntio11 of Drug Cost per Pntie11t: Quinine 
Clinic No. of R Est. Cost to treat with IV Cost to treat with PO 
patient no. of Quinine (ZAR) Quinine (ZAR) 
sin referrals 
1997 
Per Adj. Per Adj. 
patient (Referrals patient (Referrals x 
x0.7± 0.3 ± 0.15) 
0.15) 
Naas 236 0.08876 ± 20.95 ± 112.10 1643.74 ± 30.50 191.69 ± 
0.01902 4.49 779.94 157.44 
Total for Naas (IV+ PO) 1835.41 ± 
937.38 
Mangweni 271 0.08876 ± 24.05 ± 108.95 1834.48 ± 29.66 214.03 ± 
0.01902 5.15 175.81 175.81 
Total for Mangweni (IV+ PO) 2048.51 ± 
1046.25 
Table 5.42. Calculation of quinine costs per clinic, assuming first-line drug is atovaquone-proguanil 
(R=0.08876 ± 0.01902). US$1.00 = ZAR 4.6072. 
Sum111nn; 
Study Clinic Atovaquone-proguanil Cost (ZAR) 
AP Cost Quinine Cost Total Cost 
Naas 31508.78 1 835.41 ± 937.38 33 344.19 ± 937.38 
Mangweni 34 648.04 2 048.51 ± 1 046.25 36 696.55 ± 1 046.25 
Table 5.43. Total projected 1997 drug costs for the treatment of patients originating at the study 






Total Drugs Cost (Per Patient) of Malaria in 1997 
(Atovaquone-proguanil) {ZAR) 
Point Estimate Monte Carlo Simulation 
141.29 ± 3.97 141.59 ± 2.86 
135.41 ± 3.86 135.62 ± 2.73 
138.15 ± 3.91 138.61 ± 2.80 
Table 5.44. s ummary of drug costs of malaria cases originating at Naas (236 cases) and Mangweni 
nics in 1997, modelling atovaquone-proguanil as first-line agent. US$1.00 = ZAR 4.6072. (271 cases) Cli 
5.4.2.2. Consumables 
Clini C Total Consumables Cost (Per Patient) of Malaria in 1997 (Atovaquone-
proguanil) (ZAR) 
Point Estimate Monte Carlo Simulation 
Naas 24.80 ± 4.91 27.20 ± 2.91 
Mangweni 32.86 ± 4.91 35.37 ± 2.91 
Mean 28.83 ± 2.24 31.29 ± 2.91 
Table 5.45. Summary of consumable costs of malaria cases originating at Naas and Mangweni 
7, modelling atovaquone-proguanil as first-line agent. US$1.00 = ZAR 4.6072. Clinics in 199 
5.4.2.3. Clinical Staff Costs 
Clini C 






Clinics in 19 
Point Estimate Monte Carlo Simulation 
32.80 ± 11.59 32.70 ± 6.76 
32.80 ± 11.59 32.99 ± 6.83 
32.80 ± 11.59 32.85 ± 6.80 
Summary of clinical staff costs of malaria cases originating at Naas and Mangweni 
97, modelling atovaquone-proguanil as first-line agent. US$1.00 = ZAR 4.6072. 
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5.4.2.4. Transport 
Cosh-cQ is R1671.74 ± R358.27 at Naas Clinic, RcQ=0.34 ± 0.07, and RAr=0.09 ± 0.02. Therefore, 
CoslTAP for Naas is R442.41 ± R94.80. 
Similarly, CostTAr for Mangweni Clinic was estimated to be R488.97 ± R104.78. 
Clinic Total Per-Patient Transport Costs of Malaria in 1997 
(Atovaquone-proguanil) (ZAR/km) 
Point Estimate Monte Carlo Simulation 
Per Patient Per Patient per Per Patient Per Patient per 
km km 
Naas 1.87 ± 0.40 2.34 X 10-2 1.88 ± 0.41 2.35 X 10-2 
± 5.02 X 10-3 ± 5.14 X 10-3 
Mangweni 1.80 ± 0.44 2.34 X 10-2 1.82 ± 0.39 2.37 X 10-2 
± 5.77 X 10-3 ± 5.04 X 10-3 
Mean 1.84 ± 0.42 2.34 X 10-2 1.85 ± 0.40 2.36 X 10-2 
± 5.39 X 10-3 ± 5.09 X 10-3 
Table 5.47. Summary of transport costs of malaria cases originating at Naas and Mangweni Clinics 
in 1997, modelling atovaquone-proguanil as first-line agent. US$1.00 = ZAR 4.6072. 







Total Maintenance Cost (Per Patient) of Malaria in 1997 (Atovaquone-
proguanil) (ZAR) 
Point Estimate Monte Carlo Simulation 
0.66 ± 0.12 0.66 ± 0.12 
0.68 ± 0.12 0.66 ±0.12 
0.67 ± 0.12 0.66 ± 0.12 
Table 5.48. Summary of maintenance costs of malaria cases originating at Naas and Mangweni 
Clinics in 1997, modelling atovaquone-proguanil as first-line agent. US$1.00 = ZAR 4.6072. 
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5.4.3.2. Administrative & Support Staff 








Point Estimate Monte Carlo Simulation 
63.00 ± 12.57 63.25 ± 12.83 
64.06 ± 12.58 63.57 ± 12.58 
63.53 ± 12.57 126.82 ± 12.71 
s ummary of administrative & support staff costs of malaria cases originating at Naas and 
Clinics in 1997, modelling atovaquone-proguanil as first-line agent. US$1.00 = ZAR 
5.4.3.3. Utilities 
Clin ic Per-Patient Utility Cost of Malaria in 1997 (ZAR) 
Point Estimate Monte Carlo Simulation 
Naas 5.10 ± 0.91 5.12± 0.93 
Mangweni 5.31 ± 0.91 5.14 ± 0.91 
Mean 5.21 ± 0.91 5.13 ± 0.92 
Table 5.50. Summary of utility costs of malaria cases originating at Naas and Mangweni Clinics in 
ing chloroquine and atovaquone-proguanil as first-line agents. US$1.00 = ZAR 4.6072. 1997, compar 
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5.4.4. Total Costs for Atovaquone-proguanil 
5.4.4.1. Variable Costs 
Category of Cost I Naas (Per Patient) Mangweni (Per Patient) 
(ZAR) (ZAR) 
Point Estimate Monte Carlo Point Estimate Monte Carlo 
Simulation Simulation 
Drug Costs 141.29 ± 3.97 141.59 ± 2.86 135.41 ± 3.86 135.62 ± 2.73 
Clinical Staff Costs 32.80 ± 11.59 32.70 ± 6.76 32.80 ± 11.59 32.99 ± 6.83 
Consumables Costs 24.80 ±4.91 27.20 ± 2.91 32.86 ±4.91 35.37 ± 2.91 
Transport Costs 1.87 ± 0.40 1.88 ± 0.41 1.80 ± 0.44 1.82 ± 0.39 
Total 200.76 ± 20.87 203.37 ± 12.94 202.87 ± 20.80 205.80 ± 12.86 
Table 5.51. Summary of variable costs at Naas and Mangweni Clinics in the event of atovaquone-
proguanil being adopted as first-line therapy. US$1.00 = ZAR 4.6072. 
5.4.4.2. Fixed Costs 
Category of Cost Naas (Per Patient) Mangweni (Per Patient) 
(ZAR) (ZAR) 
Point Estimate Monte Carlo Point Estimate Monte Carlo 
Simulation Simulation 
In-service Training 3.24 3.24* 3.05 3.05* 
Maintenance 0.66 ± 0.12 0.66 ± 0.12 0.68 ±0.12 0.66 ±0.12 
Administrative & Support Staff 63.00 ± 12.57 63.25 ± 12.83 64.06 ± 12.58 63.57 ± 12.58 
Costs 
Utilities 5.10 ± 0.91 5.12 ± 0.93 5.31 ± 0.91 5.14 ± 0.91 
Total 72.00 ± 13.60 72.27 ± 13.88 73.10 ± 13.61 72.42 ± 13.61 
Table 5.52. Summary of fixed costs at Naas and Mangweni Clinics in the event of atovaquone-








Total Combined Fixed and 
Variable Cost per Patient 
275.64 ± 26.13 
278.22 ± 25.72 
276.93 ± 25.93 





Table 5.53. The cost-effectiveness of amodiaquine at the study clinics in 1997, compared with 
chloroquine. A mean total cost per notified patient of R462.94 ± Rl02.45 was used for the 
chloroquine, the baseline. US$1.00 = ZAR 4.6072. 
5.5. Halofantrine 
Bouchaud et al published a study on the clinical efficacy and pharmacokinetics of micronized 
halofantrine in nonimmune patients in 1994. 28 malaria-infected individuals returning to 
Europe from sun-Saharan Africa were included in the study. 24 patients were cured after 
treatment with three doses of 250mg at 6-hour intervals. Of the remainder, 2 had 
subtherapeutic plasma concentrations due to poor absorption of the drug. Isolates from the 
other 2 showed halofantrine resistance in vitro, suggesting that drug resistance was 
repsonsible for the failure of treatment. 
This study was chosen to provide an indicator of resistance because its patients were 
nonimmune, like the population found in South Africa's malarious regions, and because it 
took into account halofantrine's poor bioavailability. 
5.5.1. Derivation of R 
4 of the 28 patients studied by Bouchaud et al were not cured by treatment with halofantrine. 
This is a failure rate of 14.29%. 
R HF =0.1429 x (0.7±0.15) 
RHF = 0.1000 ± 0.02144 
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5.5. 2. Variable Costs 
5.5.2.1. Drug Costs 
Halofantrin 
Beecham at 
e is commercially available in South Africa as Halfan, marketed by SmithKline 
R39.79 (US$ 8.63) per 6 250mg tablets. 
Adult 
500mg 6-ho urly for 3 doses -- total 1500mg; 
days later. repeated 7 
Table 5.54. D osing for halofantrine (SAMF, 1998). 
Paediatric 
Up to 40kg: 8 mg/kg 6-hourly for 3 doses --
total 24 mg/kg; repeated 7 days later. 
Estimation of Drug Cost per Patient: Halofantrine 
Drug dosag es, and hence costs, for patients of different ages and gender were estimated by 





nic No. of Malaria 
Notifications in 1997 
236 
271 
Total HF Cost (ZAR) 
15 549.55 
17159.74 





Table 5.55. Modelled cost of halofantrine first-line therapy at the study clinics in 1997. US$1.00 = 
ZAR4.6072. 
131 
Estimation of Drug Cost per Pntie11t: Q11i11ine 
Clinic No. of R Est. Cost to treat with IV Cost to treat with PO 
patients no. of Quinine (ZAR) Quinine (ZAR) 
in 1997 referrals 
Per patient Adj. Per patient Adj. 
(Referrals x (Referrals x 
0.7± 0.15) 0.3 ± 0.15) 
Naas 236 0.1000 ± 23.60 ± 112.10 1851.89 ± 30.50 215.94 ± 
0.02144 5.06 878.96 177.42 
Total for Naas (IV+ PO) 2067.83 ± 
1056.38 
Mangweni 271 0.1000 ± 27.10 ± 108.95 2066.78 ± 29.66 241.14 ± 
0.02144 5.81 980.95 198.12 
Total for Mangweni (IV+ PO) 2307.92 ± 
1179.07 
Table 5.56. Calculation of quinine costs per clinic, assuming first-line drug is halofantrine. US$1.00 = 
ZAR4.6072. 
S11111111nn; 
Study Clinic Halofantrine Cost (ZAR) 
HF Cost Quinine Cost Total Cost 
Naas 15 549.55 2 067.83 ± 1056.38 17 617.38 ± 1 056.38 
Mangweni 17159.74 2 307.92 ± 1179.07 19 467.66 ± 1179.07 
Table 5.57. Total projected 1997 drug costs for the treatment of patients originating at the study 
clinics; a comparison of chloroquine and halofantrine. US$1.00 ~ ZAR 4.6072. 
Total Drugs Cost (Per Patient) of Malaria in 1997 (Halofantrine) (ZAR) 
Clinic 
Point Estimate Monte Carlo Simulation 
Naas 74.65 ± 4.48 74.72 ± 3.02 
Mangweni 71.84 ± 4.35 72.12 ± 3.10 
Mean 73.24 ± 4.41 73.42 ± 6.06 
Table 5.58. Summary of drug costs of malaria cases originating at Naas (236 cases) and Mangweni 







Clinical Staff Costs 
Total Clinical Staff Cost (Per Patient) of Malaria in 1997 
(Halofantrine) (ZAR) 
Point Estimate Monte Carlo Simulation 
36.35 ± 13.06 35.82± 7.59 
36.35 ± 13.06 36.27 ± 7.89 
36.35 ± 13.06 36.05 ± 7.74 
Table 5.59. Summ ary of clinical staff costs of malaria cases originating at Naas and Mangweni 







Total Consumables Cost per Patient of Malaria in 1997 
(Halofantrine) (ZAR) 
Point Estimate Monte Carlo Simulation 
26.11 ± 5.54 28.61 ± 3.21 
34.17 ± 5.54 36.87 ±3.37 
30.14 ± 5.54 32.74 ± 3.29 
Table 5.60. Summ ary of consumable costs of malaria cases originating at Naas and Mangweni 
g chloroquine and halofantrine as first-line agents. US$1.00 = ZAR 4.6072. Clinics in 1997, usin 
5.5.2. 4. Transport 
CostrcQ is R1 671 .7 4 ± R358.27 at Naas Clinic, RcQ=0.34 ± 0.07, and RHF=0.10 ± 0.02. Therefore, 
R498.43 ± R106.86. CoslrHF for Naas is 
Similarly, CostrnF f or Mangweni Clinic was estimated to be R550.89 ± R118.11. 
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Clinic Total Per-Patient Transport Costs of Malaria in 1997 
(Co-artemether) (ZAR/km) 
Point Estimate Monte Carlo Simulation 
Per Patient Per Patient per Per Patient Per Patient per 
km km 
Naas 2.11 ± 0.45 2.64 X 10-2 2.09 ± 0.437 2.61 X 10-2 
± 5.7 X 10-3 ± 5.47 X 10-3 
Mangweni 2.03 ± 0.50 2.64 X 10-2 2.04 ± 0.447 2.64 X 10-2 
± 6.5 X 10-3 ± 5.81 X 10-3 
Mean 2.07 ± 0.48 2.64 X 10-2 2.07 ± 0.442 2.63 X 10-2 
± 6.1 X 10-3 ± 5.64 X 10-3 
Table 5.61. Summary of transport costs of malaria cases originating at Naas and Mangweni Clinics in 
1997, using chloroquine and atovaquone-proguanil as first-line agents. US$1.00 = ZAR 4.6072. 






Total Maintenance Cost (Per Patient) of Malaria in 1997 
(Co-artemether) (ZAR) 
Point Estimate Monte Carlo Simulation 
0.73 ± 0.14 0.722 ± 0.132 
0.75 ± 0.14 0.730 ± 0.141 
0.74 ± 0.14 0.726 ± 0.137 
Table 5.62. Summary of maintenance costs of malaria cases originating at Naas and Mangweni 







Administrative & Support Staff Costs 
Per-Patient Staff Time Cost of Malaria in 1997 
(Halofantrine) (ZAR) 
Point Estimate Monte Carlo Simulation 
70.42 ± 14.16 69.62 ± 13.65 
71 .48 ± 14.18 70.48 ± 14.51 
70.95 ± 14.17 70.05 ± 14.08 
Table 5.63. Su 
Mangweni Cli 
mmary of administrative & support staff costs of malaria cases originating at Naas and 
nics in 1997, modelling halofantrine as first-line agent. US$1.00 = ZAR 4.6072. 





Per-Patient Utility Cost of Malaria in 1997 
(Halofantrine) (ZAR) 
Point Estimate Monte Carlo Simulation 
5.64 ± 1.02 5.58 ±0.987 
5.85 ± 1.03 5.64 ± 1.04 
5.74 ± 1.03 5.61 ± 1.01 
Table 5.64. Su mmary of utility costs of malaria cases originating at Naas and Mangweni Clinics in 
g halofantrine as first-line agent. US$1.00 = ZAR 4.6072. 1997, modellin 
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5.5.4. Total Costs for Halofantrine 
5.5.4.1. Variable Costs 
Category of Cost Naas (Per Patient) Mangweni (Per Patient) 
(ZAR) (ZAR) 
Point Estimate Monte Carlo Point Estimate Monte Carlo 
Simulation Simulation 
Drug Costs 74.65 ± 4.48 74.72 ± 3.02 71 .84 ± 4.35 72.12 ± 3.10 
Clinical Staff Costs 36.35 ± 13.06 35.82 ± 7.59 36.35 ± 13.06 36.27 ± 7.89 
Consumables Costs 26.11 ± 5.54 28.61 ± 3.21 34.17 ± 5.54 36.87 ± 3.37 
Transport Costs 2.11 ± 0.45 2.09 ± 0.437 2.03 ± 0.50 2.04 ± 0.447 
Total 139.22 ± 23.53 141.24 ± 14.26 144.39 ± 23.45 147.30 ± 14.81 
Table 5.65. Summary of variable costs at Naas and Mangweni Clinics in the event of halofantrine 
being adopted as first-line therapy. US$1.00 = ZAR 4.6072. 
5.5.4.2. Fixed Costs 
Category of Cost Naas (Per Patient) Mangweni (Per Patient) 
(ZAR) (ZAR) 
Point Estimate Monte Carlo Point Estimate Monte Carlo 
Simulation Simulation 
In-service Training 3.24 3.24* 3.05 3.05* 
Maintenance 0.73 ± 0.14 0.722 ± 0.132 0.75 ± 0.14 0.730 ± 0.141 
Administrative & Support Staff 70.42 ± 14.16 69.62 ± 13.65 71 .48 ± 14.18 70.48 ± 14.51 
Costs 
Utility Costs 5.64 ± 1.02 5.58 ± 0.987 5.85 ± 1.03 5.64 ± 1.04 
Total 80.03 ± 15.32 79.16 ± 14.77 81.13 ± 15.35 79.90 ± 15.69 
Table 5.66. Summary of fixed costs at Naas and Mangweni Clinics in the event of halofantrine being 








Total Combined Fixed and 
Variable Cost per Patient 
220.40 ± 28.24 
227.20 ± 29.79 
223.80 ± 29.02 





Table 5.67. The cost-effectiveness of halofantrine at the study clinics in 1997, compared with 
chloroquine. A mean total cost per notified patient of R462.94 ± Rl02.45 was used for the 
chloroquine, the baseline. US$1.Cl0 = ZAR 4.6072. 
5.6. Mefloquine 
Resistance to mefloquine in the study region had not appeared by 1990 (Freese et al, 1994), 
and was still absent in isolates tested in vitro in 1994 (Deacon et al, 1994). However, since its 
deployment for the first-line treatment of P. falcipan1111 infections in Thailand in the mid-
Eighties, antimalarial cure rates for the organism in the region declined from nearly 100% at 
the time of introduction to 50% by 1992 (White, 1992). 
Other studies conducted in sub-Saharan Africa on the efficacy of treatment with mefloquine 
(Del Nero et al, 1993; Del Nero et al, 1994; Okoyeh et al, 1997) indicate that resistance has not 
yet become a problem in the region. 
5.6.1. Derivation of R 
Mefloquine has been used extensively in Southeast Asia, but has had little exposure in sub-
Saharan Africa. This fact, combined with the evidence of mefloquine sensitivity in the study 
region published by Freese et al and Deacon et al, allows the assumption that in vivo resistance 
to mefloquine in the Shongwe and Tonga districts is not significantly different from nil. 
Hence, R=O. 
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5.6.2. Variable Costs 
5.6.2.1. Drug Costs 
The WHO recommends a dosage regimen of 25 mg mefloquine base per kilogram, not 
ding 1 500 mg, spread over 2-3 days. Mefloquine is marketed in South Africa as Lariam, 
h sells for R128.66 per package of 8 250mg tablets. This equates to R0.064 per milligram. 
excee 
whic 
Esti111atio11 of Drng Cost per Patient: Mefloq11ine 
Usin 
relati 
g the National Center for Health Statistics tables for gauging age/weight/ dosage 
onships, assuming a mean adult weight of 70 kg, and using standard dosage of 25 
kg, an adult course was estimated to cost R96.50 (using the full dose of 1 500mg). mg/ 
Clinic No. of Malaria Total Mef Cost (ZAR) Mean MEF cost per 
Notifications in 1997 Patient (ZAR) 
Naas 236 18 271.65 77.42 
Mang weni 271 20 245.94 74.71 
Mean 76.07 (US$ 16.51) 














Table 5.69. Summa ry of drug costs of malaria cases originating at Naas (236 cases) and Mangweni 
1997, modelling mefloquine as first-line agent. US$1.00 = ZAR 4.6072. (271 cases) Clinics in 
5.6.3. 0 ther Costs 
Since R=O, all othe r fixed and variable costs were identical to those calculated for artesunate 
ns in section 6.3. and its combinatio 








1. Variable Costs 
















Table 5.70. Summa ry of variable costs at Naas and Mangweni Clinics in the event of mefloquine 
rst-line therapy. US$1.00 = ZAR 4.6072. being adopted as fi 
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5.6.4.2. Fixed Costs 
Category of Cost Naas (Per Patient) Mangweni (Per Patient) 
(ZAR) (ZAR) 
Point Estimate Point Estimate 
In-service Training 3.24 3.05 
Maintenance 8.94 X 1Q-2 0.109 
Administrative & Support Staff 4.37 5.35 
Costs 
Utility Costs 0.86 1.05 
Total 8.56 9.56 
Table 5.71. Summary of fixed costs at Naas and Mangweni Clinics in the event of mefloquine being 
adopted as first-line therapy. US$1.00 = ZAR 4.6072. 
5.6.4.3. Cost-effectiveness 
Clinic Total Combined Fixed and ACER 
Variable Cost per Patient 
Naas 104.06 4.416 
Mangweni 110.41 4.224 
Mean 107.24 4.317 
(US$ 23.27) 
Table 5.72. The cost-effectiveness of mefloquine at the study clinics in 1997, compared with 
chloroquine. A mean total cost per notified patient of R462.94 ± Rl02.45 was used for the 







Cost-effectiveness at 10% Resistance 
Total Combined Fixed and 
Variable Cost per Patient 
183.48 ± 20.46 
188.54 ± 19.61 





Table 5.73. Using an arbitrary iu vivo drug resistance level of 10%, a risk simulation was run to 
determine the effect of an increased rate of resistance on the ACER. The result is a 42.34% drop in 
cost-effectiveness with respect to chloroquine. US$1.00 = ZAR 4.6072. 
5. 7. Pyronaridine 
Two studies conducted in Yaounde, Cameroon (Ringwald et al, 1996; Ringwald et al, 1998) 
found no resistance to pyronaridine in P. Jalcipan1111 in vivo using a total dose of 32 mg/kg 
over 3 days. In contrast, a Thai study found 12% resistance (3 of 26) using a total dose of 1 800 
mg over 5 days, which, using a mean adult body weight of 70 kg, is equivalent to 25.7 mg/kg 
(Looareesuwan et al, 1996). 
Pyronaridine has not been used on a large scale in sub-Saharan Africa, while it has been 
employed in Southeast Asia for some time. Also, the dosages used in the Thai study were 
lower than those used by Ringwald et al. For these reasons it was decided to accept the 
Yaounde findings of zero resistance in vivo in sub-Saharan Africa. 
5.7.1. Derivation of R 
Pyronaridine has not been used on a large scale in sub-Saharan Africa, while it has been 
employed in Southeast Asia for some time. Also, the dosages used in the Thai study were 
lower than those used by Ringwald et al . For these reasons it was decided to accept the 
Yaounde findings of zero resistance in vivo in sub-Saharan Africa; R=O.O. 
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5.7.2. Variable Costs 
5.7.2.1. Drug Costs 
The final recommended cost of an adult treatment course of pyronaridine has not yet been 
confirmed, but the WHO target cost for sub-Saharan Africa is US$ 1.00, or R4.61, using a 
mean 1997 exchange rate of 4.60720 Rands to the dollar (personal communication, Dr T 
Kanyok, WHO pyronaridine manager). Due to South Africa's perceived 'richer' status in 
Africa and the uncertainty in the price at which the drug might be made available, it was 
decided to use the cost of $3.00 (R13.82) per adult course quoted by Winstanley in 1996. 
Factors which will determine cost include the price at which industry can manufacture and 
commercialise the drug within Africa (including synthesis, finished product production, 
recoup of R&D and registration costs, distribution costs, wholesaler mark-up, and final price 
to the patient from point of local distribution). Some savings will probably be realised if the 
drug is made available directly to the Department of Health. Also critical will be the length 
and dose of an adult treatment course. WHO presently envisions this to be either 6 or 12 
mg/ kg/ day for 3 days (T Kanyok). 
For the purposes of this study, using the evidence from Yaounde and Thailand, it was 
decided to use a dose of 12 mg/kg per day for 3 days for all estimations of costs. 
Estimation of Dnig Cost per Patient: Pyro11aridine 
National Center for Health Statistics data was once again used for the estimation of 
age/weight/ dosage relationships. Assuming mean adult ~eight to be 70 kg, and standard 
dosage to be 36 mg/kg spread over 3 days, the cost of a pyronaridine course is R0.55 (US$ 
0.12) per kg. 
Clinic No. of Malaria Total PN Cost (ZAR) Mean PN cost per Patient 
Notifications in 1997 (ZAR) 
Naas 236 2438.07 10.33 
Mangweni 271 2 720.41 10.04 
Mean 10.19 (US$ 2.21) 
Table 5.74. Modelled cost of pyronaridine first-line therapy at the study clinics in 1997. US$1.00 = 
ZAR4.6072. 
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Esti111atio11 of Drztg Cost per Patiwt: Qui11i11e 
Since R=O, no quinine drug costs were assumed to be incurred. 
5. 7.3. Other Costs 
As in the case of mefloquine, other variable and fixed costs are identical to those calculated in 
section 6.3 for artesunate and its derivatives. 
5. 7.4. Total Costs for Pyronaridine 
5.7.4.1. V nriable Costs 
Category of Cost Naas (Per Patient) Mangweni (Per Patient) 
(ZAR) (ZAR) 
Point Estimate Point Estimate 
Drug Costs 10.33 10.04 
Clinical Staff Costs 3.65 3.65 
Consumables Costs 14.43 22.49 
Transport Costs 0.00 0.00 
Total 28.41 36.18 
Table 5.75. Summary of variable costs at Naas and Mangweni Clinics in the event of pyronaridine 
being adopted as first-line therapy. US$1.00 = ZAR 4.6072. 
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5.7.4.2. Fixed Costs 
Category of Cost 
In-service Training 
Maintenance 




















Table 5.76. Summary of fixed costs at Naas and Mangweni Clinics in the event of pyronaridine being 







Total Combined Fixed and 
Variable Cost per Patient 
36.97 
45.74 





Table 5.77. The cost-effectiveness of pyronaridine at the study clinics in 1997, compared with 
chloroquine. A mean total cost per notified patient of R462.94 ± R102.45 was used for the 
chloroquine, the baseline. US$1.00 = ZAR 4.6072. 
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5.7.4.4. Cost-effectiveness with Resistance and Increased Drug Cost 
Adjustment Mean Combined Total Variable ACER 
and Fixed Cost per Patient 
(ZAR) 
Cdx2 52.01 8.901 
PR=5% 83.25 ± 10.32 5.561 
PR= 5%, Cd x2 97.36 ± 7.28 4.755 
PR = 10% 128.83 ± 20.35 3.598 
PR = 10%, Cd x2 142.49 ± 14.76 3.249 
Table 5.78. The effect on the ACER of increasing resistance rate and drug cost in pyronaridine. 
Nominal Drug Cost x2 5% Resistance 5% Resistance + 10% Resistance 10% Resistance+ 
Drug Cost x2 Drug Cost x2 
Adjustment 
Figure 5.2. Increasing resistance substantially affects cost-effectiveness of modelled drugs, for 
example pyronaridine above. Drug costs play a lesser role. 
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Figure 5.3. 1997 drug costs. As=artesunate; PN=pyronaridine; SP=sulfadoxine-pyrimethamine; 
AM =artesunate-mefloquine; Mef=mefloquine; HF=halofantrine; AQ=amodiaquine; 
CQ=chloroquine; AP=atovaquone-proguanil; Co-A=co-artemether. 
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Drug Cost per Patient of Notifications Cost per Patient of Notifications Mean Total Cost 
Arising at Naas Clinic Arising at Mangweni Clinic (1997ZAR) 
(1997 ZAR) (1997 ZAR) 
Variable Fixed Total Variable Fixed Total 
Costs Costs Costs Costs Costs Costs 
CQ 213.51 ± 248.41 ± 461 .92 ± 217.83 ± 246.11 ± 463.94 ± 46294± 
49.73 50.96 100.69 50.97 53.23 104.20 102.45 
SP 56.14 ± 35.95 ± 92.09± 63.56 ± 36.02± 99.58 ± 95.86 ± 
5.97 6.15 12.12 5.62 5.97 5.80 11.86 
AQ 169.43 ± 193.30 ± 362.73 ± 175.86 ± 192.65 ± 368.51 ± 365.62± 
38.40 40.42 78.82 39.48 41.55 81.03 79.93 
As* 22.71 8.56 31.27 30.64 9.56 40.20 35.74 
As-Mef* 70.81 8.56 79.37 77.22 9.56 86.78 83.08 
As-SP* 37.63 8.56 46.19 44.94 9.56 54.50 50.35 
AP 203.37± 72.27 ± 275.64 ± 205.80 ± 72.42 ± 278.22± 276.93 ± 
12.94 13.88 26.13 12.86 13.61 25.72 25.93 
Co-A* 233.13 ± 42.18 ± 275.31 ± 235.60 ± 41.91 ± 277.51 ± 276.41 ± 
6.94 7.23 13.79 6.73 7.18 13.54 27.33 
HF 141.24 ± 79.16 ± 220.40 ± 147.30 ± 79.90 ± 227.20 ± 223.80± 
14.26 14.77 28.24 14.81 15.69 29.79 29.02 
Mef 95.50 8.56 104.06 100.85 9.56 110.41 107.24 
PN* 28.41 8.56 36.97 36.18 9.56 45.74 41.36 
Table 5.79. Summary of modelled costs per notified malaria patient cured for each studied drug. 
























Figure 5.4. Rankings of drugs according to modelled cost-effectiveness. CQ = chloroquine; AQ = 
amodiaquine; AP = atovaquone-proguanil; Co-A = co-artemether; HF = halofantrine; Mef 
mefloquine; SP = sulfadoxine-pyrimethamine; As-Mef = artesunatejmefloquine; As-SP = 
artesunatejsulfadoxine-pyrimethamine; PN = pyronaridine; As = artesunate. 
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Table 5.80. Summary of cost-effectiveness results. * Drug prices for Africa are not yet known with 
certainty. 
Artesunate and pyronaridine (with ACERs of 12.95 and 12.76 respectively, when compared to 
chloroquine) emerged as the most cost-effective monotherapeutic options, although in both 
cases South African prices were estimated from WHO recommendations and international 
prices, and could not be confirmed. 
Of the combinations, artesunate-SP proved the most cost-effective, with an ACER of 9.194 
with respect to chloroquine. Halofantrine, atovaquone-proguanil, and co-artemether were 
relatively non-cost-effective due to their high cost, which negated any advantage that might 
have been given by lower incidence of in vivo resistance. Amodiaquine and chloroquine were 
the least cost-effective, because of the effect of high resistance. 
There was a significant correlation between resistance rate and ACER (Spearman r = -0.8963, 
P = 0.0004), but no significant relationship was found between ACER and drug cost 
(Spearman r = -0.03646, P = 0.9241). 
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Co-A CQ AP AQ HF Mef As- SP As- PN* As* 
Mef* SP* 
Drug 
Figure 5.5. Comparison of cost per notified patient of modelled antimalarial drugs. Co-A = co-
artemether; CQ = chloroquine; AP = atovaquone-proguanil; AQ = amodiaquine; HF = halofantrine; 
Mef = mefloquine; As-Mef = artesunatejmefloquine; SP = sulfadoxine-pyrimethamine; As-SP = 
artesunatejsulfadoxine-pyrimethamine; PN = pyronaridine; As = artesunate. 
,. Drug prices for Africa are not yet known with certainty. 
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5.8.2. Clinic Visits and Patient Days 
Drug Naas Mangweni 
Additional Clinic Hospital Patient Additional Clinic Hospital Patient 
Visits Days Visits Days 
Chloroquine 79.15 ± 16.96 237.45 ± 50.88 90.89 ± 19.48 272.67 ± 58.44 
Sulfadoxine- 9.09 ± 1.96 27.26 ± 5.88 10.43 ± 2.25 31.30 ± 6.75 
pyrimethamine 
Amodiaquine 60.77 ± 13.02 182.31 ± 39.06 69.78 ± 14.96 209.34 ± 44.88 
Co-artemether 11.07 ± 2.37 33.21 ± 7.11 12.71 ± 2.72 38.13 ± 8.16 
Artesunate 0.00 0.00 0.00 0.00 
Artesunate- 0.00 0.00 0.00 0.00 
mefloquine 
Artesunate-SP 0.00 0.00 0.00 0.00 
Atovaquone- 20.95 ±4.49 62.85 ± 13.47 24.05 ± 5.15 72.15 ± 15.45 
proguanil 
Halofantrine 23.60 ± 5.06 70.80 ± 15.18 27.10 ± 5.81 81 .30 ± 17.43 
Mefloquine 0.00 0.00 0.00 0.00 
Pyronaridine 0.00 0.00 0.00 0.00 
Table 5.81. Comparitive benefits between the drugs studied. Hospitalised patients were assumed to 
remain at the hospital for an average of 3 days. 
Relative benefit ratios were calculated for the study drugs, in terms of the proportion of clinic 
visits averted and hospital patient days saved. Relative benefit ratio is inversely proportional 
to in vivo resistance. 
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Table 5.82. Average benefits ratios of the study drugs, comparing benefits in terms of clinic visits and hospital patient days saved ... Since resistance for artesunate, mefloquine and pyronaridine was modelled as zero, the average benefits ratio was taken to unquantifiably large. 
5.8.3. African Drug Prices 




Drug Cost per Cost per Adult ACER with 
Treatment Course Treatment Course Kenyan Cost 
(Kenyan Shillings) (ZAR) 
Chloroquine* 10.00 0.788 1.031 
Sulfa<loxine-pyrimethamine* 50.00 - 75.00 3.941 - 5.912 5.606 - 5.502 
Quinine (Oral) 180.00 14.189 N/A 
Artesunate (7 d) 200.00 15.766 10.70 
Table 5.83. Comparison of drug prices in Kenya and South Africa in 1997, and the effect of using to 
Kenyan prices to calculate ACERs. The Kenyan prices were provided by F ter Kuile & J Alaii, and 
converted to South African Rands using a conversion rate of 12.686 KSh to the Rand (mean 1997 
exchange rate, Olsen and Associates, www.oanda.coml. All ACERs were calculated using South 
African chloroquine costs as a comparator. 
•Indicates use of Kenyan quinine prices in calculation. Since there is assumed to be no resistance to 
artesunate, quinine is not incorporated in the artesunate drug model. 
5.8.3.2 . Uganda 
Drug Cost per Cost per Adult ACER with 
Treatment Course Treatment Course Ugandan Cost 
(Ugandan (ZAR) 
Shillings) 
Sulfadoxine-pyrimethamine 500 - 3 000 2.149 -12.894 5.596 - 5.072 
Artesunate (7 d) 16 000 25.789 9.142 
Table 5.84. Comparison of drug prices in Uganda and South Africa in 1997, and the effect of using to 
Ugandan prices to calculate ACERs. The Ugandan prices were provided by M Willcox, and converted 
to South African Rands using a conversion rate of 232.661 USh to the Rand (mean 1997 exchange rate, Olsen and Associates, www.oanda.com). 
In both cases, drug prices tended to vary considerably depending on the region of the country 
in which they were sold, the source of drug supply, competition between resellers, and ability 
to pay (personal communication, M Willcox). 
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5.8.4. Curve Fitting 
The model generates data lying along a curve described by the following equation: 
y = Spanl · e-K,x + Span2 · e-Kix + Plateau 
This expression describes two-phase exponential decay, and fits the model exactly (R2 = 
1.000). Each modelled drug has its own unique values for Spanl, Span2, K1, K2, and Plateau. x 
is resistance prevalence, and y is the ACER at resistance x. K1 and K2 are rate constants. The 
two phases implicit in the equation describe the patient return rate, and the ratio of patients 
treated with oral versus intravenous quinine upon admission to hospital, respectively. Spanl 
and SparL2 are constants relating to these. Plateau is the lowest possible value of the ACER, 
according to the model. Appendix C contains a table of values for Spanl, Span2, Ki, K2 and 
Plateau for each modelled drug. 
5.8.5. Critical Values for Resistance Prevalence 
Critical values of resistance prevalence for drugs were calculated to determine the levels of 
resistance at which one drug might become more or less cost-effective than another. These 
figures are not generalisable outside of South Africa, as they are based on South African costs. 
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Figure 5.6. Plots illustrating the relationships between resistance and the ACER (releative to 
chloroquine) for sulfadoxine-pyrimethamine, artesunate-SP and artesunate-mefloquine. 
5.8.5.1. Chloroquine 
In order for chloroquine to be as cost-effective than sulfadoxine-pyrimethamine in the Tonga 
district, its in vivo resistance prevalence would have to be 7.30% (using the curves derived in 
Table 5.85); to be more cost-effective than artesunate-SP, resistance would have to be under 
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2.43%, and to be more cost-effective than artesunate-mefloquine, resistance would have to be 
lower than 5.88%. 
5.8.5.2. Sulfadoxine-pyrimethamine 
For sulfadoxine-pyrimethamine to be more cost-effective than artesunate-SP, its in vivo 
resistance level would need to be under 0.54%, and to be more cost-effective than artesunate-
mefloquine, PR would have to l>e lower than 4.14% . 
5.8.5.3. Artesunate Combinations 
Artesunate-SP and artesunate-mefloquine would have equal cost-effectiveness if the i11 vivo 
prevalence of P. falcipan1111 resistance to artesunate-SP were 3.68 %. 
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Chapter 6 : Results 
COSTS INCURRED BY PATIENTS 
6.1. Introduction 
In addition to the costs incurred by the State in the treatment of falciparum malaria, 
considerable expense may be borne by patients. Although the public health system charges 
only a minimal fee to patients, each patient is required to travel to the clinic or hospital from 
their place of residence and back again, often several times. In the rural districts of Shongwe and Tonga, where an overwhelming proportion of the population is African, it was found 
that 81 % of respondents in the Central Statistical Service's October 1995 household study in 
Mpumalanga made use of public health care facilities. Of those, 45% specifically went to a 
hospital, 51 % preferred going to a clinic, but only 4% had no preference (Orkin et al, 1998). 
The same report revealed that health facilities were, in most cases, relatively close to 
households. In 25% of African households, a medical facility was within 1 km, 38% reported 
that one was located within 5 km of their home, and 37% were more than 5 km from a facility. 
The time taken by rural African families to reach their closest primary health care facility was 
substantial. 25% of families were within 15 minutes' travel, while it took 36% over an hour to 
reach medical help. 




Road distances between each source community and each of the two clinics were calculated 
from maps of the Barberton district obtained from the Department of Land Affairs 
(Directorate of Surveys and Mapping, 1988). 
In 1997, the mean distance between the average patient's residential community and Naas 
Clinic was 5.93 km, while malaria patients visiting Mangweni Clinic travelled a mean of 11.13 
km to reach it. 
Each patient referred to Shongwe from Naas Clinic was transported by State vehicle, a 
distance of about 40.5 km. The distance covered by State vehicles when transporting patients 
between Mangweni and Shongwe was about 37 km. 
The majority of Naas Clinic's malaria patient intake was divided between Albertsnek, a small 
settlement a little under 5 kilometres from the Mozambique border, and Naas itself; they 
accounted for 28.02% (102 notifications) and 25.55 % (93 notifications, 10 km distant) 
respectively. Naas Clinic's major patient intake seems to be divided among a relatively small 
number of sites; in addition to Naas and Albertsnek, only three other sites, Block C (Sibayeni, 
0.5 km distant, 12.09%, 44 notifications), Block D (Ngwenyeni, 5 km distant, 9.89%, 36 
notifications) and Block B (KwaSibhejane, 8 km distant, 4.40%, 16 notifications) accounted for 
more than 4% of patients. All three, however, are located relatively close to Naas Clinic, with 
number of patients increasing in proportion to decreasing distance from the clinic. This 
relationship is not significant, however (r2 = 2.977). 
The largest contributor community to Mangweni Clinic's malaria patient intake is Mangweni 
itself (34.70%, 152 notifications) . The remaining contributors above 4% are roughly evenly 
divided between Mbuzini (28 km distant, 7.31 %, 32 notifications); Vukuzenzele (13.5 km 
distant, 7.08%, 31 notifications); Figtree (11.5 km, 6.62%, 29 notifications); Block A (8 km 
distant, 5.94%, 26 notifications); Mandulo (11.5 km distant, 5.25%, 23 notifications); Mananga 
(30 km distant, 5.02%, 22 notifications); and Masibekela (15 km distant, 4.79%, 21 
notifications) . Again, no significant linear relationship could be shown between the distance 








Figure 6.1. Breakdown of communities from which malaria cases notified at Naas Clinic originated. 
Notifications were almost evenly divided between the largest discrete group of patients (102, 















Figure 6.2. Breakdown of communities from which notifications at Mangweni Oinic originated. 









Figure 6.3. Malaria intake areas for Naas Clinic. The radii of the circles are proportionate to the 
















Figure 6.4. Malaria intake areas for Mangweni Clinic. The radii of the circles are proportionate to 
the number of patients originating from the settlements at the centres of the circles. 
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6.2.2. Costs Incurred by Patients 
6.2.2.1. Treatment Costs 
Each patient treated, with the exception of pregnant women and children under 6, was 
charged R6.00 per clinic visit and Rl0.00 per hospital admission. Patients were charged these 
fees regardless of disease or therapy. 
Chloroquine 
Using chloroquine as first-line agent, average cost per patient depends on R, the resistance 
modifier. 
Clinic Noof Total R No of Total Total per Total per 
patients Clinic Referrals Hospital Clinic Patient 
Charges Charges (ZAR) (ZAR) 
(ZAR) (ZAR) 
Naas 236 1 416.00 0.3354 79.15 ± 791 .50 2 207.50 9.35 ± 0.72 
± 0.07188 16.96 ± 169.60 ± 169.60 
Mangweni 271 1626.00 0.3354 90.89 ± 908.90 2534.90 9.35 ±0.72 
± 0.07188 19.48 ± 194.80 ± 194.80 
Mean 9.35 ± 0.72 
(US$ 2.03 ± 
US$ 0.16) 
Table 6.1. Average cost borne by a malaria patient treated with chloroquine at a clinic in 1997. 
US$1.00 = ZAR 4.6072. 
Sulfadoxi11e-pyrin1ethan1i11e 
Substitution of chloroquine by sulfadoxine-pyrimethamine results in altered per-patient 
costs, since R is different. 
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Clinic No of Total R No of Total Total per Total per 
patients Clinic Referrals Hospital Clinic Patient 
Charges Charges (ZAR) (ZAR) 
(ZAR) (ZAR) 
Naas 236 1416.00 0.0835 9.09 ± 1.96 90.90 1506.90 6.38 ± 0.08 
± 0.0083 ± 19.60 ± 19.60 
Mangweni 271 1626.00 0.0835 10.43 ± 104.30 1730.30 6.38 ± 0.08 
± 0.0083 2.25 ± 22.50 ± 22.50 
Mean 6.38 ± 0.08 
(US$1.38 ± 
US$ 0.02) 
Table 6.2. Average cost borne by a malaria patient treated with sulfadoxine-pyrimethamine at a clinic 
in 1997. US$1.00 = ZAR 4.6072. 
6.2.2.2. Travel Costs 
Each patient accepted into the 1998 i11 vivo sulfadoxine-pyrimethamine effectiveness study 
was interviewed to determine his or her method of travel to and from the study clinic at 
which they were recruited. The results appear in the table below. 
Number of patients (of 77) Method of travel Mean Direct Cost per Patient 
(ZAR) 
2 (2.60%) Bicycle 0.00 
3 (3.90%) Family car 2.29* 
9 (11.69%) Hired transport 47.22 
15 (19.48%) On foot 0.00 
48 (62.34%) Taxi 5.44 
Table 6.3. Travel methods among the Tonga population. * The mean distance covered by patients 
using a family-owned vehicle was 4.33 km, which is equivalent to a travel cost of R2.29 per trip to 
and from the clinic. A mean cost-per-kilometre of R0.264 per km was used, as estimated in Section 
4.2.7. This figure is assumed to be reasonable due to the overall advanced age of privately owned 
vehicles and poor roads in the region. US$1.00 = ZAR 4.6072. 
Of the 125 patients recruited for the i11 vivo study, 48 did not initially present at either of the 
clinics, and have therefore been excluded from this aspect of the study. Total travel cost to the 
remaining 77 patients recruited for the study was R692.97, or a mean travel cost of R9.00 per 
patient. 
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Patients requiring admission to hospital were assumed to be conveyed by the ambulance 
service described in Section 4.2.7, thus incurring no further travel costs. 
6.2.2.3. 0 tl1er Cos ts 
Other costs are borne by patients. These include: 
• The income lost as a result of time spent absent from work while visiting the clinic and, if 
necessary, the hospital; 
• The costs of paying child-minders; and 
+ The indirect costs brought about by the patient's absence from home. 
Due to the extremely high levels of unemployment in the subregion, lost income was thought 
to be less important a factor than might be expected. Also, it was noted during the course of 
the study that child-minders are not often utilised; children generally accompany their 
parents. An informal creche exists at the hospital for this reason. 
The above additional costs to patients cannot be assumed to be negligible, but the evaluation 
of these proved to be beyond the scope of this work. 
6.2.2.4. Summary 
Chloroquine Cost (ZAR) Sulfadoxine-pyrimethamine (ZAR) 
Treatment Travel Cost Total Cost Treatment Travel Cost Total Cost 
Cost (ZAR) Cost (ZAR) 
9.35 ± 0.72 9.00 18.35 ± 0.72 6.38 ± 0.08 9.00 15.38 ± 0.08 
(US$ 3.98 ± (US$ 3.34 ± 
US$ 0.16) US$ 0.02) 
Table 6.4. Projected costs per patient for malaria treatment in 1997. US$1.00 = ZAR 4.6072. 
The introduction of sulfadoxine-pyrimethamine brought about an estimated net saving of 
16.19% in treatment and travel costs borne by patients when compared with chloroquine. 
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6.2.3. Costs Related to Death 
A critical aspect related to patient costs is that of the cost of death. While this is thought to 
affect patient-incurred costs enormously, it was not possible to quantify in this study. A 
detailed discussion of the relevant considerations appears as Section 1.8.5, on page 28. The 
mortality rate, country-wide, was 0.45 % in 1997, translating to 2.3 deaths amongst the 507 
patients included in costing (see Figure 1.3, page 4). 
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Chapter 7 
DISCUSSION OF RESULTS & 
CONCLUSION 
The following objectives were met: 
• The baseline malaria situation in the Tonga district was elucidated, with respect to 
malaria caseload and demographic profiles. 
• A model was constructed to relate the variable and fixed direct costs of malaria to the 
public health system. Data from all required categories were collected and analysed using 
the model, using sulfadoxine-pyrimethamine as a starting point. Chloroquine and a range 
of other drugs were modelled using their respective in vivo probabilities of resistance and 
drug costs per treatment course. 
• The model was used to generate an average cost-effectiveness ratio (ACER) for every 
drug relative to chloroquine. 
The following objectives were partially met: 
• The average cost of treatment to the patient was assessed (including transport costs and 
direct cost of treatment), in terms of average cost per notified patient. However, the 
detail of results obtained was not comprehensive. 
No model was constructed for chlorproguanil-dapsone ('LapDap'); insufficient data was 
available. 
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7.1. Baseline Study of Malaria in the Nkomazi Region of 
Mpumalanga 
The rapid increase in the number of malaria cases in the Mpumalanga Lowveld during the 
1987-1996 period, as seen in this analysis, is well-described (Diirrheim & Whittaker, 1996; 
Kruger et al, 1996). The Lowveld region, specifically the part thereof that includes the 
Shongwe and Tonga districts, where this study was based, borders on Mozambique in the 
east and Swaziland in the south. Mozambique's malaria control programme is hamstrung by 
a lack of funds for healthcare and a very weak economy. Malaria in that country is endemic 
and difficult to control (le Sueur et al, 1996). 
It may be inferred that much of the labour demand in the Shongwe and Tonga districts is 
filled by illegal Mozambiquan immigrants who cross the border in order to find employment, 
bringing malaria into the district, as is the case in KwaZulu Natal (Mnzava et al, 1998; 
Ngxongo, 1993). While malaria control in South Africa is relatively effective, imported 
malaria is thought to partially account for the high prevalence of malaria in South Africa's 
border regions: it is found in the Northern Province (bordering Botswana) and northern 
KwaZulu-Natal (bordering southern Mozambique and Swaziland) as well (Sharp, 1996). 
Mpumalanga's geographical and climatic profile creates ideal breeding conditions for 
A11opl1eles arabiensis, the principal vector for P. falcipanmz malaria in the subcontinent. 
Additionally, the role of increasing chloroquine resistance in increasing transmission is likely 
to be significant. 
Increased rainfall and higher temperatures in the region in recent years due to the El Nino 
effect, as well as political changes in border controls, account for the substantial increase in 
malaria in 1996. 
During the 1991-1996 period, a mean total of 57.69% of malaria smears examined by the 
district laboratory originated at Shongwe Hospital, which is located a substantially greater 
distance from the border than all the other facilities with more than 1 % of the district malaria 
load. This is an area otherwise free of the disease. This is largely explained by the results of an 
internal sh1dy conducted at Shongwe Hospital, which revealed that a lack of communication 
between the outlying clinics and slow laboratory results resulted in approximately 90% of 
thick smears being repeated upon admission to the hospital (personal communication, E 
Athan). This renders the validity of the Shongwe Hospital thick smear records as an 
epidemiological tool highly suspect. 
The clinics at Naas and Mangweni carry a degree of prestige in the community, and are 
perceived as being more efficient than the day clinics. Patients therefore might travel further 
to get to these facilities, even though another clinic might be nearer. 
Naas and Mangweni are open twenty-four hours every day, and therefore more accessible 
than other clinics in the region. It is likely that their loads would drop significantly if they 
opened only eight hours a day. Of the day clinics with a substantial number of malaria cases, 
Mbuzini is both close to the Mozambique border and a substantial distance from the hospital 
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and the 24-hour clinics. Steenbok is also near the border. Mzinti and Sihlangu are in 
Shongwe, on the South African side of the Komati River, and farther from the border than 
any of the other high-caseload clinics. Block Chas a very low malaria profile compared to its 
close neighbour, Naas. Naas is a 24-hour clinic and is the most frequently visited primary 
health care facility in the Sibayeni area. Block B is located in KwaSibhejane, which is in turn 
located in the crook of a bend in the Komati River. The geography of the region may play a 
role in the relatively high number of malaria notifications at that clinic, since breeding 
conditions for the Anoplzeles mosquito appear to be optimal at the site. 
Naas and Mangweni Clinics were chosen as sentinel sites primarily because of their 
concomitant use as sentinel sites for the i11 vivo sulfadoxine-pyrimethamine study being 
conducted by the Medical Research Council of South Africa and the provincial malaria 
control programme, but also because of their relatively central locations, and the fact that 
they do not close. 
In absolute numbers of malaria notifications, Mangweni is ranked lower than both Mbuzini 
and Steenbok. This bias is probably attributable to the effect of the substantially-higher 
number of malaria cases in 1996, concomitant with their close proximity to the 
Moazambiquan border. 
All thick smears listed as positive for malaria in the records at the laboratory are also listed as 
P. fnlcipnrum infections. In a sample consisting of 4 406 smears found to contain trophozoites, 
none was found to be infected with P. vivnx, P. ovale or P. mnlariae. These results do not concur 
with the findings of the in vivo study of chloroquine resistance carried out by the 
Mpumalanga Department of Health and Welfare and the MRC (Govere et al, 1998); this study 
detected traces of the three non-falciparum species. It would seem likely that all infections 
diagnosed by microscopy were routinely registered as P. falciparum, without species 
determination being done. However, since the 1997 introduction of ICT kits, which are 
species-specific, this can no longer happen with P. fnlcipnn1111. However, this raises concerns 
regarding the detection of other malarial species, which, after testing negative for falciparum, 
may not be correctly diagnosed as malaria. Training of clinical staff is probably necessary, if 
this has not already been done. 
7.1.1. Parasite Detection Rates 
At primary health care clinic level, detection rates (number of thick smears positive for 
malaria versus number of thick smears examined) were 2.35% ± 0.44%, or about 1 positive 
case in every 43 smears examined. The positivity rate at Shongwe Hospital was markedly 
higher (9.29% ± 2.04%). The difference may be due to greater severity of malaria symptoms 
appearing at the hospital as opposed to the clinics, where headaches and fever are 
automatically assumed to be possible cases of malaria and tested. Differences in staff 
expertise may also play a role. The routine re-testing of patients referred with malaria from 
rural clinics is a clear source of bias. 
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A seasonal fluctuation in thick smear positivity rate was detected (Fig. 3.4, p 48), with peaks 
corresponding to high positivity occurring approximately annually, in the high transmission 
periods of the malaria season between January and March. This was an expected result, as the 
rains began and temperatures began to rise. 
Thick smears originating from Shongwe accounted for 23.4% of those analysed. The clinics at 
Mbuzini, Steenbok, Naas, Mangweni, and Block B also accounted for large numbers of tests 
analysed at the laboratory, which was not unexpected, considering the high number of 
malaria cases presenting at those sites and the resulting selection bias of staff. 
Thick smears have not been used for the detection of malaria since the full-scale introduction 
of immunochromatographic tests (ICTs) for P. Jalcipantm in the district in 1997. 
7.1.2. The Active Surveillance Programme 
The diagnostic efficiency of the active surveillance programme in the region is far lower. Of 
404 836 thick smears evaluated, only 1 639 cases of malaria were detected, representing an 
overall positivity rate of 0.399% ± 0.047%, or 1 in 250. During the six-year period under 
investigation, the annual hit rate varied between 1 in 103 (1991) and 1 in 513 (1993). In 
contrast, passive surveillance at clinic and hospital level detected 4 406 malaria cases (2.7 
times more) using 89 939 thick smears, almost fivefold fewer tests . Bearing in mind the 
reportedly high costs of running the programme, the results suggest that passive surveillance 
alone is more cost-effective. However, active surveillance may have an effect on treatment-
seeking behaviour. Visits from active surveillance personnel may increase community 
awareness of malaria and thereby encourage future malaria patients to seek treatment from 
public health care centres rather than from traditional healers. Active surveillance may also 
increase early treatment of malaria, thus reducing transmission. This suggests an area for 
additional pharmacoeconomic research; an appraisal of the costs and benefits of the active 
surveillance programme. 
The on-the-spot treatment of suspected malaria cases with antimalarials no longer represents 
as large a resistance-inducing risk as it once did. The advent of ICTs allows the immediate 
and accurate diagnosis of falciparum malaria, something not possible before. Drugs would 
therefore only be administered when appropriate. 
7.1.3. General Observations 
The trend towards seasonal peaks in thick smear positivity noted in passive detection at the 
clinics and Shongwe Hospital was absent in the positivity rates associated with the active 
surveillance programme, with the exception of an increase in 1996 (Fig 3.5, page 51). 
Positivity never reached 3% between 1991 and 1996, and decreased to half its 1991 levels in 
mid-1992, where it remained until the 1996 epidemic. Cases were passively detected outside 
the malaria season in greater numbers than during the season. A possible explanation is the 
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detection of low-grade infections in semi-immune individuals originating in holoendemic 
transmission areas, such as Mozambique. It is also likely that non-immune persons 
contracting falciparum malaria would seek medical attention almost immediately, leading to 
their detection at a clinic or hospital rather than at the active surveillance level, which would 
account for the lower or equivalent numbers observed during peak season. It is not apparent 
why the same semi-immune carriers would not be detected at an equal rate during peak 
season; one possibility is seasonal demand for labour. Harvesting on the farms in the region, 
for example, might require hiring extra staff, generally recruited from the immigrant labour 
pool. 
The malaria caseloads at Naas (236 notifications, 0.78% of total patient throughput) and 
Mangweni (271 notifications, 1.10% of total patient throughput) are lower than those seen at 
the day clinics with the highest throughput of malaria patients, but the smaller day-clinics 
lack the infrastructure to support studies of this size. Additionally, the numbers of patients 
seen by the smaller clinics at Mbuzini (548 notifications, 5.79%) and Steenbok (175 
notifications, 2.29%) are comparable to the 24-hour clinics. 
The demographic data show that mean age of malaria patients in the Nkomazi district, 
comprising today's Shongwe and Tonga districts, was far lower than that found in other 
districts such as Barberton, White River, and Nelspruit. This may be due to a younger 
general population in the region compared to the others. It may also reveal that mean age of 
malaria patients in the area is increasing with time, although most cases still occur in the 
prepubescent population. 
The mean age of new malaria patients throughout the region is relatively low in comparison 
to the general population, but this is explained by the pyramid structure of the South African 
population as a whole. The area comprises a 'young population' typical of many developing 
countries. According to 1995 census estimates, 39% of the African population of 
Mpumalanga is under 15 years, and only 3% is over 65 (Orkin et al, 1998). Only the African 
population in the area has been highlighted, since it is this group which makes virtually 
exclusive use of the public clinics and Shongwe Hospital. Privileged populations rely on 
private sector providers. 
7.2. Modelling 
7.2.1. Development of the Model 
The model was successfully constructed to detail carefully defined, discrete variable and 
fixed costs accrued by the public health system as a result of malaria, based on the 1997 in 
vivo study of sulfadoxine-pyrimethamine efficacy in the Tonga district of Mpumalanga. 
However, the model has a number of inherent shortcomings. It assumes that all patients 
suffering from malaria eventually present at a primary health care facility, as South Africans 
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comprise a non-immune population who will become symptomatic when infected . They 
must therefore receive adequate treatment or die. Some patients may seek treatment from 
traditional healers, but it seems unlikely that such treatment will be effective; in most, 
traditional treatment is likely to fail and other sources of treatment will need to be sought. 
Since formal private practitioners are both scarce and expensive, it is reasonable to assume 
that a public health facility -- such as a rural clinic -- will be visited by the majority of patients 
at some point during the course of their infections. 
For those patients not cured by the first-line antimalarial, a return rate of 70% ± 15% was 
estimated, based upon expert interviews with three public health care workers and officials in 
the region. Owing to small discrepancies in their opinions, a sensitivity adjustment was 
included. No data regarding treatment-seeking behaviour among rural Mpumalanga 
populations exists. However, since cases were estimated to have a 95% probability of falling 
between 55% and 85%, this was considered a reasonable method of assessing return rate, 
especially since there is no other effective source of treatment in the area. The model 
indirectly allows for patients returning to other clinics for treatment, as costs between 24-hour 
and day clinics did not differ significantly. Staff numbers were identical (personal 
communication, R Raubenheimer, Mpumalanga Department of Health and Welfare) and 
other parameters were either identical or the difference was insignificant (fixed costs did not 
vary significantly from clinic to clinic, regardless of whether they were open 8 hours or 24 
hours a day). 
The model did not take into account expenses associated with the pharmacodynamics of the 
drugs themselves. Sulfadoxine-pyrimethamine, for instance, does not necessarily alleviate 
symptoms, but merely clears parasitemia. Patients in whom the drug has been effective may 
nonetheless return to the clinic on the assumption that the drug has not worked. 
Side effects of the drugs were also not considered. While the side effect profiles of 
chloroquine are mild and unlikely to cause problems in first line treatment, other agents may 
generate more serious adverse effects. The neuropsychiatric effects associated with 
mefloquine are usually mild at therapeutic doses, but severe derangement is known to occur 
in an estimated 1 in 215 cases treated therapeutically. Sulfadoxine-pyrimethamine therapy is 
associated with significant, although rare, side effects, notably severe cutaneous adverse 
reactions (SCARs), including erythema exudativum multiforme, Stevens-Johnson syndrome, 
toxic epidermal necrolysis, and cutaneous vasculitis. Frequency appears to vary according to 
geographical location. The US Centers for Disease Control reported cutaneous reactions in 
1:5000 to 1:8000 cases, with fatalities in the order of 1:10000 to 1:25000 (Tester-Dalderup, 
1996). Other side effects of SP include hematological and respiratory adverse effects. No 
severe adverse events have been reported since the introduction of SP as first-line therapy for 
malaria in Mpumalanga. Halofantrine treatment carries with it the risk of severe cardiac 
adverse events, especially where a pre-existing cardiac conduction abnormality exists. The 
drug also exhibits a severe interaction profile with chloroquine, quinine and possibly 
mefloquine (Tester-Dalderup, 1996). Amodiaquine carries a risk of agranulocytosis. 
Artesunate' s side effect profile remains unclear. There appears to be no serious side effect 
thus far, but its long term effects are unknown; its neurological effects on laboratory animals 
are a source of concern. Pyronaridine appears to be safe, but substantial research followed by 
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careful post-marketing surveillance must be conducted before confidence may be attached to 
this, considering its structural homology to amodiaquine. 
The impact of side effects on costs may be considerable. For instance, a cardiac adverse event 
(in the case of halofantrine) would likely result in an extended hospital stay. Hospitalisation 
is the most costly element in the costs associated with first line antimalarial treatment. If a 
significant number of these adverse effects were to manifest, it would dramatically reduce the 
cost-effectiveness of halofantrine. 
The model succeeds mainly in determining the relative cost-effectiveness of the antimalarials 
examined, rather than providing an exact quantitative assessment of cost. Although not every 
cost was measured, every drug was assumed to be used within the same public health 
infrastructure; none were assumed to require any substantial restructuring of the way in 
which first line malaria cases are treated. Further, drug resistance levels and costs were as 
accurate as possible. Therefore, the relative positions of the drugs and combinations on the 
ranking scale in Figure 5.2 are likely to remain accurate. 
Time was a factor that was excluded by the design of the model, which concentrated on a 
single year, 1997, and modelled the predicted relative costs of using each of the 11 drugs and 
combinations evaluated in the study for first line therapy during that single year. 
Many things change from year to year: malaria transmission, drug costs (including the expiry 
of patents), and particularly in vivo drug resistance, which is accelerated as parasite 
populations are exposed to antimalarial agents. The rate of developing resistance was not 
taken into account, but is of critical importance when deciding whether to change first line 
treatment, and if so, which drug or combination to adopt. For instance, the experience so far 
suggests that the selection of specific mutations bestowing sulfadoxine-pyrimethamine 
resistance on P. falcipanm1 is a great deal faster than selection for artesunate resistance. 
Drug costs, especially, are a source of variation, but their impact on the ACER is relatively 
small. However, a reduction in the costs of both quinine and sulfadoxine-pyrimethamine, as 
described in Kenya, is enough to change the ACER rankings. SP, using these costs and 
assuming equal in vivo resistance, would become more cost-effective than artesunate-
mefloquine. However, the Kenyan cost of mefloquine is not known and would likely change 
the order, and resistance to SP in Kenya is higher than in South Africa. This underscores the 
importance of resistance as a determinant of cost-effectiveness, rather than drug cost. 
7.2.2. Modelling of the Drugs 
Chloroquine and sulfadoxine-pyrimethamine were modelled most accurately. Exact data on 
cost and i11 vivo resistance by P. falciparztm to both drugs in the Tonga district were known. 
In vivo drug resistance is the single most important factor determining cost-effectiveness. It 
has been shown that large variations in drug cost do not affect the ACER significantly. The 
only exception is quinine, the second line drug, and then only if resistance is high. In the case 
of high resistance, variations in the price of quinine will affect the ACER, since the drug is 
170 
used to treat hospitalised patients, numbers of which increase in proportion to resistance. All 
other factors, such as staff time and consumables, are governed by resistance alone. 
PR for amodiaquine was thought to be accurate, owing to the fact that it was based upon a 
review of 15 clinical trials, most within sub-Saharan Africa. PRs for co-artemether, 
atovaquone-proguanil, and halofantrine were based upon careful selection of single studies 
within sub-Saharan Africa, but these estimates of the proportion of resistant cases may not be 
applicable to South Africa. The model relies on the assumption that they are accurate. 
Mefloquine resistance developed extremely quickly in Southeast Asia within 5 years of its 
introduction (White, 1992). Recent in vitro studies of P. fal cipanmz isolates from the 
Mpumalanga region suggest that resistance has not yet developed (Freese et al, 1994). The use 
of mefloquine in South Africa as a prophylactic agent would, however, suggest that some 
drug pressure has already taken place and that development of resistance is more likely. 
Costs could not accurately be obtained in the case of either amodiaquine or co-artemether, 
considering the drugs are not registered in South Africa and an estimated price had to be 
estimated based upon export prices in US dollars and Swiss francs, respectively. 
Multinational drug companies tend to standardise prices globally. 
One million doses per annum of atovaquone-proguanil, in the form of Malarone, have been 
donated to African malaria control programmes by Glaxo Wellcome. Free supplies of the 
drug becoming available in South Africa were not considered during the development of the 
model, since this is unlikely to occur. 
Artesunate (and its combinations) and pyronaridine presented problems with respect to both 
drug prices and estimates of i11 vivo resistance. As mentioned earlier, South Africa is 
perceived by multinational drug companies as more able to pay high prices for drugs than 
other African nations. Artesunate was valued according to its Thai market price, which was 
later confirmed as being the most realistic estimate of what it might cost in Africa (personal 
communication, M Gomes, Artesunate Product Manager, Special Programme for Research 
and Training in Tropical Diseases, WHO) . The South African price may well be higher, 
though, and this should be taken into account when comparing artesunate and its 
combinations to drugs such as atovaquone-proguanil, which are registered in South Africa. 
The projected price of pyronaridine is estimated to be $3.00 per adult course in 1996 
(Winstanley, 1996) but it is unclear whether this will apply to South Africa. 
The artemisinin derivatives have been slow to induce resistance, even in the Southeast Asian 
milieu of high drug pressure. For that reason, it was reasonable to assume that resistance in 
southern Africa, where the drug has never been used, is nil. Pyronaridine resistance has 
already appeared in Southeast Asia (Looareesuwan et al, 1996), but has not yet been reported 
in Africa. 
Some of the data used to model some of the drugs were not ideal, and for this reason it is 
necessary to ' grade' each drug or combination according to the estimated accuracy of the 
results. The most accurately modelled drugs were sulfadoxine-pyrimethamine and 
chloroquine, followed by amodiaquine, halofantrine, atovaquone-proguanil, co-artemether, 
artesunate and its combinations, and finally pyronaridine. 
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7.2.3. Recommendations 
On the basis of the model, it is clear that artesunate and its combinations, as well as 
pyronaridine, potentially represent the most cost-effective treatment options in the region. 
Although artesunate is first-rank, in practice and allowing for poor compliance, artesunate 
alone has too long a therapy regimen to be a serious alternative for first-line treatment. Its 
deployment as a monotherapeutic option may also be unwise from the standpoint of 
developing drug resistance. Following from this, artesunate in combination with mefloquine 
or sulfadoxine-pyrimethamine is recommended as replacement therapy before the level of SP 
resistance becomes too high. There are several reasons for this: 
+ Primarily, the superior cost-effectiveness of artesunate-SP and artesunate-mefloquine 
compared with other agents and combinations; 
+ The advantages of combination therapy in delaying the emergence of resistance 
(especially to SP); and 
+ The slow emergence of artesunate resistance in spite of high drug pressure, based 
upon the Southeast Asian experience. 
Care should be exercised in deciding between artesunate-mefloquine and artesunate-SP. 
While artesunate-SP is more cost-effective than artesunate-mefloquine, SP will already have 
been used extensively as first line therapy in the region. If SP resistance is high, its protective 
function will be lessened. 
A caveat in the choice of an artesunate combination for first line management of malaria is 
the safety of the drug. The artemisinin derivatives have been shown to be neurotoxic in high 
doses in laboratory animals. Artesunate is water-soluble and therefore assumed to be the 
least toxic of the artemisinin derivatives, and initial clinical evidence from Southeast Asia 
suggests that the drug is safe in therapeutic doses. However, no studies have been conducted 
on the neurological effects of multiple doses of artesunate on paediatric patients with 
developing nervous systems. Research is urgently needed in this area. Price et al, however, 
reported in April 1999 that no neurological effects were detected in 836 patients treated with 
artemisinin derivatives, and concluded that artemether and artesunate were safe and well-
tolerated in their study population. In the same study 2 826 patients were treated with 
mefloquine in combination with an artemisinin derivative; this population showed a 
significant increase in side effects over the group treated with artemisinin derivatives alone. 
A third group of 1303 patients was treated with mefloquine alone. 
Some antimalarials examined here present problems not explicit in the model. Safety, 
efficacy, and compliance, as well as cost-effectiveness, should be considered when selecting 
treatment. 
The fast emergence of multiple drug resistance in P. falcipanm1 indicates that combination 
therapy represents a better long-term solution. A novel agent with high efficacy may be 
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protected from developing resistance by combining it with another agent, thereby reducing 
the likelihood that any organisms will survive treatment to produce resistant populations. 
This is particularly true when drugs with different modes of action are combined. Also, 
combinations tend to use shorter treatment course regimens, which is likely to improve 
compliance. 
The results show that it became cost-effective to switch to sulfadoxine-pyrimethamine from 
chloroquine when i11 vivo parasite resistance to the latter drug reached 7.30% . Based on this, it 
would have been cost-effective to switch to artesunate-SP when resistance to SP alone 
reached 0.49% in the field . These figures, however, are highly sensitive to any change in any 
parameter in the equation and should be interpreted as such. 
7.3. Treatment Costs Incurred by Patients 
The completion of the questionnaires proved problematic. An ideal approach would have 
been to recruit workers from the community, train them, and station them at each of the two 
clinics for the duration of the study. However, this was not possible due to local political 
considerations. 
An acceptable compromise was reached by an agreement with the Mpumalanga Malaria 
Control Programme that their clinic assistants would collect the necessary data from the 
patients used in their own study. 
It would have been useful to collect information regarding prior visits to traditional medical 
practitioners, as well as exact salary details, but this was not possible. Members of the 
community were extremely reluctant to divulge information of this kind. Clinical staff in the 
formal medical sector are perceived to frown upon traditional medicine. Patients were 
suspicious of questions regarding employment; many were Mozambiquan immigrants fearful 
of deportation, or afraid that they would be dismissed if word of their illness reached their 
employers (personal communications, E Athan). Patients were also extremely reluctant to 
divulge details of citizenship. 
7.4. General Application of These Findings 
African drug policy is a source of growing worldwide concern, and pharmacoeconomic 
evaluation is emerging as a valuable tool to assist in the formulation of rational policy. Other 
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work in this field has already begun, such as a study on the cost-effectiveness of sub-Saharan 
malaria control, recently published by Goodman et al. 
The model may be applied to malaria areas anywhere in the world where drug policy, supply 
and distribution is well regulated, with some modifications: area-specific factors such as local 
treatment-seeking behaviour and the immune status of the feeder population (semi-immune 
patients need not be hospitalised) . Treahnent policies are likely to vary from place to place, 
and this must be taken into account. South Africa is a special case in that treatment is 
supplied by the public sector. 
In areas different from the Tonga district of Mpumalanga, precise details of treatment-seeking 
behaviour must be known in order to predict what proportion of patients are seeking 
treatment at clinics, what proportion are self-medicating with legal or black-market drugs, 
what proportion of patients are likely to return to clinics if initial treatment is a failure, and 
what percentage of treatment failures are hospitalised. It is critical to know what the 
proportions of intravenous compared with oral quinine are, at hospital level. Once these 
structural adaptations have been applied, the model should be generalisable. 
The model may be employed to determine average cost-effectiveness ratios for interventions 
used in the treatment of other diseases, such as tuberculosis and sexually-transmitted 
diseases. Any infectious disease that is treatable using the tiered pharmacotherapy paradigm 
used in rural malaria management may hypothetically be modelled using the methodology 
developed here. 
7.5. Limitations 
Most notably, this study does not address the problems and costs associated with side effects 
of antimalarials considered in the meta-analysis, which may be substantial (as detailed in 
section 7.2.2) . Also, additional costs incurred due to wastage of drugs and materials (such as 
IV drips that need to be re-sited) have not been evaluated. 
This work has concentrated on direct costs, including fixed and variable costs, without 
considering indirect costs. Indirect costs incurred as a result of the choice of first-line 
antimalarial agent may be substantial. 
The Tonga district is dominated by the farming industry. If a first-line antimalarial agent is 
ineffective in such an area of high transmission, it follows that patients will need to spend 
more time absent from work, either recuperating or while seeking treatment. Employees will 
therefore not be productive to industry while they are absent, with a resulting drop in 
production, which may, if the numbers of stricken employees are sufficient, have an adverse 
effect on the provincial economy. The high level of unemployment in the region, the 
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proclivity of malaria for individuals under working age, and high numbers of migrant 
workers may also have an effect on factors such as these. 
Another limitation of the study is its lack of consideration of the passage of time. The meta-
analysis and model were developed with only one year, 1997, in mind. 
The probability of resistance may change rapidly over time, depending on both the 
characteristics of the drug and the degree of drug pressure. Rates of change of drug resistance 
were beyond the scope of this work, but they are a major factor. Every drug and drug 
combination has a different rate of resistance development associated with it. Costs will 
appreciate with time in proportion to the inflation rate. However, if cost increases are 
uniform, ACERs will be largely unaffected; increasing resistance, however, will cause a 
significant and immediate drop in cost-effectiveness. Compliance with each drug regimen 
may also vary, affecting rate of change of resistance development. 
A major problem with taking the perspective of the public healthcare provider is dealing with 
the patients who do not return to the clinics for treatment once first-line therapy fails . The 
estimate of a 70% ± 15% return rate is not based upon hard data and should be improved 
before any further studies of this kind are done. The number of 'fall-out' patients is directly 
related to the efficacy of tl1e drug: patients not cured who seek help elsewhere may not 
achieve parasite clearance, which will likely result in an increase in transmission and 
therefore an increase in cases. Also, a highly inefficient public health service using an 
ineffective but inexpensive drug may find it is cost-effective to continue to use it unless fall-
out patients are addressed. 
A critical issue in ranking is compliance. No weighting was applied to any of the evaluated 
drug regimens to address this: artesunate, for instance, is recommended for use with a 7-day 
regimen. Without constant monitoring of patients, this is unlikely to be completed as 
directed. Sulfadoxine-pyrirnethamine, conversely, is used as a single and immediate dose, 
making it the ideal treatment from a compliance point of view. Ranking of drugs in the 
model is unlikely to be seriously affected, however: apart from artesunate, only halofantrine, 
with its complex dosage schedule, and sulfadoxine-pyrimethamine would be affected. All the 
other drugs and combinations evaluated has reasonably ·short regimens, typically 3 days. 
Additionally, halofantrine's toxicity issues would effectively disqualify it as a first-line agent 
in any event. Sulfadoxine-pyrimethamine would likely become somewhat more cost-
effective. There is a need to include compliance in future modelling of antimalarial cost-
effectiveness. Without a full-scale compliance study being first conducted in Mpumalanga, 
any such refinement of the model would, however, be arbitrary 
Finally, the study should be interpreted as a qualitative (rather than quantitative) assessment 
of the relative cost-effectiveness of first-line antimalarials. Not all costs were exhaustively 
considered, but since all the drugs were assumed to operate within the same infrastructure, 
ACERs would retain the same positions relative to each other. Many estimations had to be 
made in the assessment of costs, so a degree of error is inevitable. The sensitivity analysis will 
have eliminated much of this error, but the omission of certain costs cannot be corrected for, 
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although it is identical in all the modelled drugs and therefore will not alter their relative 
ACERs. 
7.6. Future Research 
Scope exists to continue and improve on this work. 
+ The costs and benefits of the active surveillance programme must be determined with a 
view to assessing accurately its cost-effectiveness. 
+ Treatment-seeking behaviour in Mpumalanga patients needs to be elucidated. The 
proportion of patients visiting traditional healers in preference to or in combination with 
formal public health facilities is unknown. This is true of many areas in sub-Saharan 
Africa. Also, the clinic return rate of patients in whom first-line therapy fails must be 
accurately determined. 
+ The model created here may be used to assess the relative cost-effectiveness of 
antimalarial drugs in other parts of the country, and indeed sub-Saharan Africa and 
globally, with modifications for region-specific aspects. 
+ The indirect costs of malaria treatment should be described. Malaria is a burden not only 
on the public health system, but for individual patients, their caregivers, their 
dependants, their employers, and the nation's economic output. This information must be 
known for rational malaria policy to be implemented. 
+ The effect of compliance on cost-effectiveness must be determined. 
+ The effect of the use of antimalarial combinations in delaying the emergence of resistance 
requires further research. It is of critical importance in determining costs. 
7.7. Conclusion 
Falciparum malaria is concentrated in the regions of Mpumalanga close to the Mozambiquan 
border. The highest number of cases detected at clinic level occur at the 24-hour clinics at 
Mangweni and Naas, confirming their choice as sentinel sites, as well as at the day clinics at 
Steenbok, Mbuzini, and Block B. 
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The positivity rate for the clinics and the hospital is low, generally under 30% . However, this 
is tenfold higher than the maximum positivity recorded for the active surveillance 
programme in the region. The active surveillance programme detects extremely low 
numbers of true malaria cases in comparison to the number of tests performed, suggesting 
that it may be inefficient in terms of resource use. 
A model for assessing the relative cost-effectiveness of various antimalarial drugs and 
combinations in an area of high compliance with policy and strict control of drugs was 
successfully developed. 
The variable and fixed costs of chloroquine and sulfadoxine-pyrimethamine, when used as 
first line therapy for malaria, were evaluated with a view to determining cost-effectiveness. 
Sulfadoxine-pyrimethamine emerged as 4.8 times more cost-effective than chloroquine, 
confirming that its adoption as a replacement for chloroquine has been a sound decision. 
Other treatment regimens were evaluated: in comparison to chloroquine, artesunate 
monotherapy was 13 times more cost-effective, artesunate in combination with sulfadoxine-
pyrimethamine was 9.2 times more cost-effective, artesunate in combination with mefloquine 
was 5.6 times more cost-effective, and pyronaridine was 11.2 times more cost-effective. All 
represent cost-effective substitutes for the current first-line drug, sulfadoxine-pyrimethamine. 
Other drugs evaluated, but found unlikely to be cost-effective in comparison to chloroquine, 
included amodiaquine (1 .3 times as cost-effective), atovaquone-proguanil (1 .7 times as cost-
effective), co-artemether (1 .7 times as cost-effective), halofantrine (2.1 times as cost-effective) 
and mefloquine (4.3 times as cost-effective). Chloroquine was the least cost-effective drug 
studied, despite its low cost, as a result of high resistance. 
It was concluded that an artesunate combination with either sulfadoxine-pyrimethamine or 
mefloquine would be the most desirable successor therapy to sulfadoxine-pyrimethamine, 
due to the high cost-effectiveness of these, the advantages of combinations, and the slow 
development of artesunate resistance in other parts of the world. It is assumed that artesunate 
will prove to be safe. 
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Appendix A: Staff SalanJ Tables 
Position Number of Time spent on Monthly wage Annual fringe Total annual Category staff (Q,) malaria in or salary (ZAR) benefits (ZAR) cost of position months (T,} (W,) (FB,) including 
benefits (ZAR) 
((Q, x [(T, x W,) 
+ FB,])) 
Admin 
Admin. Oflicer 2 12 4620.75 22179.60 155257.20 
Director: Admin, I 12 7035.25 33769.20 l 18192.20 Asst 
Data Typist Gr I 3 12 2138.25 10263.60 107767.80 
Typist Gr I 2 12 2138.25 10263.60 71845.20 
Admin Clerk Gr I 27 12 2138.25 10263.60 969910.20 
Personne l Otlicer I 12 2138.25 10263.60 35922.60 Gr I 
Personnel Officer I 12 4620.75 22179.60 77628 .60 Pr 
Account Clerk Gr I 4 12 2138.75 10263.60 143690.40 
Prov Admin Clerk 5 12 2138.75 10263.60 179613.00 Gr I 
General and Domestic 
Cleaner I 113 12 1583.50 7600.80 3006116.40 
Messenger I 12 1583.50 7600.80 26602.80 
Groundsman 20 12 1583 .50 7600.80 532056.00 
Porter 7 12 1583.50 7600.80 186219.60 
Principal Porter 3 12 2138.25 10263.60 107767.80 
Gent Worker I 2 12 1583.50 7600.80 53205 .60 (Stores) 
Genl Worker I 9 12 1583 .50 7600.80 239425 .20 (Therapy) 
Laundry Manager I 12 2138.25 10263.60 35922.60 
Seamstress I 2 12 1583.50 7600.80 53205.60 
Food Services Aid I 27 12 1583.50 7600.80 718275.60 
Food Services 5 12 2138.25 10263.60 179613 .00 Supervisor 
Laundry Aid I 27 12 1583.50 7600.80 718275.60 
Laundry Aid II I 12 1824.00 8755.20 30643 .20 
Laundry Manager I 12 2138.25 10263.60 35922.60 
Security Guard Gr I I 12 1583.50 7600.80 26602.80 
Operator 4 12 I 583 .50 7600.80 106411 .20 
Telecom Operator 6 12 2138 .25 10263.60 215535 .60 Gr! 
Medical 
Medical Officer 18 12 7035.25 86111.46 3069620.28 
Med/Dent Super. I 12 12566.50 I 53813 .96 304611.96 Sen 
Appendix A: Staff Sa/an; Tables 
Nursing 
Nurse, Prof. 85 12 3709.50 17805.60 5297166.00 
Nurse. Pro( Sen I 12 4620.75 22179.60 77628.60 
Nurs Serv. Asst Dir 2 12 7035 .25 33769.20 236384.40 
Staff Nurse 51 12 2533 .00 12158.40 2170274.40 
Staff Nurse, Sen 8 12 2996.50 14383.20 402729.60 
Nursing Assistant 131 12 2138.25 10263.60 4705860.60 
Supplementary Health Services 
Dietician I 12 3709.50 17805.60 623 I 9.60 
0cc Therapist I 12 3709.50 17805.60 62319.60 
Physiotherapist I 12 3709.50 17805.60 623 I 9.60 
Radiographer I 12 3709.50 17805.60 62319.60 
Pharmacist 2 12 3709.50 17805.60 124639.20 
Emerg Care Pract 8 12 2533 .00 12158.40 340435 .20 
Food Services 2 12 2138.25 10263.60 71845.20 Manager 
Operator 3 12 1583.50 7600.80 79808.40 
SASO: Therapy 2 12 1583 .50 7600.80 53205.60 Asst 
Aux Services 13 12 1583.50 7600.80 345836.40 Officer I 
Primary Health Care 
Med/Dent I 12 10391.00 127185.84 251877.84 Superintendent 
Nurse, Prof 3 12 3709.50 17805.60 186958.80 
Nurs Serv, Asst Dir 2 12 7035.25 33769.20 236384.40 
Admin Clerk Gr I 2 12 2138.25 10263.60 71845 .20 
Maintenance 
Tradesman Aid I 12 12 1583.50 7600.80 319233 .60 
Genl Worker I 4 12 1583.50 7600.80 106411.20 (lncin) 
Operator 5 12 1583 .50 7600.80 133014.00 
Lab Services 
Medical 8 12 3709.50 17805.60 498556.80 Technologist 
Total R 27 465 234.48 
Table A. I. Breakdown of staff makeup and salaries at Shongwe Hospital in 1997. 
Appendix A: Staff SalanJ Tables 
Post Number Annual Salary Additional Benefits Total Annual 
Salary for Post 
Including Benefits 
Prof. nurse II 44514 .00 40% 685515 .60 
Staff nurse I 30396.00 40% 42554.40 
Emerg. care practitioner 3 30396.00 40% 127663.20 
Admin. clerk I 25659.00 40% 35922.60 
Cleaner 5 19002.00 40% 133014.00 
Groundsman I 19002.00 40% 26602.80 
Nursing assts 7 25659.00 40% 251458.20 
Total 
R 1302 730.80 
Table A.2. Breakdown of staff makeup and sa laries at Naas Clinic in 1997. 
Post Number Annual Salary Additional Benefits Total Annual 
Salary for Post 
Including Benefits 
Prof. nurse II 44514.00 40% 685515 .60 
Staff nurse I 30396.00 40% 42554.40 
Emerg. care practitioner 4 30396.00 40% 170217.60 
Admin. clerk I 25659.00 40% 35922.60 
Cleaner 5 19002.00 40% 133014.00 
Groundsman I 19002.00 40% 26602.80 
Nursing assts 7 25659.00 40% 251458.20 
Total R 1 345 285.20 
Table A.3. Breakdown of staff makeup and salari es at Mangweni Cli nic in 1997. 
Appe11dix B: Sample in vivo study questiomzaire (Mpumalanga Malaria Control Programme). T/1e 11m1te n11d address fields /zave been erased to preserve patient anonymity . 
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Appendix C: Values for Spanl, Span2, K1, K2 and Plateau for modelled dmgs. 
Drug Spa11l Spa112 K1 K2 Plateau 
CQ 4.413 8.820 0.0469 0.2708 0.497 
SP 4.255 5.236 0.0488 0.2897 0.493 
AQ 5.303 7.891 0.0568 0.3616 0.500 
As 5.048 7.202 0.0548 0.3439 0.499 
As-Mef 2.786 2.336 0.0376 0.1946 0.475 
As-SP 3.986 4.642 0.0468 0.2717 0.491 
Atova-P 1.658 0.8576 0.0278 0.1260 0.439 
Co-A 1.292 0.5495 0.0239 0.1033 0.418 
HF 2.505 1.903 0.0353 0.1771 0.468 
Mef 2.298 1.612 0.0336 0.1645 0.463 
PN 3.924 4.497 0.0463 0.2676 0.490 
Table C.1. Variable values for each drug. 
